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1. INTRODUCTION 
1. 1. HERBAL MEDICINES 
Nature always stands as a golden mark to exemplify the outstanding phenomena of 
symbiosis. Herbal medicines have been widely utilized as effective remedies for the 
prevention and treatment of multiple health conditions for centuries by almost every 
known culture. The first documented records of herbal medicine use date back 5,000 years 
in China. Similarly, India’s Ayurvedic medicine tradition is thought to be more than 5,000 
years old and herbal medicines remain an essential component of its practice. Herbal 
medicine is still the mainstay of about 75 - 80% of the world population, mainly in the 
developing countries, for primary health care. This is primarily because of the general 
belief that herbal drugs are without any side effects besides being cheap and locally 
available. According to the World Health Organization (WHO), the use of herbal remedies 
throughout the world exceeds that of the conventional drugs by two to three times.152, 153, 41, 
59, 46, 35, 132 
Tribal healers in most of the countries, where ethnomedical treatment is frequently 
used to treat cut wounds, skin infection, swelling, aging, mental illness, cancer, asthma, 
diabetes, jaundice, scabies, eczema, venereal diseases, snakebite and gastric ulcer, provide 
instructions to local people as how to prepare medicine from herbal. They keep no records 
and the information is mainly passed on verbally from generation to generation. World 
Health Organization (WHO) has shown great interest in documenting the use of medicinal 
plants used by tribals from different parts of the world. Many developing countries have 
intensified their efforts in documenting the ethnomedical data on medicinal plants. 
Research to find out scientific evidence for claims by tribal healers on Indian herbs has 
been intensified. Once these local ethnomedical preparations are scientifically evaluated 
and disseminated properly, people will be better informed regarding efficacious drug 
treatment and improved health status. 
Herbal medicines are currently in demand and their popularity is increasing day by 
day. About 500 plants with medicinal use are mentioned in ancient literature and around 
800 plants have been used in indigenous systems of medicine. India is a vast repository of 
medicinal plants that are used in traditional medical treatments. The various indigenous 
systems such as Siddha, Ayurveda, Unani and Allopathy use several plant species to treat 
different ailments. The use of herbal medicine becoming popular due to toxicity and side 
effects of allopathic medicines. This led to sudden increase in the number of herbal drug 
manufactures. Herbal medicines as the major remedy in traditional system of medicine 
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have been used in medical practices since antiquity. The practices continue today because 
of its biomedical benefits as well as place in cultural beliefs in many parts of world and 
have made a great contribution towards maintaining human health.6 
In India around 20,000 medicinal plant species have been recorded recently but 
more than 500 traditional communities use about 800 plant species for curing different 
diseases. Currently 80% of the world population depends on plant-derived medicine for the 
first line of primary health care for human alleviation because it has no side effects. Plants 
are important sources of medicines and presently about 25% of pharmaceutical 
prescriptions in the United States contain at least one plant-derived ingredient. In the last 
century, roughly 121 pharmaceutical products were formulated based on the traditional 
knowledge obtained from various sources. 
Herbal medicines are also in great demand in the developed world for primary 
health care because of their efficacy, safety and lesser side effects. They also offer 
therapeutics for age-related disorders like memory loss, osteoporosis, immune disorders, 
etc. for which no modern medicine is available. The strong historic bond between plants 
and human health began to unwind in 1897, when Friedrich Bayer and Co. introduced 
synthetic acetyl salicylic acid (aspirin) to the world. Aspirin is a safer synthetic analogue 
of salicylic acid, an active ingredient of willow bark, and was discovered independently by 
residents of both the New and Old worlds as a remedy for aches and fevers. Herbal 
medicine is the use of plants, plant parts, their water or solvent extracts, essential oils, 
gums, resins, exudates or other form of advanced products made from plant parts used 
therapeutically to provide proactive support of various physiological systems; or, in a more 
conventional medical sense, to treat, cure, or prevent a disease in animals or humans.110 
About 25% of the drugs prescribed worldwide come from plants, 121 such active 
compounds being in current use. Of the 252 drugs considered as basic and essential by the 
World Health Organisation (WHO), 11% are exclusively of plant origin and a significant 
number are synthetic drugs obtained from natural precursors. Examples of important drugs 
obtained from plants are digoxin from Digitalis spp., quinine and quinidine from Cinchona 
spp., vincristrine and vinblastine from Catharanthus roseus, atropine from Atropa 
belladonna and morphine and codeine from Papaver somniferum. India has had a rich, 
vibrant and diverse cultural history. An important component of this culture and tradition 
is that of health and healing. Thus there is a large health and healing related knowledge 
base present in all ethnic communities across the diverse ecosystems. However, over the 
last few centuries, this knowledge base has been diluted with increased influences from the 
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mainstream culture, which is derisive of local health traditions. It is important to urgently 
put in place effective documentation and assessment programs to revitalize local health 
traditions otherwise this great people’s health culture will be irretrievably lost. This 
country is perhaps the largest producer of medicinal herbs and is rightly called the 
botanical garden of the world. There are very few medicinal herbs of commercial 
importance which are not found in this country. India officially recognizes over 3000 
plants for their medicinal value. It is generally estimated that over 6000 plants in India are 
in use in traditional, folk and herbal medicine, representing about 75% of the medicinal 
needs of the Third World countries. It is estimated that there are over 7800 medicinal drug 
manufacturing units in India, which are estimated to consume about 2000 tons of herbs 
annually. Three of the ten most widely selling herbal medicines in the developed countries, 
namely preparations of Allium sativum, Aloe arbedensis and Panax sp. are available in 
India. There are about 7000 firms manufacturing traditional medicines with or without 
standardization.110,52,123 
Thus, the modern social context and economic view of health services, the needs of 
the pharmaceutical market and the recognition that research on medicinal plants used in 
folk medicine represents a suitable approach for the development of new drugs have led to 
an increase in the number of publications in this field, and private and governmental 
institutions are now financially supporting research programmes worldwide. Even though 
is not the fruit of a fully scientific methodology, it is surprising to observe, simply typing 
the word. phytotherapy in one of the most used scientific data banks in the world, the 
growing use of this term by scientists. However, the potential use of higher plants as a 
source of new drugs is still poorly explored of the estimated 250,000. 500,000 plant 
species, only a small percentage has been investigated phytochemically and even a smaller 
percentage has been properly studied in terms of their pharmacological properties; in most 
cases, only pharmacological screening or preliminary studies have been carried out. It is 
estimated that 5000 species have been studied for medical use. 7,115,116 
Ayurveda, one of the major traditional forms of medical practice in India, has 
produced many useful leads in developing medications for chronic diseases. Almost 25 
centuries ago, Hippocrates proclaimed, let food be thy medicine and medicine be thy food. 
Combining the strengths of the knowledge base of traditional systems such as ayurveda 
with the dramatic power of combinatorial sciences and High Throughput Screening will 
help in the generation of structure activity libraries. Ayurvedic knowledge and experiential 
database can provide new functional leads to reduce time, money and toxicity. These 
INTRODUCTION 
 
 Page 4 
 
records are particularly valuable, since effectively these medicines have been tested for 
thousands of years on people. Efforts are underway to establish pharmaco epidemiological 
evidence base regarding safety and practice of Ayurvedic 
medicines. Development of standardized herbal formulations is underway as an initiative 
of the Council for Scientific and Industrial Research (CSIR) New Millennium Indian 
Technology Leadership Initiative (NMITLI). 31,18,43 
In 1991 WHO developed guidelines for the assessment of herbal medicine. 
Suggestions for herbal medicine standardization are out lined. The scenario and perception 
of herbal medicine are discussed. The publics belief that herbal and natural products are 
safer than synthetic medicines can only be ascertained by imposing regulatory standards 
on these products that should be manufactured using these Good Practices. Implementing 
standard operating procedures (SOP) leading to Good Agricultural Practice (GAP), Good 
Laboratory Practice (GLP), Good Supply Practice (GSP) and Good Manufacturing 
Practice (GMP) for producing these medicinal products from herbal or natural sources. 99,24 
1. 2. OBESITY 
Obesity is defined as “a condition of abnormal or excessive accumulation of 
adipose tissue, to the extent that health may be impaired. “People with abdominal fat 
distribution or android obesity are at greater risk to its consequences than those with the 
less serious gynoid fat distribution where fat is more evenly and peripherally distributed 
around the body. 
Sedentary lifestyle of modern living, combined with the abundant availability of 
tempting, high-fat (junk) foods has caused almost an epidemic of obesity in the affluent 
nations. The current estimate indicates that the number of ‘over weight’ individuals in the 
world is almost the same as that of ‘Underweight’ ones.  However, not everyone who 
partakes of such food becomes obese. The tendency to become obese is definitely 
inherited. The mortality rises exponentially with increasing bodyweight and the incidence 
of heart disease, hypertension, diabetes, sleep apnea, osteoarthritis and bowel cancer is 
higher in the obese than in the non-obese. 
Obesity is a substantial public health crisis in the United States, and internationally, 
with the prevalence increasing rapidly in numerous industrialized nations. In 2009-2010, 
the prevalence of obesity among American men and women was almost 36%.  126 
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Fig. No. 1: Obesity & Health 
 
 
Background 
The annual cost of managing obesity in the United States alone amounts to 
approximately $190.2 billion per year, or 20.6% of national health expenditures, according 
to a recent study.68 Compared with a nonobese person, an obese person incurs $2741 more 
in medical costs (in 2005 dollars) annually. In addition, the annual cost of lost productivity 
due to obesity is approximately $73.1 billion,17 and almost $121 billion is spent annually 
on weight-loss products and services.84 
In a 2016 position statement, the American Association of Clinical 
Endocrinologists (AACE) and the American College of Endocrinology (ACE) proposed a 
new name for obesity, adiposity-based chronic disease (ABCD). The AACE/ACE did not 
introduce the name as an actual replacement for the term obesity but instead as a means of 
helping the medical community focus on the pathophysiologic impact of excess weight.46 
Classification of obesity 
Although several classifications and definitions for degrees of obesity are accepted, the 
most widely accepted classifications are those from the World Health Organization 
(WHO), based on BMI. The WHO designations include the following: 
 Grade 1 overweight (commonly and simply called overweight) - BMI of 25-29.9 
kg/m 2 
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 Grade 2 overweight (commonly called obesity) - BMI of 30-39.9 kg/m 2 
 Grade 3 overweight (commonly called severe or morbid obesity) - BMI greater 
than or equal to 40 kg/m 2 
The cut-off for each grade varies according to an individual’s ethnic background. For 
example, a BMI of 23 kg/m2 or higher may define grade 1 overweight and 27.5 kg/m2 or 
higher may define grade 2 overweight (obesity) in many Asian populations, in which the 
risk was shown to be high and extremely high for grade 1 and 2 overweight at these levels, 
respectively. Other BMI cutoffs identified as potential public health action points in these 
populations are 32.5 and 37.5 kg/m2.45 
The surgical literature often uses a different classification to recognize particularly 
severe obesity. The categories are as follows: 
 Severe obesity - BMI greater than 40 kg/m 2 
 Morbid obesity - BMI of 40-50 kg/m 2 
 Super obese - BMI greater than 50 kg/m 2 
In children, a BMI above the 85th percentile (for age-matched and sex-matched control 
subjects) is commonly used to define overweight, and a BMI above the 95th percentile is 
commonly used to define obesity. 
Pathophysiology 
Hypertrophic versus hypercellular obesity 
The Adipocytes, which is the cellular basis for obesity, may be increased in size or 
number in obese persons. Hypertrophic obesity, characterized by enlarged fat cells, is 
typical of android abdominal obesity. Hypercellular obesity is more variable than 
hypertrophic obesity; it typically occurs in persons who develop obesity in childhood or 
adolescence, but it is also invariably found in subjects with severe obesity. 
Hypertrophic obesity usually starts in adulthood, is associated with increased 
cardiovascular risk, and responds quickly to weight reduction measures. In contrast, 
patients with hypercellular obesity may find it difficult to lose weight through nonsurgical 
interventions. 
Adipocytes 
Products 
The Adipocytes is increasingly found to be a complex and metabolically active 
cell. At present, the adipocyte is perceived as an active endocrine gland producing several 
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peptides and metabolites that may be relevant to the control of body weight; these are 
being studied intensively.66 
Many of the adipocytokines secreted by adipocytes are proinflammatory or play a 
role in blood coagulation. Others are involved in insulin sensitivity and appetite regulation. 
However, the function of many of these identified cytokines remains unknown or unclear. 
Proinflammatory products of the adipocyte include the following180 
 Tumor necrosis factor–alpha 
 Interleukin 6 
 Monocyte chemoattractant protein–1 (MCP-1) 
Other adipocyte products include the following  
 Lipotransin 
 Plasminogen activator inhibitor-1 (PAI-1) - Associated with cardiovascular risk 
 Adipocyte lipid-binding protein 
 Acyl-stimulation protein 
 Prostaglandins - Coagulation role 
 Adipsin 
 Perilipins 
 Lactate 
 Leptin - Appetite regulator 
 Adiponectin - Major role in insulin sensitivity 
 Monobutyrin 
 Phospholipid transfer protein 
Metabolism and function 
Critical enzymes involved in adipocyte metabolism and function include the following: 
 Endothelial-derived lipoprotein lipase - Lipid storage 
 Hormone-sensitive lipase - Lipid elaboration and release from adipocyte depots 
 Acyl-coenzyme A (acyl-CoA) synthetases - Fatty acid synthesis 
In addition, a cascade of enzymes is involved in beta-oxidation and fatty acid 
metabolism. The ongoing flurry of investigation into the intricacies of adipocyte 
metabolism has not only improved our understanding of the pathogenesis of obesity but 
has also offered several potential targets for therapy. 
Development 
Another area of active research is investigation of the cues for the differentiation of 
preadipocytes to adipocytes. The recognition that this process occurs in white and brown 
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adipose tissue, even in adults, has increased its potential importance in the development of 
obesity and the relapse to obesity after weight loss. 
Among the identified elements in this process are the following transcription factors: 
 Peroxisome proliferator-activated receptor–gamma (PPAR-gamma) 
 Retinoid-X receptor ligands 
 Perilipin 
 Adipocyte differentiation–related protein (ADRP) 
 CCAAT/enhancer-binding proteins (C/EBP) alpha, beta, and delta 
PPAR-gamma agonists increase the recruitment, proliferation, and differentiation of 
preadipocytes (healthy fat) and cause apoptosis of hypertrophic and dysfunctional 
adipocytes (including visceral fat). This results in improved fat function and improved 
metabolic parameters associated with excessive fat–related metabolic diseases (EFRMD), 
including type 2 diabetes mellitus, hypertension, and dyslipidemia.37 
Hormonal influences on appetite 
In addition to neurotransmitters and neurogenic signals, many hormones affect 
appetite and food intake. Endocannabinoids, through their effects on endocannabinoid 
receptors, increase appetite, enhance nutrient absorption, and stimulate lipogenesis. 
Melanocortin hormone, through its effects on various melanocortin receptors, modifies 
appetite. 
Several gut hormones play significant roles in inducing satiety, including 
glucagonlike peptide-1 (GLP-1), neuropeptide YY (PYY), and cholecystokinin. Leptin and 
pancreatic amylin are other potent satiety hormones. On the other hand, ghrelin, which is 
secreted from the stomach fundus, is a major hunger hormone. 
Odor detection threshold 
Smell plays an important role in feeding behavior. Differences in the odor detection 
threshold (ie, the lowest concentration of a substance detectable by the human olfactory 
sense) were found in a study that measured thresholds in 8 lean, fasted individuals before 
and during a 2-hour hyperinsulinemic euglycemic insulin clamp.37  
Increased insulin led to reduced smelling capacity, potentially reducing the 
pleasantness of eating. Therefore, insulin action in the olfactory bulb may be involved in 
the process of satiety and may be of clinical interest as a possible factor in the 
pathogenesis of obesity.31 
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Leptin 
Friedman and colleagues discovered leptin (from the Greek word leptos, meaning 
thin) in 1994 and ushered in an explosion of research and a great increase in knowledge 
about regulation of the human feeding and satiation cycle. Leptin is a 16-kd protein 
produced predominantly in white subcutaneous adipose tissue and, to a lesser extent, in the 
placenta, skeletal muscle, and stomach fundus in rats. Leptin has myriad functions in 
carbohydrate, bone, and reproductive metabolism that are still being unraveled, but its role 
in body-weight regulation is the main reason it came to prominence. 
Since this discovery, neuromodulation of satiety and hunger with feeding has been 
found to be far more complex than the old, simplistic model of the ventromedial 
hypothalamic nucleus and limbic centers of satiety and the feeding centers of the lateral 
hypothalamus. Potentially, leptin sensitizers may assist in changing feeding habits. 
The major role of leptin in body-weight regulation is to signal satiety to the 
hypothalamus and thus reduce dietary intake and fat storage while modulating energy 
expenditure and carbohydrate metabolism, preventing further weight gain. Unlike the 
Ob/Ob mouse model in which this peptide was first characterized, most humans who are 
obese are not leptin deficient but are instead leptin resistant. Therefore, they have elevated 
levels of circulating leptin. Leptin levels are higher in women than in men and are strongly 
correlated with BMI.50 
Patients with night-eating syndrome have attenuation of the nocturnal rise in 
plasma melatonin and leptin levels and higher circadian levels of plasma cortisol. These 
individuals have morning anorexia, evening hyperphagia, and insomnia. In one study, 
patients with night-eating syndrome averaged 3.6 awakenings per night; 52% of these 
awakenings were associated with food intake, with a mean intake per ingestion of 1134 
kcal. [38] 
Genetics 
Mutations resulting in defects of the leptin receptor in the hypothalamus may 
occur. These mutations result in early onset obesity and hyperphagia despite normal or 
elevated leptin levels, along with hypogonadotropic hypogonadism, and defective 
thyrotropin secretion. 
Murray et al first reported on a sequence variant within the leptin gene that 
enhances the intrinsic bioactivity of leptin, but which was associated with reduced weight 
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rather than obesity.62 This sequence variant within the leptin gene is also associated with 
delayed puberty. 
Measurements of obesity 
Obesity represents a state of excess storage of body fat. Although similar, the term 
overweight is puristically defined as an excess of body weight for height. Normal, healthy 
men have a body fat percentage of 15-20%, while normal, healthy women have a 
percentage of approximately 25-30%.181  However, because differences in weight among 
individuals are only partly the result of variations in body fat, body weight is a limited, 
although easily obtained, index of obesity. 
The body mass index (BMI), also known as the Quetelet index, is used far more 
commonly than body fat percentage to define obesity. In general, BMI correlates closely 
with the degree of body fat in most settings; however, this correlation is weaker at low 
BMIs. 
An individual’s BMI is calculated as weight/height2, with weight being in 
kilograms and height being in meters (otherwise, the equation is weight in pounds ´ 
0.703/height in inches2). Online BMI calculators are available. 
A person’s body fat percentage can be indirectly estimated by using the 
Deurenberg equation, as follows 
Body Fat Percentage = 1.2(BMI) + 0.23(age) - 10.8(sex) - 5.4 
with age being in years and sex being designated as 1 for males and 0 for females. 
This equation has a standard error of 4% and accounts for approximately 80% of 
the variation in body fat. 
Although the BMI typically correlates closely with percentage body fat in a 
curvilinear fashion, some important caveats apply to its interpretation. In mesomorphic 
(muscular) persons, BMIs that usually indicate overweight or mild obesity may be 
spurious, whereas in some persons with sarcopenia (eg, elderly individuals and persons of 
Asian descent, particularly from South Asia), a typically normal BMI may conceal 
underlying excess adiposity characterized by an increased percentage of fat mass and 
reduced muscle mass. 
In view of these limitations, some authorities advocate a definition of obesity based 
on percentage of body fat. For men, a percentage of body fat greater than 25% defines 
obesity, with 21-25% being borderline. For women, over 33% defines obesity, with         
31-33% being borderline. 
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Other indices used to estimate the degree and distribution of obesity include the 4 
standard skin thicknesses (ie, sub scapular, triceps, biceps and suprailiac) and various 
anthropometric measures, of which waist and hip circumferences are the most important. 
Skinfold measurement is the least accurate means by which to assess obesity. 
Dual-energy radiographic absorptiometry (DXA) scanning is used primarily by 
researchers to accurately measure body composition, particularly fat mass and fat-free 
mass. It has the additional advantage of measuring regional fat distribution. However, 
DXA scans cannot be used to distinguish between subcutaneous and visceral abdominal fat 
deposits. 
The current standard techniques for measuring visceral fat volume are abdominal 
computed tomography (CT) scanning (at L4-L5) and magnetic resonance imaging (MRI) 
techniques. A simpler technique, using bioelectrical impedance, was recently 
introduced.185 
Fig. No. 2: Medical complications of Obesity 
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Co morbidities of Obesity 
Apart from total body fat mass, the following aspects of obesity have been 
associated with co morbidity 
 Fat distribution 
 Waist circumference 
 Age of obesity onset 
 Intra-abdominal pressure 
Fat distribution 
Accumulating data suggest that regional fat distribution substantially affects the 
incidence of co morbidities associated with obesity.19 Android obesity, in which adiposity 
is predominantly abdominal (including visceral and, to a lesser extent, subcutaneous), is 
strongly correlated with worsened metabolic and clinical consequences of obesity. 
Waist circumference 
The thresholds used in the National Cholesterol Education Program Adult 
Treatment Panel III definition of metabolic syndrome169 state that significantly increased 
cardiovascular risk (metabolic central obesity) exists in men with waist circumferences of 
greater than 94 cm (37 in) and in women with waist circumferences of greater than 80 cm 
(31.5 in), as well as waist-to-hip ratios of greater than 0.95 in men and of greater than 0.8 
in women. Circumferences of 102 cm (40 in) in men and 88 cm (35 in) in women indicate 
a markedly increased risk requiring urgent therapeutic intervention. 
These thresholds are much lower in Asian populations. After analyzing survey 
results of Chinese, Malay, and Asian-Indian cohorts, Tan and colleagues concluded that a 
waist circumference of greater than 90 cm in men and of more than 80 cm in women were 
more appropriate criteria for metabolic central obesity in these ethnic groups.170 
Age of obesity onset 
An elevated BMI during adolescence (starting within the range currently 
considered normal) is strongly associated with the risk of developing obesity-related 
disorders later in life, independent of adult BMI.80 Increases in BMI during early adulthood 
(age 25-40 y) are associated with a worse profile of biomarkers related to obesity than are 
BMI increases during later adulthood.186 This is consistent with most emerging data 
regarding timing of changes in BMI and later health consequences. 
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Intra-abdominal pressure 
Apart from the metabolic complications associated with obesity, a paradigm of 
increased intra-abdominal pressure has been recognized. This pressure effect is most 
apparent in the setting of marked obesity (BMI ≥ 50 kg/m2) and is espoused by bariatric 
surgeons.48 
Findings from bariatric surgery and animal models suggest that this pressure elevation 
may play a role (potentially a major one) in the pathogenesis of comorbidities of obesity, 
such as the following56 
 Pseudotumor cerebri 
 Lower-limb circulatory stasis 
 Ulcers 
 Dermatitis 
 Thrombophlebitis 
 Reflux esophagitis 
 Abdominal hernias 
 Possibly, hypertension and nephrotic syndrome 
Additional comorbidities 
Overweight and obese individuals are at increased risk for the following health conditions: 
 Metabolic syndrome 
 Type 2 diabetes 
 Hypertension 
 Dyslipidemia 
 Coronary heart disease 
 Osteoarthritis 
 Stroke 
 Depression 
 Non-alcoholic fatty liver disease (NAFLD) 
 Infertility (women) and erectile dysfunction (men) 
 Risk of stillbirth [24, 25] 
 Gall bladder disease 
 Obstructive sleep apnea 
 Gastroesophageal reflux disease (GERD) 
 Some cancers (eg, endometrial, breast, and colon)184,155,71  
 Asthma 
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Pickwickian syndrome 
The so-called Pickwickian syndrome is a combined syndrome of obesity-related 
hypoventilation and sleep apnea. It is named after Charles Dickens’s novel The Pickwick 
Papers, which contains an obese character who falls asleep constantly during the day. 
The hypoventilation in Pickwickian syndrome results from severe mechanical 
respiratory limitations to chest excursion, caused by severe obesity. The sleep apnea may 
be from obstructive and/or central mechanisms. Obstructive sleep apnea is common among 
men with collar size greater than 17 in (43 cm) and women with collar size greater than 16 
in (41 cm). 
Increased and decreased sleep duration 
Sleep duration of less than 5 hours or more than 8 hours was associated with 
increased visceral and subcutaneous body fat, in a study of young African Americans and 
Hispanic Americans.88 This association relates mostly to decreased leptin hormone and 
increased ghrelin hormone levels.74 
Causes 
The etiology of obesity is far more complex than simply an imbalance between energy 
intake and energy output. Although this view allows easy conceptualization of the various 
mechanisms involved in the development of obesity, obesity is far more than simply the 
result of eating too much and/or exercising too little (see the energy-balance equation, 
below). 
Possible factors in the development of obesity include the following: 
 Metabolic factors 
 Genetic factors 
 Level of activity 
 Endocrine factors 
 Race, sex, and age factors 
 Ethnic and cultural factors 
 Socioeconomic status 
 Dietary habits 
 Smoking cessation 
 Pregnancy and menopause 
 Psychological factors 
 History of gestational diabetes 
 Lactation history in mothers 
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International statistics 
The prevalence of obesity worldwide is increasing, particularly in the industrialized 
nations of the Northern hemisphere, such as the United States, Canada, and most countries 
of Europe. Available data from the Multinational Monitoring of Trends and Determinants 
in Cardiovascular Disease (MONICA) project suggest that at least 15% of men and 22% of 
women in Europe are obese.79,37  
Similar data are being reported in other parts of the world, including from many 
developing nations. Reports from countries such as Malaysia, Japan, Australia, New 
Zealand, and China have detailed an epidemic of obesity in the past 2-3 decades. Data 
from the Middle Eastern countries of Bahrain, Saudi Arabia, Egypt, Jordan, Tunisia, and 
Lebanon, among others, indicate this same disturbing trend, with levels of obesity often 
exceeding 40%. 
Internationally, rates of obesity are higher in women than in men. A somewhat 
higher rate would be expected, given the biologically higher percentage of body fat in 
women. 
Information from the Caribbean and from South America highlights similar trends. 
Although data from Africa are scant, a clear and distinct secular trend of profoundly 
increased BMIs is observed when people from Africa emigrate to the northwestern regions 
of the world. Comparisons of these indices among Nigerians and Ghanaians residing in 
their native countries with indices in recent immigrants to the United States show this 
trend poignantly. 
Conservative estimates suggest that as many as 250 million people (approximately 
7% of the estimated current world population) are obese. Two to 3 times more people than 
this are probably overweight. Although socioeconomic class and the prevalence of obesity 
are negatively correlated in most industrialized countries, including the United States, this 
correlation is distinctly reversed in many relatively undeveloped areas, including China, 
Malaysia, parts of South America, and sub-Saharan Africa. 
Finucane et al conducted a comprehensive, constructive study that revealed 
growing global trends in BMI. This study may serve as wake-up call and initiate large-
scale interventions in an effort to combat increasing body weight and associated adverse 
health consequences.169 
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Race-related demographics 
Obesity is a cosmopolitan disease that affects all races worldwide. However, 
certain ethnic and racial groups appear to be particularly predisposed. The Pima Indians of 
Arizona and other ethnic groups native to North America have a particularly high 
prevalence of obesity. In addition, Pacific islanders (eg, Polynesians, Micronesians, 
Maoris), African Americans, and Hispanic populations (either Mexican or Puerto Rican in 
origin) in North America also have particularly high predispositions to the development of 
obesity. 
Secular trends clearly emphasize the importance of environmental factors 
(particularly dietary issues) in the development of obesity. In many genetically similar 
cohorts of high-risk ethnic and racial groups, the prevalence of obesity in their countries of 
origin is low but rises considerably when members of these groups emigrate to the affluent 
countries of the Northern Hemisphere, where they alter their dietary habits and activities. 
These findings form the core concept of the thrifty gene hypothesis espoused by Neel and 
colleagues.48 
The thrifty gene hypothesis posits that human evolution favored individuals who 
were more efficient at storing energy during times of food shortage and that this historic 
evolutionary advantage is now a disadvantage during a time of abundant food availability. 
Age-related demographics 
Children, particularly adolescents, who are obese have a high probability of 
becoming adults who are obese; hence, the bimodal distribution of obesity portends a 
large-scale obesity epidemic in the next few decades. Taller children generally tend to be 
more obese than shorter peers, are more insulin-resistant, and have increased leptin 
levels. [64] 
Adolescent obesity poses a serious risk for severe obesity during early adulthood, 
particularly in non-Hispanic black women. This calls for a stronger emphasis on weight 
reduction during early adolescence, specifically targeting groups at greater risk.85 
Diagnosis 
Laboratory studies 
 Fasting lipid panel 
 Liver function studies 
 Thyroid function tests 
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 Fasting glucose and hemoglobin A1c (HbA1c) 
Evaluation of degree of body fat 
BMI calculation, waist circumference, and waist/hip ratio are the common measures 
of the degree of body fat used in routine clinical practice. Other procedures that are used in 
few clinical centers include the following: 
 Caliper-derived measurements of skin-fold thickness 
 Dual-energy radiographic absorptiometry (DEXA) 
 Bioelectrical impedance analysis 
 Ultrasonography to determine fat thickness 
 Underwater weighing 
Physical Examination 
In the clinical examination, measure anthropometric parameters and perform the 
standard, detailed examination required in evaluating patients with any chronic, 
multisystem disorder, such as obesity. 
Waist and hip circumference are useful surrogates in estimating visceral fat; serial 
tracking of these measurements helps in estimating the clinical risk over time. Neck 
circumference is predictive of a risk of sleep apnea, and its serial measurement in the 
individual patient is clinically useful for risk stratification.169 
Examination of organ systems should include the following: 
 Cutaneous - Search for intertriginous rashes from skin- on- skin friction; also search 
for hirsutism in women, acanthosis nigricans, and skin tags, which are common with 
insulin resistance secondary to obesity 
 Cardiac and respiratory - Exclude cardiomegaly and respiratory insufficiency 
 Abdominal - Attempt to exclude tender hepatomegaly, which may suggest hepatic 
fatty infiltration or NASH, and distinguish the striae distensae from the pink and 
broad striae that suggest cortisol excess 
When examining the extremities, search for joint deformities (eg, coxa vara), 
evidence of osteoarthritis, and any pressure ulcerations. Localized and lipodystrophic fat 
distribution should also be identified, because of their common association with insulin 
resistance. 
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Management 
Treatment of obesity starts with comprehensive lifestyle management (ie, diet, 
physical activity, behavior modification).62 The 3 major phases of any successful weight-
loss program are as follows: 
 Preinclusion screening phase 
 Weight-loss phase 
 Maintenance phase - This can conceivably last for the rest of the patient's life but 
ideally lasts for at least 1 year after the weight-loss program has been completed 
Surgery 
Among the standard bariatric procedures are the following: 
 Roux-en-Y gastric bypass 
 Adjustable gastric banding 
 Gastric sleeve surgery 
 Vertical sleeve gastrectomy 
 Horizontal gastroplasty 
 Vertical-banded gastroplasty 
 Duodenal-switch procedures 
 Biliopancreatic bypass 
 Biliopancreatic diversion 
Medications 
Currently, the 3 major groups of drugs used to manage obesity are as follows: 
 Centrally acting medications that impair dietary intake 
 Medications that act peripherally to impair dietary absorption 
 Medications that increase energy expenditure 
1. 2. 1. Anorexiants and Treatment of Obesity147, 139, 118 
Regulation of energy balance 
Obesity is a disorder of energy balance. Hypothalamus is a major centre that 
regulates food consumption by modulating hunger and satiety. It intergrates neural, 
hormonal and nutrient messages from elsewhere and sends signals to higher centres, 
leading to the feeling of hunger or satiety, Hypothalamus also controls the energy 
expenditure via the adrenergic nervous system and the pituitary hormones. 
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The central control of body weight is a complex phenomenon, not well understood, 
regulated by Multiple brain nuclei and many neurotransmitters  of these neuropeptide Y  
is the most potent appetite stimulant and is abundantly present in the hypothalamus.  It also 
suppresses sympathetic activity and thus reduces energy expenditure. 
Neuropeptides affecting energy balance: 
 Increase food intake 
Noradernaline, GHRH Neuropeptide Y, Ghrelin, Opioids,Endogenous 
Cannabinoids. 
 Inhibit food intake 
5-HT, Dopamine, Cholecystikinin (CCK), CRH, Neurotensin, Bombesin and 
Glucagon-like peptide, a MSH 
Treatment of Obesity   
Principles of treatment of Obesity 
 Nutritionally adequate, low calorie diet, containing at least 1 gm of protein/kg 
of desirable body weight. 
 Fat intake below 25% of total calories prescribed. 
 Liberal use of fiber- containing foods 
 Regular exercise 
 Behavioural Therapy for change  in life-style 
 Anorectic drugs – as adjunctive therapy 
In an obese individual if an organic cause such as an endocrine disease is present, it 
should be treated. Commonly obesity is due to excessive eating and lack of adequate 
excerise. The patient must be made to appreciate this at the beginning of the treatment and 
explained that diet is the mainstay of treatment of obesity;   he/she adequately motivated 
by the concept of ‘positive health’. It must also be emphasized that dietary treatment of 
obesity consists of a lifelong reorientation of his eating habits (and often those of his 
family) and not merely of a ‘course’ of dieting .Those who look upon dieting as a course 
of treatment are bound to regain the lost weight.  
There are many diets for obesity. It has, however, been established that nothing 
about the diet matters except its calorie content. Hence, the best diet is one which is low in 
calorie content (1000-1500 per day), contains all the essential nutrients, provides a variety 
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and is simple for the patient to follow for prolonged periods. Drastic one-step calorie 
reduction may not be tolerated by patient; it is better to reduce the daily calorie intake 
progressively in steps of 500 calories.  
The results of therapy are likely to be more satisfactory in hypertrophic obesity 
(enlarged, distended fat cells, with usual onset in adult life) than in the hyper plastic 
variety (more numerous fat cells, with usual onset in childhood).  
The patient should be told at the onset of therapy that an average weekly loss of 
0.5-0.8 kg is adequate and would result in annual  loss of about 25 kg. This can be 
achieved by consuming 500-1000 fewer calories per day.  
Classification of drugs used for obesity 
I Centrally acting, appetite Suppressants (Anorexiants) 
 Adrenergic agents eg : Benzamphetamine, Phentermine, Mazindol, 
Phendimetrazine , Diethylpropion 
 5-HT agonists   eg. Fenfluramine, Dexfenfluramine, Fluoxetine, Lorcaserin. 
 Drugs acting on both adrenergic and  5 – HT systems  eg  Sibutramine 
 Cannabinoid receptor antagonists   eg  Rimonabant 
II Drugs acting in the GI tract  
 Bulk  anorexiants eg. Dietary fibre, Methylceelulose, Guargum. 
 Non-absorbable fat substitutes eg.  Olestra 
 Lipase inhibitors eg. Orlistat  
III Drugs combinations   
 Eg:  Phenteramine + Topiramate, Bupropion + Naltrexone 
IV Miscellaneous   Eg: Metformin  
Anorexiants   
Amphetamine and related compounds:   
 Their anorexiant effect appears to be related to central relase of DA and NA from 
the adrenergic cells.  They also inhibit the reuptake of NA and DA. Their major drawbacks 
are drug dependence and sympathomimetic ADR like hyper tension, tachycardia, insomnia 
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and nervousness. Hence, sympathomimetics are rarely recommended in the treatment  of 
obesity Methylamphetamine is highly addictive and is extensively abused. 
 Other related drugs are phenteramine, phendimetrazine, mazindol and 
diethylpropion. 
Fenfluramine:   This drug, once used extensively, acts by increasing the brain 
synaptic 5-HT by accelerating it’s release and reducing its re-Uptake. However, it was 
found to cause cardiac valvular injury and primary pulmonary hypertension. It has been 
withdrawn from the market. 
Fluoxetine:  This 5-HT reuptake inhibitor antidepressant , in the dose of 
60mg/day, is associated with weight loss ; but its long term use should be avoided in view 
of the experience with fenfluramine. 
Lorcaserin:  This is a selective central 5HT2 receptor agonist. It suppreses  the 
appetite. It has a t1/2 of 11 hours and is extensively metabolised by the liver. Headache, 
nausea,dizziness and euphoria ( at doses > 40mg) are the frequently reported adverse 
effects. Lorcaserin inhibits CYP 2D6 and hence increases the concentration of other drugs 
metabolised by this enzyme (eg.dextromethorphan). 
It took over 30years to detect the serious adverse reaction to fenfluramine.  This 
emphasies the vital importance of continued and vigilant post-marketing adverse drug 
reaction surveillance. Similar long term toxicity is likely to occur following the use of oter 
drugs acting as 5-HT agonists. 
Sibutramine and rimonabant   are no more used because of their cardio vascular 
and neuropsychiatric toxicity respectively. 
Limitations of centrally acting anorexiants  
 Short term efficacy 
 Relapse of weight gain 
 Possible toxicity during long term therapy; 
 Weight cycling as a result of drug holiday, leading to adverse outcomes such as 
coronary heart disease; and 
 Inability to prevent obesity- related illnesses and to prolong life 
 Poor compliance 
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Drugs acting in the GI tract  
Bulk  anorexiants  
Methylcellulose, a non-digestible polysaccharide, when ingested, swells and adds 
to the bulk in the diet. Though used as an appetite satiator, it is no more effective than the 
high residue low caloric diet for the obvious reason that an obese person is interested in 
eating good food and not something that would merely distend the stomach. It forms an 
important, cheap constitutent of many ‘costly’ commercial preparations advertised for the 
treatment of obesity. Guar gum, Karaya gum (Sterculia gum, Kanormal) and 
glucomannan are the other bulking agents. 
Digestion inhibitors 
Olestra 
This is a mixture of sucrose – fatty – acid esters that is neither digested nor 
absorbed from the GI tract. When used as a component of diet, it increases the bowel 
function and stool bulk. It is recommended as a fat substitute in cooking. Long term effects 
on the health are yet not fully known. It is expensive. 
Orlistat  
Orlisatat (Tetrahydrolipostatin) is related to a lipase inhibitor, lipostatin produced 
by the mould, streptomyces  toxytricini.  It acts by inhibiting pancreatic and other lipases 
including phospholipase A2. It is not absorbed and the effects are confined to the GI tract, 
where it prevents the lipase-catalysed breakdown (GI lipase inhibiton ) of TG and  
subsequent absorption of about 1/3rd of the dietrary fat. The additional benefit is a modest 
reduction in the plasma levels of total cholesterol and LDL cholesterol but not of TG. It is 
modestly effective and causes weight loss over 1-4 years. It is almost completely excreted 
unchanged in feces. The common adverse effects are abdominal pain, flatulence,increased 
defecation of oily /fatty stools with anal leaking ,which can be inconvenient and socially 
embarrassing.  
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Drug Combinations 
(a)Phenteramine   in combination  with topiramate, an antiepileptic, given as OD cause 
dose dependent weight loss. However because of ADR, the discontinuation rate is nearly 
40%. Topiramate is also a carbonic anhydrase inhibitor and can cause metabolic acidosis. 
(b)Bupropion ,  a week antidepressant , also stimulates hypothalamic neurons to produce 
anorexigenic effects. However, these neurons also secrete beta endorphin, an endogenous 
opioid, which counters this action. Hence, bupropion is combined with naltrexone, an 
opioid antagonist. The combinations are reported to cause weight loss but the effect may 
not be sustained.  
Miscellaneous:   The antidiabetic, metformin induces weight loss in diabetic and some 
nondiabetic obese subjects. 
Experts recommend that drugs may be considered in adults with a BMI of over 27 
in the presence of an obesity-related complication and in those with a BMI of over 30 even 
in the absence of such a complication. For persons with a BMI of over 40,bariatric surgery 
may be considered. As Obesity is a chronic disease and as relapse is common after 
cessation of drug therapy, prolonged, lifelong, drug therapy may be desirable. However, 
none of the available drugs is safe enough for prolonged use. They also fail to maintain 
weight loss over 10% in a year. Evidence suggests that combined drug therapy is no better 
than drug monotherapy. Irrespective of the drugs used, if significant weight loss does not 
occur within 4-6 months of therapy, the drug is discontinued. Drug should not be used 
simply for cosmetic weight control. 
Thus the treatment of obesity mainly depends on permanent lifestyle modifications 
such as change in eating habits and regular physical excerise, supported by behavioural 
therapy. 
Some drugs causing anorexia 
 Aminophylline 
 Amphetamines and related drugs 
 Antimicrobials:  Metronidazole, Fluoroquinolones, Erythromycin , 
Nitrofurantion, Tetracycline 
 Antimalarials 
 Metformin  
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 Digitalis 
 Levodopa 
Drugs which may cause weight gain 
 Antipsychotics,   especially Olanzapine 
 Antidepressants:   Tricyclics, SSRI,MAOI, Mirtazapine 
 Hormones: Glucocorticoids , Insulin Progestogens, Oral Contaceptives and 
Danazol 
 Beta Blockers 
 Oral Hypoglycemic agents : SulfonylUreas, Glitazones 
 Anticonvulsants: Phenytoin , Sodium Valproate 
 Antihistaminics, especially the first generation agents Pizotifen 
1. 3. ANTIHYPERLIPIDEMIC DRUGS172, 148,135,119 
Fig. No. 3: Formation of Plaque in the Coronary artery 
 
Antihyperlipidemic Drugs   
These drugs act predominantly on: 
 Elevated Cholesterol, e.g HMG-CoA reductase inhibitos (statins), Cholestyramine 
resin, Ezetimibe Fibre: 
 Elevated triglycerides,eg Fibric acid derivatives (fibrates),Fish oil or 
 Both, eg; Nicotinic acid  
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STATINS (HMG – CoA - reductase inhibitors) 
Table No. 1: Statins and dose recommended 
Statins          High intensity statin  
therapy (mg/day)                
Moderate intensity statin 
therapy (mg/day) 
Atorvastatin  40 to 80 10 to 20 
Rosuvastatin  20 to 40 5 to 10 
Simvastatin - 20 to 40 
Pravastatin  - 40 to 80 
Lovastatin - 40 
Fluvastatin - 80 as extended release; if 40 
twice a day 
Pitavastatin - 2 to 4 
Mechanism of action 
Normally, about 70-75% of plasma LDL is removed by hepatocytes, by receptor – 
mediated endocytosis. Cholesterol esters from LDL molecules are hydrolysed in the liver 
to free cholesterol. The liver also produces cholesterol by de now synthesis by a pathway 
involving formation of mevalonic acid by the enzyme Hydroxy Methyl Glutaryl Co -
enzyme A reductase (HMG -CoA reductase). Statins inhibit this rate -limiting enzyme.  
This decreases hepatic cholesterol synthesis, which leads to increased synthesis of high 
affinity LDL receptors (up regulation) on the surface of liver cells. This results into 
increased clearance (uptake) of cholesterol-rich plasma LDL with subsequent. 
Hepatic regulation of synthesis of Cholesterol and bile acids 
Site of action of statins;(II) Site of action of resins and ezetimibe reduction in 
plasma LDL cholesterol This action is dose dependent and is observed in 10 days. Full 
effect is generally seen within 6 weeks. Effect of statins on HDL-C is variable. 
Absorption, fate and excretion  
Given orally, the absorption of all the statins (except fluvastatin) varies between 
40% and 90% .Fluvastatin is absorbed almost completely.Lovastatin and simvastatin are 
prodrugs and are hydrolysed in the GI tract to the active metabolites. Atorvastatin, 
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fluvastatin and rosuvastatin are fluorinated compounds that are active as such. All undergo 
first pass metabolism and most of the dose is excreted in the bile; only about 5-20% is 
excreted in the urine. 
Adverse reactions 
Generally statins are well tolerated.  ADR are mostly mild and dose dependent. 
They may cause reversible rise in hepatic aminotransferase levels. Small rise in the plasma 
creatine kinase level is not uncommon. Rarely it may be marked and accompanied by 
muscular pains (myositis) and even myopathy. Rhabdomyolysis is rare. 
Rarely, Statins may cause impotence, gynecomastia, peripheral neuropathy, 
memory loss, insomnia, mood changes and depression. 
Clinical trials demonstrate that statins may increase the risk of new-onset diabetes 
but incidence is not as much as they reduce the cardiovascular risk. 
Statins are contraindicated in pregnancy and in a woman planning to become 
pregnant, during breast-feeding, in children and in patients with severe liver disease. 
Drug interactions 
Combination of a statin with a fibric acid derivative and nicotinc acid potentiates 
the rise in plasma  CPK level. 
Lovastatin, Simvastatin and atorvastatin undergo extensive first pass metabolism 
by CYP3A4 and their toxicity can be increased by the concurrent use of hepatic 
microsomal enzyme inhibitors. Fluvastatin and rosuvastatin are metabolized by hepatic 
CYP2C9. Inhibitors of this enzyme such as ketoconazole, metronidazole and cimetidine 
can increase the plasma levels of these statins. 
Maximum dose of simvastatin recommended is 10mg in patients taking 
amiodarone,diltiazem or verapamil and 20mg/day in those on amlodipine and ranolazine. 
Therapeutic uses 
Statins are useful in both primary and secondary prophylaxis of hypercholesterolemia. 
Their main indications are  
 MI or any cardiovascular event 
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 Patients less than 70 years with known IHD 
 Familial hypercholesterolemia 
 Diabetes mellitus 
 Subjects with strong family history of premature cardiovascular disease. 
Statins used alone in maximum doses, can lower LDL level by 30-50%. Statin 
therapy can reduce the 5 year incidence of major coronary events, and stroke significantly, 
largely irrespective of the initial lipid level. 
In general statins are more effective in subjects with high risk factors than a 
particular LDL cholesterol level. Currently they are indicated in : 
(i) Individuals with clinical evidence of atherosclerotic cardiovascular disease 
(ASCVD) eg IHD,MI 
(ii) Subjects with primary elevation of LDL cholesterol >190mg% 
(iii) Subjects with age 40-75 years with diabetes mellitus and LDL cholesterol 
between 70-189mg % without clinical evidence of ASCVD 
(iv) Subhects with age 40-75 years, having LDL cholesterol between 70-189 mg% 
with no evidence of diabetes mellitus or ASCVD but having estimated 10 years 
ASCVD risk of 7.5% or higher. This risk is calculated based on the presence of 
risk factors in a given patient. 
Patients with clinical evidence of ASCVD and those with LDL 
cholesterol>190mg% are treated with high intensity statin therapy, which reduces 
LDL-cholesterol by >50%. Others are treated with high intensity statin 
therapy,wherein a decrease by 30 to 50 %  is expected  
There is no unanimity about what can be considered as an “ideal” level of 
serum cholesterol and hence currently importance is given to the clinically relevant 
risk factors rather than chasing a particular target level for LDL cholesterol. 
Routine use of statin in subject with>75 years and without evidences of ASCVD 
and those with NYHA class II, III and IV HF do not seem to be benefitted. 
Statins also possess other lipid-independent effects. These are 
 Decrease in platelet aggregation and in fibrinogen levels. 
 Improvement in endothelial function and increase in local NO production 
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 Decrease in macrophage infiltration into the vessel wall 
 Decrease in the arterial muscle proliferation 
 Retardation of the progression of hypertrophy of the vessel wall; and 
 Decrease LDL oxidation in the vessel wall  
These effect contribute to anti-inflammatory potential of statins, 
Choice of Statin 
Therapeutically there are no clear differences among various statins. Hence the 
choice of statins depends upon the degree of LDL elevation, drug pharmacokinetics, drug 
interactions, presence of hepatic/renal disease and cost. Atorvastatin and simvastatin are 
more efficacious than others, and therefore may be preferred. Atorvastatin and fluvastatin 
need no dose adjustment in patients with renal impairment. Pravastatin and fluvastatin are 
not metabolized by CYP3A4 and are likely to cause few drug interactions. Atorvastatin 
and rosuvastatin jave long t1/2 (14 and 19 hours, respectively) and can be taken at any time 
of the day 
Since most cholesterol synthesis occurs during the night the short t1/2 compounds 
are best administered at night as a single dose. 
Table No. 2: Doses of commonly used statins in Asia Population 
Statins Starting/Max.Dose (mg/day) 
Atorvastatin 10/40 
Rosuvastatin 2.5/20 
Simvastatin 5/20 
Pravastatin 10/20 
Lovastatin 10/80 
Fluvastatin 20/60 
Note: Atorvastatin may be given at any time of the day; Paravstatin and Fluvastatin at 
bedtime; others with evening meal. 
Ezetimibe 
This prodrug 2-azetidinone, is converted in intestine to an active metabolise 
ezetimibe glucuronide (t1/2-22hr). It binds to a intestinal mucosal transporter and 
decreases delivery of dietary and biliary cholesterol to the liver. Thus, it inhibits absorption 
of cholesterol by the small intestine. Reduction of hepatic cholesterol stores casuses 
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increases in LDL receptors on the hepatocytes ( up-regulartion) and an increased LDL 
cholesterol clearance from the circulation. The plasma total and LDL cholesterol decreases 
with minimal increase in HDL-C table 40.1.It also interrupts the entero-hepatic cycling of 
cholesterol. It is 90% bound to plasma proteins and is largely excreted in the faeces. 
Adverse reactions are fatigue, dizziness, headache, abdominal discomfort, 
diarrhea, arthralgia and hypersensitivity reactions. 
Therapuetic uses- It can be used as monotherapy in the dose of 5-10mg day. 
However, it acts synergistically when combined with statins and is particularly useful in 
patients who do not tolerate large doses of statins. However, this decreases the progress of 
atherosclerosis. It should be avoided in children and in pregnant/lactating women. 
Cholestyramine Resin 
This insoluble chloride salt of a basic anion exchange resin, has a strong affinity for 
bile salts (cholates) in the intestine. It bind the cholates into an insoluble complex which is 
excreted in faeces(fig 40.1) The result is decreased absorption of exogenous cholesterol 
and increased metabolism of endogenous cholesterol in to bile acids in the liver. This lead 
to increased LDL receptors on liver cells and increased removal of LDL from the 
circulation. The drug, however, does not significantly lower the plasma levels of 
triglycerides. The dose is 12-24g per day in a single or divided doses. 
Adverse Reactions 
These include nausea,vomiting,heartburn and constipation. Large doses may 
interfere with absorption of fats and fat soluble vitamins, causing steatorrhoea. It also 
interferes with the absorption of thyroid hormones, tetracyclines, warfarin, digoxin and 
phenobarbitone. 
 It is now rarely used to treat hyperlipidemia It may be useful in relieving pruritus 
associated with biliary cirrhosis and cholestatic jaundice. 
Colestipol and Colesevalam like cholestyramine are bile acid sequestrants. 
Gugulipid- This is the steroidal fraction derived from the plant commiphora mukul 
and has moderate and variable hypocholesterolemic activity. It is well tolerated. It is 
available as 25 mg tablets. 
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Fibre -  Soluble fibres (pectins in citrus fruits, mucilages in psyllium seeds, gums 
in oat products and in beans) have a modest effect in lowering serum cholesterol. Psyllium 
seeds (Isapgol) is administered in the dose of 2.5-5g twice a day; oat bran is used in the 
dose of 50-150g a day. Insoluble fibre such as is present in wheat bran is not effective in 
lowering serum cholesterol 
Fibrates are the derivatives of fibric (isobutyric) acid and include 
gemfibrozil,bezafibrate and fenofibrate. Clofibrate is no more used 
Mechansim of action 
These drugs stimulate the nuclear transcription receptor, Peroxisome proliferator 
Activated Receptor alpha (PPAR-α) that controls the expression of genes, which 
mediate Tg metabolism. They increase lipoprotein lipase (lpL) activity and the hydrolysis 
of TG and promote HDL production. They reduce the incorporation of fatty acid into 
VLDL in the liver, this inhibiting its synthesis and secretion. The plasma TG declines by 
50% and cholesterol by 10-15% HDL increases by 20%. They are claimed to reduce 
plasma fibrinogen levels to increase fibrinolysis and to reduce abnormal platelet stickiness.  
Absorption, fate and excretion-   They are almost completely absorbed from the 
gut, are highly protein bound (more than 90%) They are largely excreted unchanged in the 
urine.  
Adverse reactions- Fibrates are generally well tolerated although, they 
occasionally produce allergic reactions,nausea  and diarrhoea. Though rare, potentially 
serious effects on the skeletal (myositis) and cardiac muscle have been reported. Fibrates 
should be avoided in patients with renal or hepatic damage and in alcoholics (with 
hypertriglyceridemia) who are predisposed to myositis. Long term therapy is associated 
with an increase in gall stone formation. The combination of a fibrate and a stain increases 
the chance of rhabdomyolysis and myopathy. These drugs displace acidic drugs from their 
plasma protein binding and may enhance the action of warfarin and sulfonylureas. 
Preparations and dosage 
(i) Fenofibrate: 67,134,200 mg single dose capsules. Dose: one capsule OD 
with a meal. 
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(ii) Gemfibrozil 300 mg capsules. Dose 600 mg twice a day 30 minutes before 
meals. 
(iii) Bezafibrate: 200 mg tablets.  Doses: 200 mg three times a day with meals. 
Therapeutic Uses 
These drugs are effective in reducing mainly plasma TG Fenofibrate is preferred to 
gemfibrozil. 
Fish oil 
Epidemiological evidence suggests that fatty fish eating communities have a lower 
incidence of IHD than non-fish-eaters. Omega 3 PUFA in the fish oil decreses hepatic 
production of TG and increases its clearance. Thus they reduce plasma TG but have little 
effect on HDL and LDL cholesterol and can sometimes increase total cholesterol upto 50% 
They  also lead to synthesis of leukotrienes and prostaglandins of series 1 and 3 , which are 
less pro inflammatory than those of series 2. Unlike gemfibrozil and niacin, omega-3- 
PUFAs do not interact with statins to enhance the incidence of myositis. They may 
decerase the risk of cardiac death in recent MI.  But, in chronic IHD there is a possibility 
of a proarrhythmic effect. 
Adverse effects 
These include eructions, dyspepsia and unpleasant after taste. Large doses of 
omega 3 – PUFA can inhibit platelet aggregation and may worsen glycemic control in 
diabeties. 
Eating fatty fish may be beneficial in healthy people but there is no convincing 
evidence supporting the prevention of cardio vascular disease in the general population. 
The drug is contraindicated in patients with type Ila hyperlipidemia. The dose is five 1g 
capsule bid. 
Omega-3 fatty acids  are also prevent in nuts (especially walnuts) dark green leafy 
vegetables,soya beans,flax seeds  and flax seed oil and hemp seeds. 
Icosapent ethyl, the ethyl ester of eicosapentanoic acid is available as 1 gram 
capsule. A dose, 2 gm bid with food can lower serum TG without increasing LDL 
cholesterol. 
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Table No. 3: Choice of lipid lowering drugs 
Drug 
Hypercholesterolemia 
(elevated LDL-C+   
TG<200 mg/dl) 
Combined 
hyperlipidemia 
(elevated LDL-C+  
TG 200-400 mg/dl) 
Hypertriglyceridemia 
(TG>400 mg/dl) 
Statins Drugs of choice Effective - 
Fibrates 
 
- 
Effective in high 
doses 
Drugs of choice 
Nicotinic acid 
Effective – usefulness 
limited by adverse 
effects of full doses 
Drug of choice 
Effective But Poorly 
Tolerated 
Note: Statins can be combined with (a) nicotinic acid, or (b) a fibrate, in resistant cases. 
Nicotinic Acid 
This vitamin in large doses effectively and rapidly reduces plasma TG by lowering VLDL 
levels; LDL levels diminish more slowly, whereas HDL level rise during therapy 
Nicotinamide lacks these actions. 
Mechanism of action 
In the adipose tissue, nicotinic acid inhibits adenylyl cyclise, and prevents lipolysis 
by hormone sensitive lipase. This reduce the transport of fatty acid to the  liver. In the 
liver, it reduces both synthesis and esterification of fatty acids. The end result is reduction 
in the hepatic production of VLDL and in plasma TG, VLDL cholesterol and LDL 
cholesterol. 
Adverse reactions  
In pharmacologicl doses, nicotinic acid produces intense cutaneous flushing and 
pruritus by increasing the local prostaglandin levels. This can be minimized by starting 
with a small dose and gradually building it up to the full dose, and by taking the drug with 
meals; further , one tablet of aspirin, taken 30 minutes earlier, markedly reduces, the flush. 
Other adverse reactions are nausea, vomiting, diarrhoea; abnormalities of liver function, 
clinical jaundice; hyperuricemia, hyperglycemia; and potentation of hypotension casused 
by antihypertensives  
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Therapeutic Uses 
Nicotinic acid is usefull in all forms of hyperlipoproteinemias except type I and is 
drug of choice in type V hyper-lipoproteinemia.The usual dose is 2-8 g/day, in divided 
doses, with meals.  It is advisable to start with 100 mg tid with meals and to build up the 
dose in 2-4 weeks. 
Folic Acid Supplements are used to prevent homocysteinemia 
1.4. Anxiety and Anxiolytics171,146,138,117 
Anxiety is actually an adaptive response which prepares a person to face the 
challenges of life. Anxiety is characterised by psychologic symptoms (tension, fear, 
apprehension, lack of concentration etc) as well as by sympathetic plus somatic symptoms 
(tachycardia, tremors, sweating, GIT distress etc). Fatigue and sleep disturbances are also 
common. If anxiety persists it impairs person’s ability to perform the job and often lead to 
visceral organ dysfunction and neurological problems.  
Classification of Anxiolytics  
1. Benzodiazepines 
This is the most important group with multifarious uses and may be divided according to 
their duration of action. 
Short Acting 
 Triazolam, Oxazepam, Midazolam 
Intermediate Acting 
 Alprazolam, Estazolam, Temazepam, Lorazepam, Nitrazepam 
Long Acting 
 Diazepam, Flurazepam, Clonazepam, Chlordiazepoxide 
2. Non Benzodiazepine Hypnotics 
Zolpidem , Zaleplon, Zopiclone, Eszopiclone 
3. Atypical Anxiolytics 
Buspirone, Ipsapirone, Gepirone  
4. β-Adrenoceptor Antagonists (Non-Sedating Anxiolytics) 
Propranolol 
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5. Barbiturates 
Long Acting 
Phenobarbital, Mephobarbital 
Short Acting  
Pentobarbital, Amobarbital 
Ultra-Short Acting 
Thiopental, Methohexital 
6. Miscellaneous Group 
Melatonin, Ramelton, Triclophos, Hydroxyzine and Promethazine  
Benzodiazepines (BZDs) 
Site of Action 
BZDs exhibit relatively greater depressant action on limbic system (which 
regulates thoughts and mental functions) compared to midbrain ascending RAS (which 
maintains Wakefullness). Hence they reduce anxiety at a dose which has little depressant 
effects on RAS, i.e., they elicit anxiolytic action with less sedative effects. At higher doses, 
however, they depress RAS and induce sedative-hypnotic action but this property differs 
qualitatively with individual drug. Muscle relaxation is produced by a medullary site of 
action, by inhibiting polysynaptic reflexes in the spinal cord. Ataxia is due to their action 
on cerebellum.  
Mechanism of Action  
Normally a balance between excitatory inputs (mostly glutamatergic) and the 
inhibitory inputs (mainly GABAergic) determines the prevailing level of neuronal activity 
in limbic system and RAS of the brain.  If the balance swings in favour of GABA, 
nervousness and anxiety are reduced while sedation, amnesia, muscle relaxation and ataxia 
appear. In contrast, a reduction in GABAergic activity elicits arousal, anxiety, insomnia 
and restlessness. GABA acts on two distinct classes of receptors. 
 GABA A receptors which are located mainly post-synaptically. These are 
directly linked with Cl ion channels, opening of which causes hyper-
polarisation and reduction in membrane excitability 
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 GABA B receptors which are G-Protein coupled receptors. Their activation 
decreases cAMP formation. They cause pre and postsynaptic inhibition by 
inhibiting ca2+ channel opening and increasing K+ conductance 
GABA receptor has several different binding sites which include: 
 The neurotransmitter GABA-binding site 
 The modulatory sites to bind benzodiazepines, their antagonists like 
flumazenil and inverse agonists such as B-carbolines 
 The modulatory as well as blocking site at chloride ion channel 
GABA A receptors are the target for several important centrally acting drugs like 
benzodiazepines, barbiturates, neurosteroids and picrotoxin. BZDs which have powerful 
sedative and anxiolytic effects, selectively bind, with high affinity, to the modulatory site 
on GABA A receptor in such a way that the binding of GABA to GABA A receptor is 
facilitated. This modulatory site of GABA A receptor is distinct from the GABA binding 
site and is specific for BZDs; hence it is also referred to as “Benzodiazepine receptor”  
BZDs neither substitute for GABA, nor activate GABA A receptor but rather  enhance  
binding  of  GABA to the GABA binding site of GABA A receptor . They appear to 
increase the frequency (rather than duration) of GABA gated chloride channel opening. A 
model of hypothetical GABA-BZD-CT ion channel receptor complex with sites of action 
for agonists, antagonists, inverse agonists channel blockers and channel modulators  
BZD Inverse Agonists and Antagonists 
Inverse agonists (e.g., β-carboline) exert opposite effects to that of conventional 
BZDs producing signs of anxiety and convulsions BZD inverse agonists have no 
therapeutic utility except as research tools. BZD antagonist flumazenil blocks the actions 
of BZD and BZD agonists and is however used clinically. It undergoes significant first 
pass metabolism in liver, hence not used orally. On I.V injection, the effect starts 
spontaneously and lasts for 1- 2 hrs. Plasma half life i.e. 1- 2 hrs. Its main use is to reverse 
BZD anaesthesia (0.5 mg I.V) or to treat BZD overdose toxicity (0.2mg/ min; maximum 5 
mg; till patient regains consciousness). Side effects are rate except anxiety, tremors and 
discomfort. 
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Pharmacokinetic Characteristics 
There are marked pharmacokinetic variations among BZDs. Except for midazolam 
(given I.V or I.M), all can be given orally (though absorption varies). Although some of 
BZDs (diazepam, oxazepam, and chlordiazepoxide) are more than 90% protein bound no 
significant drug displacement reactions occur because of their marked volume of 
distribution. They cross placental barrier (caution in Pregnancy).  Most BZDs are 
metabolised by Phase I metabolic processes and the resultant metabolites are subsequently 
conjugated (phase II reactions)to form water – soluble metabolities that are excreted in 
urine. However, many phase I metabolites are pharmologically active which extend the 
half-life (and hence duration of action) of parent drug. These include midazolam (which 
acts through its active metabolite, hydroxymethyl midazolam); diazepam (active 
metabolite oxazepam and nordiazepam also called clorazepate); flurazepam (active 
metabolite desmethylflurazepam and hydroxymethylflurazepam); chlordizepoxide (active 
metabolite desmethyldiazepam and oxazepam) and alprazolam (active metabolite, alfa-
hydroxyalprazolam), 
Accumalation,with multiple dosing, is not clinically significant with short-acting 
BZDs but is significant with intermediate acting and long acting BZDs. Because of longer 
t1/2, withdrawal effects are milder with long-acting BZDs. 
Drugs Interactions 
 BZDs potentiate the effects of other CNS depressants, such as alcohol, hypnotics 
and neuroleptics 
 Smoking decreases the activity of BZDs 
 Aminophylline antagonises sedative effects of BZDs 
 Enzyme inhibitors like cimetidine and Ketoconazole enhance BZD action 
Non-Benzodiazepine Hypnotics 
Several non-benzodiazepines discussed below are more selective in their central 
actions as they act as agonist at the modulatory site of GABA receptor to which BZDs 
bind. Two types of BZD receptor have been suggested: BZD receptor type I (BZ) found 
throughout the brain and in large concentrations in the cerebellum and BZD receptor type 
II (BZ2) found mainly in the cerebral cortex, hippocampus and spinal cord. It is the BZ1 
receptor that is thought to be responsible for antianxiety, sedative and hypnotic action 
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while BZ2 receptor appears to be associated with muscle relaxation, anticonvulsant action 
and amnesia. Most BZDs act on both BZ1 and BZ2 receptors. Non-Benzodiazepines such 
Zolpidem,  Zaleplon, Zopiclone and Eszopiclone act on BZ1 receptor only; while 1-5 – 
benzodiazepines such as clobazam act preferably at BZD receptor to elicit muscle relaxant 
and anticonvulsant actions. 
Zolpidem, Zopiclone, Eszopiclone and Zaleplon 
These drugs act on BZ1 receptors and have hypnotic actions. As hypnotic, 
Zolpidem (t1/2 2-3 hrs) and Zaleplon (t1/2 3-4 hrs) have faster onset of action with shorter 
duration of hypnotic effects while Zopiclone (t1/2 6-8 hrs) and eszopiclone   (t1/2 6 hrs) 
are slightly longer acting. In therapeutic doses they hardly alter REM sleep pattern and 
have minimal daytime residual sedation. The problem of rebound insomnia (after 
withdrawal of the drug) is also minimal.  Zolpidem (10 -20 mg) and Zaleplon (10-20 mg) 
at bed time are used to treat short-term insomnia. While Zopiclone (7.5mg) and 
eszopiclone (1-3 mg) at bed time are used to treat short term insomnia. Their effects can be 
blocked by flumazenil, which is antagonist at both BZ1 and    BZ@ receptors. 
These drugs have negligible muscle relaxant and anticonvulsant action. The risk of 
tolerance and dependence is much less after their withdrawal as compared to BZDs. Side 
effects and safety in overdoses are almost similar to BZDs. Dose reduction  is needed in 
hepatic disease and in elderly patients. Headache, daytime drowsiness and nightmares can 
occur with higher doses. 
Atypical Anxiolytics 
Buspirone, Ipsapirone and Gepirone 
These drugs act through non-GABAergic systems and have low propensity of side 
effects by acting as a partial agonist primarily at brain 5-HT receptors. Hence, by selective 
activation of the inhibitory presynaptic 5-HT receptor, they suppress 5-HT 
neurotransmission through neuronal system. The drug buspirone (5-10 mg TDS) is used in 
anxiety states. However, the useful anxiolytic effects of buspirone are delayed for more 
than two weeks, which makes it unsuitable for management of acute anxiety states. It has 
no muscle relaxant, or anticonvulsant or hypnotic action. 
Buspirone has minimal abuse liability and elicits no withdrawal reactions like 
rebound anxiety and insomnia etc., on abrupt discontinuation.  Buspirone  causes lesser 
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impairment of psychomotor skills and does not potentiate the CNS depressant effects of 
ethanol (non-sedating anxiolytic  drug). However, it can cause tachycardia, nervousness, 
GIT distress and paresthesias. Although mechanism is unknown, it causes dose-dependent 
pupillary constriction. 
Barbiturates 
Mechanism of Action 
Barbiturates act on the channel modulatory site of GABA a receptor and potentiate 
the GABA mediated inhibitory effects by increasing the duration of chloride channel 
opening.  At higher concentrations, barbiturates directly increase chloride ion conductance 
i.e. they exhibit a GABA mimetic action and not a GABA facilitatory action (as exhibited 
by BZDs) 
Pharmacokinetics 
 The rate of absorption of barbiturates depends on their lipid solubility. The pH 
of solutions of their sodium salts is usually alkaline and therefore cannot be 
given by I.M or S.C routes for fear of necrosis and pain at the site of injection. 
But these can be given slow I.V., orally and at times rectally. These are weakly 
acidic drugs. Hence, they remain unionised in acidic pH and fully ionized at 
alkaline pH 
 These are widely distributed depending upon their lipid solubility and the 
regional blood flow to the different part of the body. The action of the ultra-
short-acting barbiturates such as thiopental is terminated primarily as a result of 
redistribution from brain to lean tissues muscles and then fat and adipose tissue. 
 These are metabolized by both phase-I (liver microsomal oxidation) and phase-
II (glucuronyl conjugation) processes. Their prolonged use leads to an 
induction of liver microsomal enzymes, which results in the development of 
metabolic tolerance.  
 Although excreted through urine, these get readily reabsorbed from renal 
tubules. Alkalinisation increases their ionization and therefore increases their 
renal excretion 
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Adverse Effects 
 Repeated use of barbiturates leads to the development of metabolic tolerance due to 
enzymatic induction. This leads to various drug interactions because of the 
accelerated metabolism of concomitantly administered drugs along with 
barbiturates. 
 Barbiturates have considerable abuse liability and exhibit both psychic as well as 
physical dependence on withdrawal  after prolonged use. Withdrawal symptoms 
include tremors, insomnia, headache, restlessness and delirium 
 They cause hangover, impairment of judgement and “drug automatism” 
 They cause respiratory depression, laryngeal  oedema and hypersensitivity 
reactions (skin rash , swelling of lips and eyelids) 
Drug Interactions 
Barbiturates reduce the effectiveness of various concomitantly administered drugs 
due to induction of their metabolism. Such drugs include oral contraceptives, 
anticoagulants, tolbutamide and  theophylline. 
Contraindications 
These are contraindicated in liver dysfunctions, Kidney disease and sever 
pulmonary insufficiency e.g., emphysema 
Patients having family history of porphyria or in cases of acute intermittent 
porphyria because barbiturates cause induction of ALA - synthetase enzyme in 
mitochondria. This leads to increased synthesis of porphyrins and hence porphyria and 
neurotoxicity. 
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1.5. Analgesics173,149,136,120 
Pain - Introduction 
Pain is an unpleasant sensory and emotional experience, associated with actual or 
potential tissue damage or described in terms of such damage. It  is a subjective experience 
which cannot be objectively defined or qualified satisfactorily. Pain act as a warning signal 
against disturbances in the body and thus has a protective function. However, on many 
occasions pain seems pointless, only contributing to the discomfort in the subject. As a 
symptom, pain demands instant relief and in practice its dramatic relief highly impresses a 
layman. 
Pain receptors are disturbed throughout the body. Clinically, pain can be considered as  
 Superficial or cutaneous pain 
 Deep non-visceral pain from muscles, joints, ligaments and bones 
 Visceral pain 
 Referred pain  
 Deafferentiation or neuropathic pain and 
 Psychogenic or functional pain 
Pain arising from the skin and from the deep non-visceral structures like muscles, 
bones and joints is also termed as somatic pain. It is usually well defined and is generally 
caused by an inflammatory reaction in the tissues; it may be accompanied by contraction 
of the surrounding skeletal muscles as in patients with rheumatoid arthritis. However, 
other causes such as direct irritation of a nerve as in trigeminal neuralgia, herpes zoster, 
increased pulsation of the intracranial arteries as in migraine, or vascular insufficiency as 
in thromboangitis obliterans are also incriminated in the genesis of somatic pain. 
Pain arising from the skin and superficial mucous membrane or nerves is felt as 
pricking, if brief, and stinging, smarting or burning if prolonged. 
Deep nonvisceral (Skeletomuscular) pain usually has a dull character and it may be 
accompanied by a sickening sensation dut to an autonomic response. Sometimes it spreads 
to other areas and may even occur as referred pain. BP and pulse,however, are nott much 
affected,unless the pain is acute and severe. 
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Visceral Pain, unlike the somatic pain, is diffuse, less easily localised and ofter 
‘referred’. It is dull-aching or colicky in character and is often accompanied by sweating, 
nausea, fall in BP and even shock. In addition, muscle rigidity and hyperaesthesia are 
common accompaniments. In practice, visceral pain may be due to spasm (renal or biliary 
colic), ischemia (myocardial infarction), inflammation (appendicitis,pancreatitis)  or 
stimulation of the sensory nerve endings (peptic ulcer). 
Deep pain, whether visceral or somatic in origin , may be misinterpreted as coming 
from some part of the body other than the actual site of stimulation. This is called referred 
pain.  
Thus, cardiac pain is commonly referred to the left arm and diaphragmatic pain to 
the shoulder. Usually, the pain is referred to a cutaneous area which receives its nerve 
supply form the same spinal segment as the affected viscus. 
Although various theories have been prosposed  to explain the pain mechanism 
none can explain all its aspects. The assimilation of sensory pain at the level of 
consciousness depends on various factors such as the nature of sensory receptors, the 
intensity of the impulses transmitted to the CNS, their intergration and finally their 
modulation by other sensory information. The conscious appreciation of pain appears to 
depend upon the widespread activity of the entire cortex; and individuals differ widely in 
their reactions to similar painful experiences. 
Deafferentiation pain is caused by partial damage to axons and nerve membranes, 
which become very sensitive to mechanical and chemical stimuli. Such pain may either be 
of burning, superficial (dysathetic) type; or of stabbing (lancinating) character. It has a 
peculiarly unpleasant quality about it and may not respond to opioids nor to NSAID. 
Psychogenic or functional pain is usually a vague pain which follows no definite 
anatomical pattern of distribution. Such pain is usually continuous from day to day and 
involves more than one part of the body. It however, does not disturb sleep. Psychogenic 
pain is often preceded by a phase of exhaustion while organic pain brings about 
exhaustion. However, psychic element is present in all types of pain. 
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Pain pathways 
Painful stimuli may primarily be physical stimuli such as pressure or heat, or they 
may be chemical stimuli from the product of inflammation.  
A Variety of naturally occurring compound, can elicit pain response in 
experimental animals, e.g. histamine, acetylcholine, bradykinin, PGs, 5-HT and substance 
P. These substances are present oin venoms and products of inflammation. 
Nociception is a physiological process by which pain is perceived. The specialised 
peripheral neurons responsible for this are called nociceptors.  Their cell bodies are 
located in posterior horns of the spinal cord. 
It appears that tactile sensation is transmitted by large diameter (L), Fast  
conducting nerve fibres and pain via small diameter (S), slow conducting nerves fibres 
(nociceptors). Impluses from the nociceptors, on reaching the spinal cord, activate the first 
transmission cell and also the collateral cells in the substantia gelatinosa (SG). 
Anatomically, these nerve fibres are carried in the dorsal nerve root and end in the SG ried 
in the dorsal gray horn. The SG cells inhibit the passage of signals and thus decrease the 
output reaching the higher centres. If,however, pain stimulus is more intense, then the SG 
cells are inhibited, releasing the dorsal horm cell from inhibiton, resulting in higher outpur 
reaching in the higher centres, leading to  perception of pain. This gate control mechanism 
allows the sensory input to be decreased or augmented depending on the relative activity 
of L fiberes and S fibres. 
Activation of nociceptor casuses release of various neuro transmitters leading to 
activation of secondary axons. The secondary axons arising from the dorsal horn travel 
through the opposite spinothalamic tract, which terminate in the thalamus that projects to 
the post central gyrus which is mainly responsible for localisation of pain. Although the 
thalamus is responsible for perception of pain, the cerebral cortex is essential for its 
discriminative, bral cortex is essential for its discriminative,exact and meaningful 
interpretation and for some of it emotional components. The other intermingled  fibres 
which form an ascending multisynaptic pathway terminate in the thalamus and from there 
project to frontal and limbic systems,and the hypothalamus. This system is concerned with 
the emotional concomitants of pain. 
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Higher centres, through their central inhibitory and facilitatory mechanisms exert 
modulating influence on the gating mechanism. Thus clinically the sensation of pain has 
several components including the emotional psychic reaction. 
Analgesics are the drugs which relieve pain without causing loss of consciousness. 
Classification  
Analgesics are classified into: 
1. Opioid 
2.  Non-Opioid 
Opioid analgesics 
The word opiates refers to the products obtained from the opium poppy. The term 
Opioid (opiate-like) is used to denote all naturally occurring, semi-synthetic and synthetic 
drugs which have a morphine like tha action viz relief from pain and depression of the 
CNS, both reversed by naloxone. These drugs wereformerly called ‘narcotic’ analgesics 
because some of them (such as morphine) induce sleep. The term ‘narcotic’ is no longer 
applied to opioids but is restricted in the legal sense to drugs capable of producing 
dependence. 
The opioids are further sub classified as 
 Agonists  such as morphine and compounds which  resemble it in most of their 
actions, viz. derivatives of morphine, codeine and its derivatives synthetic 
compounds such as pethidine, methadone, levorphanol and tramadol 
 Partial agonists e.g.  buprenorphine and meptazinol. They have partial agonist 
action only on the mu receptors  
 Mixed agonist- antagonists which act as agonists at one type of opiod receptors 
and as competitive antagonists at another type of receptors           e.g. 
nalbuphine, pentazoxine, and butorphanol. Patients who have received repeated 
doses of morphine - like drug to the point of physical dependence may 
experience an opioid withdrawal reaction when given a mixed           agaonist-
antagonist. 
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 Opioid antagonists, by themselves, produce few effects unless an opioid are 
activated as in shock or stress, an opioid antagonist does produce visible eggects. 
 Opioid receptors are part of family of G-protein coupled receptors. They have 
been classified in to mu (μ1, μ2) delta (δ1, δ2), kappa (κ1, κ2, κ3) and nociceptin 
(orphamin) types, when activated they 
(i) Open K+ channels to inhibit post-synaptic neurons and  
(ii) Close Ca++ channels on the presynaptic neurons to inhibit release of the 
neurotransmitters from nonciceptive nerve teriminals. These actions reduce 
neuronal excitability 
 Opioid receptors are also present in the peripheral nerves where they respond to 
peripherally applied opiods and locally released endogenous peptides during inflammation. 
 The pharmacological effects associated with theses receptor subtypes and 
selectivity of the various opioid drugs for these receptors are summarised. 
 The vast majority of opioid drugs used as analegesics are agonistat mu receptors. 
Similarly the opioid antagonists naloxone and naltrexone, show a high selectivity for mu 
receptors. Drug with moxed agonist-antagonist properties bind to more than one receptors 
class at the usual clinical doses. 
1.6. Anthelmintic Drugs175,150,137,121 
Worm infestation (helminthiasis) is one of the major global public health problems, 
more so in tropical countries. Besides the environmental conditions peculiar to tropics, 
poverty, illiteracy, lack of adequate sanitary facilities and of pure water supply make total 
eradication of this problem very difficult. The commonest parasites observed are round 
worms, hookworms, thread worms, tape worms, filarial worms and schistosomes. 
Worms can cause various GI and general symptoms. In addition, some of them 
cause blood loss, nutritional deficiencies, urticaria and other allergic manifestations, 
intestinal obstruction and hepatosplenomegaly. Roundworms have been implicated in the 
pathogenesis of bronchial spasm in endemic areas. Peripheral blood eosinophilia occurs in 
all nematode infestations (except enterobiasis). A careful examinations of stool may often 
spare the unnecessary removal of teeth and tonsils, usually blamed for ‘spectic foci’, in 
cases with ‘ resistant urticaria’ 
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The helminths are multicellular organisms possessing three germ layers and 
exhibiting a bilateral symmetry.They are classified into two major phyla (1) Phylum 
nemathelminthes (roundworms; nematodes) and (2) phylum platyhelminthes  (flat 
worms : cestodes and trematodes). Anthelmintics are drug used in the treatment of 
helminthiasis. 
An anthelmintic drug which kills the worm is called vermicidal, while that which affects 
the worm in such a way that it is easily expelled is known as vermifuge. 
Drug Therapy of Roundworms 
Mebendazole - This broad spectrum anthelmintic is a benzimidazole derivative. 
Given orally it is poorly (<10%) absorbed. It inhibits microtubule polymerisation by 
binding to beta-tubulin. 
It is highly effective in ascariasis, enterobiasis, trichuriasis and in hookworm 
infestation. It is the drug of choice in enterobiasis and in trichuriasis. It also has some 
action against S.stercoralis. The drug is slow acting and it may take 2-3 days for parasitic 
clearance from the gut. It also adversely affects the ova of the trichuris and the hookworm. 
It is effective in vio against the larve of Trichinella spiralis and exerts a lethal effect on the 
germinal membrane of the larvae of Echinococcus granulosus (Hydaid worm). 
Adverse reactions 
These are usually mild and consist of abdominal pain, nausea and diarrhoea. Large 
oral doses, may cause vertigo, dizziness,headache and arthalgia. Benzimidazoles are 
embryotoxic and teratogenic in animals, and should be avoided in pregnancy. 
Preparation and Dosage  
It is available as 100 mg tablets and liquid suspension 
Threapeutic Uses 
 Enterobiasis: A single dose of 100 mg repeated after one week. 
 Hookworm and round worm infestation: 100mg bid for 3 days. 
 Taenia infestation: 300 mg tid for 3 days. 
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 Hydatid eysts of the liver: 400 -600 mg tid for 21-30 days for regression of 
hydatid cysts. Such treatment, though rarely, may cause bone narrow aplasia.  
Hence albendazole is preferred. 
Albendazole 
This broad spectrum benzimidazole has actions similar to those of mebendazole. It 
also has larvicidal actions in hydatid disease, ascariasis and ankylostomiasis and ovicidal 
properties in ascariasis, ankylostomiasis and trichuriasis. 
Given orally, it is rapidly absorbed and has better bioavailability than mebendazole. 
After absorption, it undergoes first pass metabolism in the liver to its active 
metabolite,albendazole sulfoxide. It is well distributed in tissues, bile CSF and hydatid 
cyst. It has plasma t1/2 8-12 hours. Its major advantage is that its effective against many 
common intestinal worms in a single dose and is cost effective. 
The drug is well tolerated and adverse reactions are mild, mainly GI disturbances. 
When used in hydatid disease for long term therapy it may cause alopecia, liver damage 
and bone marrow depression. 
Threapeutic Uses 
 Ascariasis, ankylostomiasis and trichuriasis -   Usually 400 mg single dose. 
Hookworm and trichuriasis may need a repeat dose. 
 Enterobiasis - 400 mg single dose,repeated after 4 weeks. 
 Hydatid disease - 400 mg bid for one months, repeated if necessary. 
 Strongylodiasis - 400 mg twice daily for 3 days, repeated after 3 weeks if 
necessary. 
 Trichinella spiralis - 400 mg bid for 8-14 days. 
 Cysticercosis - It is considered the drug of choice because of short course, less 
toxicity than praziquantel, better penetration into CSF and cost. It is given 400 mg 
bid for 21 days. A Glucocorticoid is stared prior to albendazole to reduce the 
intensity of the inflammatory reactions to the dead parasites. 
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Pyrantel Pamoate 
This drug, a tetrahydropyrimidine derivative, is highly effective against round 
worms and E.vermicularis and a little less effective against hook worms. It has a 
depolarising, neuromuscular blocking action and causes spastic paralysis of the worms. It 
is not much absorbed from the gut. 
In ascariasis and enterobiasis, it is usually given in a single dose (10 mg/kg upto a 
maximum of 1 g); for hookworm infestation, the same dose is repeated on the three 
successive days. The dose can be repeated after 2 weeks, if needed. It can be used during 
pregnancy. 
Adverse reactions 
These are usually mild and include GI disturbances, abdominal pain, headache, 
drowsiness and skin rashes. 
Oxantel pamote,   an analogue of pyrantel, it also claimed to be useful in trichuriasis. It is 
given in a single dose. 
Piperazine 
This drug was extensively used in the therapy of ascariasis and enterobiasis. 
Mechanism of action 
It act as a GABA agonist and causes hyperpolarization of ascaris muscle resulting 
in faccid paralysis of the worms which are then easily expelled by peristaltic movements. 
This eliminates the danger of worm migration. 
Absorption, fate and excretion 
Piperazine is absorbed from the gut, to the extent of about 30% The drug is partly 
metabolised in the body and partly excreted unchanged in the urine. 
Adverse reactions 
Piperazine has a wide margin of safety.     Adverse effects are uncommon. They 
include nausea, vomiting, diarrhoea and urticaria.  Neurotoxic effects, observed rarely; 
include vertigo, muscular incoordination, hypotonia, ataxia of cerebellar type (‘worm- 
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wobble’), paraesthesiae, blurring of vision and very rarely ,seizures. The drug appears to 
be safe during pregnancy. 
Levamisole 
Levamisole is I-tetramisole and accounts for most of the antehelmintic activity of 
the racemic mixture, tetramisole. Like pyrantel, it casuses sustained contracture of somatic 
muscles of the worm by an irreversible non-competitive, depolarisation type of 
neuromusucular block. It is rapidly and considerably absorbed and about 60% is excreted 
in the urine, mostly as metabolities, within 24 hours. 
Levamisole also has immunostimulant properties. 
Adverse reactions 
Reported are usually mild and include nausea, vomiting, abdominal pains, 
diarrhoea, giddiness and drowsiness. 
These drugs are not active against larvae and hence follow up re-evaluation of 
treated patients is necessary. 
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2. LITERATURE SURVEY 
1.  Rajiv P et. al., (2017) studied Screening for Phytochemicals and FTIR Analysis of 
Myristica dactyloids Fruit Extracts and the results reveals that the alkaloids, steroids, 
flavonoids, phenolic compounds, proteins, carbohydrates, cardio glycosides and saponins 
were present in methanolic extract when compared to other solvent extracts. FT-IR 
analysis shows the presence of different functional groups such as carboxylic acids, 
aromatics, alkanes, alcohols, phenols, aliphatic amines, alkenes and amine groups in the 
fruit extracts. 114 
 
2. Kadam AB et. al., (2017) carried out work on Assessment of Acute Oral Toxicity 
of Synergistic Formulation Extract of Traditional Contraceptive Plants. It was a single 
high extract dose of 2000mg/kg administered and the effects on mortality, behavioral 
pattern as well as spontaneous locomotors activity were evaluated. The limit dose of 
2000 mg/kg did not cause any mortality. The findings suggested that the LD50 value of 
aqueous and petroleum ether was found to be greater than 2000 mg/kg. Hence, 
synergistic extract of plants is nontoxic. 58 
 
3. Qian Chen et. al., (2017) studied Effects of Natural Products on Fructose-Induced 
Nonalcoholic Fatty Liver Disease (NAFLD) and as a sugar additive, fructose is widely 
used in processed foods and beverages. Excessive fructose consumption can cause 
hepatic steatosis and dyslipidemia, leading to the development of metabolic syndrome. 
Recent research revealed that fructose-induced nonalcoholic fatty liver disease (NAFLD) 
is related to several pathological processes, including: (1) augmenting lipogenesis; (2) 
leading to mitochondrial dysfunction; (3) stimulating the activation of inflammatory 
pathways; and (4) causing insulin resistance. 109 
 
4. Neelam B Bare et. al., (2017) reported Pharmaceutical Importance of Withania 
Coagulans in Health and Diseases. The berries of the shrub are used for milk 
coagulation. They are also used in dyspepsia, flatulent colic and other intestinal 
infections. Withania coagulans (Stocks) Dunal is used to treat nervous exhaustion, 
disability, insomnia, wasting diseases, failure to thrive in children, impotence. Its fruits 
are used for liver complaints, asthma and biliousness. In particular withanolide isolated 
from the plants are considered to have Antimicrobial, antiinflammatory, antiumor, 
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hepatoprotective, antihyperglycemic, cardiovascular, immunosuppressive, free radical 
scavenging, antimutagenic and central nervous system depressant activities of the plant 
have been reported. 89 
 
5. Avinash Shankar et. al., (2016) carried out work on Withania Coagulans in 
Management of Diabetes Mellitus. Withania coagulans fruit extract orally early morning 
and evening at bed time as an adjuvant with continuing anti diabetics in old cases and 
with OHA in fresh cases progressively established normoglycemic level both fasting and 
pp and spared the dose of continuing anti diabetic drug and patients taking insulin 
become completely free of insulin prick. It also bioregulated lipid profile, alleviated 
diabetic complication and reduced the dose of OHA without any alteration in hemato, 
hepatic and renal function.13 
 
6. Chavan RT et. al., (2016) reported HPTLC fingerprint analysis and antimicrobial 
activity of leaf extracts of Cassia fistula L. The phytochemical screening showed the 
presence of alkaloids, carbohydrates, glycosides, saponins, triterpenes, tannins, 
flavonoids, photobatalin and anthraqunies in methanol and aqueous extracts of leaf. The 
analysis of methanolic extract of leaves by HPTLC confirmed the presence of 
flavonoids(Peak 4) and alkaloids(Peak 3).20 
 
7. Sandhiya V et. al., (2016) performed studies on Effect of Chloroform Fraction of 
Withania coagulans Bud on the Regulation of GLUT4 and PPAR γ-Expressions Levels 
in Diabetic L6 Myotubes. The free radical scavenging activity of chloroform fraction 
(CF) of a crude drug shows 510μg/ml of scavenging activity. The IC50 value for MTT 
assay was found to be 84.7μg/ml. The GLUT4 study shows significant uptake of glucose. 
PPAR gamma activity regulation of glucose disposal and insulin sensitivity in the 
skeletal muscles shows concentration dependence response using standard Pioglitazone. 
The bud of Withania coagulants will be a promising medicine for more ailments.130 
 
8. Nandagoapalan V et. al., (2016) carried out work on Phytochemical Analysis of 
Some Traditional Medicinal Plants and in the study, principal phytoconstituents of 25 
traditional medicinal plants were identified in order to relate their presence with 
bioactivities of the plants. Screening of the plants was performed using standard methods 
and resulted in the detection of the presence of tannins, flavonoids, phenolics, saponins, 
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steroids, cardiac glycosides and alkaloids. Flavonoids were present in 19 of 25 plants 
while alkaloids were present in sixteen plants. The presence of these phytochemicals can 
be correlated with medicinal potential of these plants.86  
 
9. Salem Mohamed Edrah et. al., (2016) reported Qualitative and quantities analysis 
of phytochemicals of various extract for Ephedra altissima from Libya. The chemical 
constituents (Qualitative and Quantities analysis) all most presented in crude extracts of 
plant (Tannins, Saponins, Flavonoids, Cardiac glycosides and Alkaloids) formerly 
Steroids; Terpenoids and Anthraquinones not presented in some crude extracts were 
considered. 129 
 
 
10. Nguyen Le Bao Duy et. al., (2016) suggested Preliminary Phytochemical, Acute 
Oral Toxicity and Anticonvulsant Activity of the Seed Extract of Brassica juncea and the 
phytochemical study showed the presence of alkaloids, flavonoids, saponins, tannins, 
terpenoids, and phenolic compounds in the seeds of B. juncea. The Acute oral toxicity 
study indicated that the extract was safe and non-toxic to mice up to 5000 mg/kg body 
weight. 91 
 
11. Idris Bello et. al., (2016) concluded the Acute and Sub-Acute Toxicity Evaluation 
of the Methanolic Extract of Alstonia scholaris Stem Bark. The results demonstrate that, 
while a single dose and short term oral intake of Alstonia scholaris bark extract caused 
no toxicity up to a dose of 2000 mg/kg b.w., toxic effects manifested in the long term 
treatment at the highest dose (500 and 1000 mg/kg). The long-term toxic effect was 
found to be associated with alterations in hematological compositions and end-organ 
damage to the liver. 51 
 
12. Shah MA et. al., (2016) studied Toxicity Study of Brassica oleracea Var. Italica 
Extracts in Sprague Dawley (SD) Rats and there was no mortality or any significant 
changes noticed in the SD rats after the administration of tested plant extract of 300, 
2000 and 4000 mg/kg body weight respectively. The experimental animals did not 
showed any drug related changes in behavior, breathing, skin effects, water consumption, 
impairment in food intake and temperature. Furthermore B. oleracea Var. Italica extract 
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did not produce any remarkable change in biochemical and hematological parameters 
following the administration of tested crude plant extract of 400 and 8000 mg/kg body 
weight for 28 consecutive days. 142 
 
13. Shandesh Bhattarai et. al., (2016) Studied Antibacterial Activity of Selected 
Ethnomedicinal Plants of Sagarmatha Region of Nepal. Among 15 extracts examined, 13 
(86 %) extracts showed antibacterial property against Staphylococcus aureus followed by 
8 (53 %) extracts against Escherichia coli and 6 (40 %) extracts each against 
Pseudomonas aeruginosa and Klebsiella pneumonia. Plant extracts were more likely to 
inhibit Gram-positive bacteria, Staphylococcus aureus. With respect to Gram-negative 
bacteria, it was more common for plant extracts to inhibit Escherichia coli than 
Pseudomonas aeruginosa or Klebsiella pneumonia. 145 
 
14. Bahmani Nasrin et. al., (2016) reported Evaluation of antibacterial effects of 
Withania coagulans and Cynara cardunculus extracts on clinical isolates of Brucella 
strains and among the tested antibiotics there was only 10% resistance to rifampin. 
Examination for plant extracts showed the mean zone of inhibition growth for 
C.cardunculus and W.coagulans were 28 and 17mm (in 40mg/ml) respectively by disk 
diffusion method and the highest Minimum inhibitory concentration (MIC) were 
10.81μg/ml for C.cardunculus and 43.24μg/ml for W.coagulans. The present study 
showed C.cardunculus extracts possess compounds with antibacterial properties, 
therefore can be used as antimicrobial agents in new drugs for therapy of brucellosis.14 
 
15. Maryam Sarbishegi et. al., (2016) studied Neuroprotective effects of Withania 
coagulans root extract on CA1 hippocampus following cerebral ischemia in rats . WCE 
showed neuroprotective activity by significant decrease in MDA level and increase in the 
SOD, CAT and GPx activity in pretreated groups as compared to I/R groups (p<0.001). 
The number of intact neurons was increased while the number of TUNEL positive 
neurons in CA1 hippocampal region in pretreated groups were decreased as compared to 
I/R group (p<0.001). 72 
 
16. Rajagopal PL et. al., (2016) studied Anthelmintic activity of the flowers of 
Sesbania grandiflora Pers. Three concentrations (100, 150, 200 mg/ml) of each extract 
were studied. This study is mainly concerned with the determination of time of paralysis 
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and time of death of the worms. When there was a gradual increase in the dose, a gradual 
increase in the anthelmintic activity was observed. The ethanolic extract of the flower 
showed a significant anthelmintic activity at highest concentration of 200 mg/ml.111 
 
17. Dilpesh Jain et. al., (2016) studied Evaluation of Anti-obesity Effect of Fattolin, a 
Polyherbal Formulation in Progesterone Induced Obesity in Mice and Fattolin treatment 
(200 and 400 mg/kg) significantly decreased food intake, body weight and liver weight. 
A significant increase in number of ambulation and rearing and decrease in grooming 
was also observed. Moreover it significantly decreased levels of blood glucose, 
triglycerides, total cholesterol, LDL, VLDL and liver enzymes; however more significant 
difference was observed with Fattolin 400 mg/kg treatment. Structural abnormality of 
hepatocytes like mild congestion and focal necrosis induced by progesterone 
administration was markedly improved with Fattolin treatment at both doses.29  
 
18. Nishesh Sharma et. al., (2015) studied a review on Biological properties and 
conservation of critically endangered plant Withania coagulans - Indian Rennet.       W. 
coagulans possesses several medicinal properties and is used in treatment of various 
diseases. Plant is known to possess many bioactive compounds responsible for its 
biological and pharmacological activities, withanolides being the main acitive 
biochemical constituent. The plant has become endangered due to unrestricted collection 
from wild stands for both traditional as well as medicinal purposes. Low germination rate 
and reproductive failure have also contributed towards the present endangered status of 
the plant. 94 
 
19. N. Durga Maha Lakshmi et. al., (2015) carried out work on Phytochemical 
Screening and FTIR Analysis of Clitoria Ternatea Leaves. The phytochemical analyses 
showed presence of proteins, carbohydrates, glycosides, resins, alkaloids, steroids, 
tannins, and phenols. The FTIR spectra analyses confirmed the presence of different 
functional groups with a peak value of Phenols at 3389.57, Alkanes at 2925.41 and 
2856.66, Primary amines at 1632.33, Aromatic amines at 1409.06, Carboxylic acids at 
1057.61, Alkenes at 926.50, Primary and Secondary Amines at 869. 33 
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20. Nandha Kumar S et. al., (2015) studied Phytochemical screening and 
characterization of the bioactive compounds from the leaves of Hyptis suaveolens and 
Spathodea campanulata. The crude extracts were scanned in the wavelength ranging 
from 200-800 nm and the characteristic peaks were detected. FTIR method was 
performed in mid infrared region 4000-400 cm-1 which was used to detect the 
characteristic peak values and their functional groups. The maximum compounds were 
found in the methanolic extract of H. suaveolens and the aqueous extract of 
S.campanulata with the presence of primary amines, alkanes, carboxylic acid, aromatics, 
alcohols, ketones and phenols. 87 
 
21. Florence AR et. al., (2015) studied FTIR and GC-MS spectral analysis of Gmelina 
asiatica L. Leaves. The FTIR spectroscopic studies revealed the presence of alcohols, 
phenols, alkanes, alkynes, alkyl halides, aldehydes, carboxylic acids, aromatics, nitro 
compounds and amines. The results of the GC-MS analysis provide different peaks 
determining the presence of 50 phytochemical compounds in the extracts. The major 
phytoconstituents are Ethyl α-D-glucopyranoside (21.86%); 2-Hexadecen-1-OL, 
3,7,11,15- Tetramethyl-, [R-(R*,R*-(E)] (14.96%); 9,12,15-Octadecatrienoic acid 
(14.96%); Pentadecanoic acid (10.71%); Ethyl (9Z, 12Z) -9,12-Octadecadienoate 
(7.12%). 39 
 
22. Aparna Saraf et. al., (2015) demonstrated HPTLC Fingerprint Profile and 
Antimicrobial Activity of Leaves of Achyranthes Aspera Linn. The in vitro antibacterial 
activity was performed on extracts of leaf of Achyranthes aspera Linn in petroleum 
ether, chloroform, acetone, ethanol, methanol and water against multi drug resistance 
organisms such as Pseudomonas aeruginosa, Escherichia coli, Bacillus subtilis and 
Staphylococcus aureus. The organic extracts of leaves of the plant at a concentrations of 
0.005%, 0.007% and 0.01% were taken and their activities were measured. The results 
revealed that all the extracts had variable degree of antibacterial activity. 10 
 
23. Mohamed El Hasan Shayoub et. al., (2015) performed Phytochemical analysis of 
leaves extract of Eucalyptus camaldulensis Dehnh and the result of the phytochemical 
screening showed the presence of tannins, sterol, triterpenoids , saponins, flavonoids, and 
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phenolic compounds. There were a complete absence of alkaloids, Anthraquinone 
glycoside and cyanogenic glycoside. 76 
 
24. Muhammad Ahmed et. al., (2015) studied Acute Toxicity (Lethal Dose 50 
Calculation) of Herbal Drug Somina in Rats and Mice and at the end of the study, all the 
animals in all the dose groups were sacrificed and the internal organ-body was compared 
with values from the control group. The LD50 was found to be >10,000 mg/kg body 
weight upon oral administration in mice and rats as no mortality was observed after 
single dose administration. According to Hodge and Sterner toxicity scale, the obtained 
value of LD 50 > 10,000 mg/kg classified the Somina as Practically non-toxic herbal 
medicine.81 
 
25. Wataru Hiruma et. al., (2015) carried out work on Antitumor Effects and Acute 
Oral Toxicity Studies of a Plant Extract Mixture Containing Rhus verniciflua and Some 
Other Herbs. The single dose toxicity study of Rv-PEM01 did not result in any deaths or 
abnormalities in daily behavior, body weight gain, or anatomical observations at 
necropsy. Thus, so we could not calculate the 50% lethal dose (LD50) in mice, but it 
would be higher than 5.0 g/kg. Treatment with Rv-PEM01 at a dose of 2.5 g/kg tended to 
show antitumor activities on mice bearing Colon26 tumors compared with the control 
group. It was concluded that the formula was a safe antitumor agent with no side effects 
on mouse physiological function as judged by survival and organ weight.182 
 
26. Alowanou Goué G et. al., (2015) performed Acute oral toxicity activity of aqueous 
extract of Combretum glutinosum Perr. ex De leaves in wistar rats. A single dose of 2000 
mg/kg bw were given in one single administration by gavage female rats. No animal died 
and no behavioral signs of acute toxicity were observed.. It was concluded that the 
aqueous extract of C. glutinosum is safe for oral use at single dose of 2000 mg/kg bw. On 
condition of chronic evaluation of the toxicity of the aqueous extract of C. glutinosum 
leaves, could therefore be continuously used by small breeders to control small ruminant 
helminthes.8 
 
27. Vidya Sabbani et. al., (2015) demonstrated Acute Oral Toxicity Studies of Ethanol 
Leaf Extracts of Derris Scandens & Pulicaria Wightiana in Albino Rats.  No mortality 
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and no significant changes were observed in body weight and wellness parameters at 
175, 550 and 2000 mg/kg body wt. doses of both Derris scandens and Pulicaria wightiana 
which reveal the safety of these plants in the doses up to 2000 mg/kg body weight. 178 
 
28. Preeti et. al., (2015) reported Medicinal plants possessing anxiolytic activity: A 
brief review. There are very few anti-anxiety remedies available for the management of 
anxiety. Thus urgent need for new anti-anxiety drugs is a global concern. Therefore, the 
demand of herbal medicines is increasing due to their wide application and therapeutic 
efficacy with least side effects. The review collected the information of anti-anxiety 
potential plants with emphasis their botanical source, common name and other biological 
activities, which are helpful to develop new anti-anxiety herbal formulations.106 
 
29. Shadab Ahmed et. al., (2015) found out Analgesic Activities of Methanol Extract 
of Terminalia chebula Fruit and different doses (300, 500 and 1000 mg/kg) were 
assessed for analgesic activity by tail immersion technique and acetic acid induced 
writhing test. Results of both tail flick method and acetic acid induced writhing test 
revealed that T. chebula fruit extract possessed varying degree of analgesic activity 
significant at 300 mg/kg and highly significant at 500 and 1000 mg/kg in comparison to 
control.141 
 
30. Suresh Kumar dev et. al., (2015) studied Analgesic and anti-nociceptive activity of 
hydroethanolic extract of Capparis deciduas (Forssk.) Edgew. and the maximum effect 
was observed at 60 min at a dose of 200 mg/kg p.o., which was higher than the standard 
drug morphine sulfate (1.5 mg/kg i.p.) while in the tail flick model, effect was 
comparable with morphine sulfate. In formalin-induced paw licking model, 
administration of CDHE completely abolished the early phase at 100 and 200 mg/kg p.o. 
and in the late phase, the result of CDHE (200 mg/kg p.o.) was superior than 
indomethacin (10 mg/kg p.o.). CDHE was effective in both non-narcotic and narcotic 
models of nociception, signifying its possible action via peripheral and central 
mechanism. 165 
 
31. Debasmita Dutta Pramanick et. al., (2015) studied Pharmacognostic evaluation of 
Withania coagulans Dunal (Solanaceae) - an important ethnomedicinal plant. Physico-
chemical and phyto-chemical screening of drug material are done for determination of 
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quality/purity of crude drug and for detection of plant constituents respectively. The plant 
is characterized by shrubby habit with dioecious and polygamous flowers; fruits (berries) 
enclosed in persistent leathery calyx; seeds ear-shaped, with fruity smell. Fruit pedicel 
with branched and unbranched trichomes, massive collenchymatous cortex, intra-xylary 
phloem and hollow pith; calyx with spongy parenchyma; pericarp with exocarp, 
mesocarp and endocarp; seeds with highly lignified sclerenchyma cells and strongly 
thickened endosperm. The plant is rich in alkaloids, esterase, carbohydrates, steroids, 
phenolic compounds, tannins, free amino acids and organic acids. 26 
 
32. Avijit Chatterjee et. al., (2015) carried out work on Anti-inflammatory and 
Analgesic Activity of Methanolic Extract of Medicinal Plant Rhodiola rosea l. Rhizomes. 
The orally administered methanolic extract of Rhodiola rosea demonstrated a significant 
analgesic and anti-inflammatory in animal model. The findings in the study suggest that 
the methanolic extract of the herb Rhodiola rosea possesses analgesic and anti-
inflammatory activities. 12 
 
33. Trini Suryowati et. al., (2015) carried out work on Antihyperlipidemic Activity of 
Torbangun Extract (Coleus amboinicus Lour) on Diabetic Rats Induced by 
Streptozotocin. Oral administration with graded doses T1 and T2 of torbangun leaf 
ethanol extract exhibited antihyperglycemic and antihyperlipidemic activity in 
streptozotocin-induced diabetic rats. Data were analyzed with test followed Post-Hoc test 
with 95% significance level. The daily oral treatment with torbangun leaf ethanol extract 
showed a significant reduction in blood glucose. There were decreased serum contents of 
triglycerides and significantly total cholesterol, whereas HDL-cholesterol was 
increased.170 
 
34. Claudia I Gamboaet. al., (2015) identified Plants with Potential use on Obesity and 
its Complications and explained the anti-obesity potential and reported mechanisms of 
action of diverse plants such as: Camellia sinensis, Hibiscus sabdariffa, Hypericum 
perforatum, Persea americana, Phaseolus vulgaris, Capsicum annuum, Rosmarinus 
officinalis, Ilex paraguariensis, Citrus paradisi, Citrus limon, Punica granatum, Aloe 
vera, Taraxacum officinale and Arachis hypogaea is summarized.22 
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35. Sushmitha J et. al., (2015) suggested on Evaluation of Anti-Obesity Activity of 
Hordeum vulgaregrains in Albino Rats. The successful management of obesity is 
possible through lifestyle changes in diet and physical activity. Hordeum vulgare is 
traditionally used as weight losing remedy so, present study selected grains of Hordeum 
vulgare plant for evaluation of anti-obesity activity by using high fat diet induced, anti-
psychotic drug induced obesity in rats.166 
 
36. Adnyana IK et. al., (2014) performed studies on Anti-Obesity Effect of the 
Pomegranate Leaves Ethanol Extract (Punica Granatum l.) in High-Fat Diet Induced 
Mice. The pomegranate leaves ethanol extract at a dose 50 mg/kg and 100 mg/kg b.w. 
showed a significant decrease of body weight, faeces index, total fat index, food index, 
and lee’s index compared to control mice. Furthermore, significantly inhibitory activity 
also showed from in vitro assay.5 
 
37. Souravh Bais et. al., (2014) was undertaked Antiobesity and Hypolipidemic 
Activity of Moringa oleifera Leaves against High Fat Diet-Induced Obesity in Rats and 
indicate that the rats treated with Moringa oleifera (MO) have significantly attenuated 
the body weight without any change in the feed intake and also elicited significant 
thermogenic effect and to act as hypolipidemic and thermogenic property in obesity 
related disorders.158 
 
38. Pankti P Dalwadi et. al., (2014) evaluated Anti hyperlipidemic activity of 
Tephrosia purpurea plant extracts in poloxomer 407 induced hyperlipidemic rats and 
Estimation of lipid profile shows that Tephrosia purpurea stem extract (500mg/kg), 
Tephrosia purpurea leaves extract (400mg/kg), Tephrosia purpurea whole plant extract 
(300mg/kg) shows the less significant antihyperlipidemic activity. While Tephrosia 
purpurea whole plant extract at the dose of 600mg/kg shows potent antihyperlipidemic 
activity. It decreases TC, TG, LDL, VLDL and increases HDL levels. Tephrosia 
purpurea whole plant extract 600 mg/kg shows significant antihyperlipidemic activity as 
standard drug Atorvastatin. 98 
 
39. Ashok Kumar Gupta et. al., (2014) studied Protective effect of Ficus infectoria 
plant extract against fructose induced hyperlipidemia and hyperglycemia in rats and 
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explored the antihyperlipidemic and hypoglycemic potential of the methanolic extract of 
Ficus infectoria in Wistar rats. Hyperlipidemia and hypoglycemia in rats were induced 
by fructose solution (10% w/v, p.o., ad libitum) for 3rd and 8th weeks respectively. 
These activities were measured by estimating the triglyceride, total cholesterol, LDL, 
VLDL, HDL and serum glucose levels. F. infectoria at 200mg/kg and 400mg/kg showed 
significant effect. 11 
40. Rajesh Asija et. al., (2014) carried out work on Anti Inflammatory and Analgesic 
Activity of Medicinal Plants - A Review. The various plants have a potential medicinal 
implication. Medicinal plants are considered as imperative therapeutic aid. Therapy of 
classical NSAIDs and the opoids in the management of inflammatory and pain 
stipulation are major problems. The conservative drug available in the marketplace treat 
inflammation and analgesia produces various side effects. For conquer this problems 
medicinal plants play a major role to alleviate many diseases related with inflammation 
and analgesia. 112 
 
41. Meda Ramesh et. al., (2014) performed a Review on Anxiolytic Activity of Some 
Herbal Plants. These herbal plants extraction processes used to different solvents present 
in phytochemical constituents. They need further evidence base via clinical studies. 
Anxiety disorders are commonly researched but the efficacy of herbal medicines in these 
disorders needs to be studied further. The review addresses herbal therapy, safety issues 
and future areas of application in the field.73 
 
42. Shan P Mohammed et. al., (2014) studied Evaluation of Anxiolytic Activity of 
Ixora coccinea Linn. Ethanolic Extract in Swiss Albino Mice and the anxiolytic activity 
of Ixora coccinea ethanolic extract. The methods used for this study are elevated plus 
maze paradigm test and Hole board test. The ethanolic extract ICEE shows a significant 
(P<0.01) anxiolytic effect during the elevated plus maze test and the hole board test in a 
dose dependent manner when compared with the standard dose of diazepam.144 
 
43. Muhammad Riaz et. al., (2014) studied Neuropharmacological effects of 
methanolic extracts of Rubus fruticosus L.All extracts were found to be anxiolytic in 
nature, while no muscle relaxing activity or sedative effect was observed. The order of 
central nervous system (CNS) depressant effect for various parts of R. fruticosus was 
fruit > root > leaves > stem.82 
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44. Priyadarshini L et. al., (2014) performed Acute Toxicity and Oral Glucose 
Tolerance Test of Ethanol and Methanol Extracts of Antihyperglycaemic Plant Cassia 
Alata Linn . Mice appeared to be normal and no mortality was observed in the acute 
toxicity test after treated with an extract up to a concentration of 3000mg/kg body 
weight. It ensures that the plant as safe for use as a medicinal plant. The glucose 
utilization (OGTT) was evaluated using STZ induced diabetic mice. The study provides 
remarkable evidence about the ability of the extracts in reducing blood glucose level. The 
% glycaemic change of ethanol and methanol extract is 18.74 and 8.35 respectively after 
180min of glucose load, which is lesser than the DC (diabetic control) which showed a % 
glycaemic change of 132.94. 107 
 
45. Manjulika Yadav et. al., (2014) carried out work on Preliminary Phytochemical 
Screening of Six Medicinal Plants Used In Traditional Medicine and carbohydrates, 
glycosides and coumarins were present in all the selected plants except P. dactylifera and 
R. sativus. Alkaloids were present in all the selected plants except F. religiosa, P. 
dactylifera and R. sativus. Proteins were present only in F. religiosa and S. chirata. 
Whereas emodins, anthraquinones, anthocyanins and leucoanthocyanins were absent in 
all the selected six plants.70 
 
46. Snehlata Pandey et. al., (2014) performed Phytochemical Screening of Selected 
Medicinal Plant Cinnamon Zeylanicum bark extract, Area of research; Uttarakhand, 
India. Extracts of this medicinal plant was utilized the standard screening method 
(Guevarra, et al, 2005) for the detection of secondary metabolites. The phytochemicals 
are important in human health this is because they display different biological activities 
such as antifungal, antibacterial activities. Quantitative phytochemical analysis of this 
plant confirms the presence of various phytochemicals like alkaloids. Flavonoids, 
tannins, saponins, steroid and glycosides in their six solvents cold, hot, warm water, 
acetone, ethanolic and methanolic bark extracts. 157 
 
47.  Mohanty C et. al., (2014) studied Development of phytochemical fingerprint of an 
Indian medicinal plant Chitrak (Plumbago zeylanica L) using High Performance Thin 
Layer Chromatography (HPTLC). Root and leaf extracts by ethanol, chloroform and 
acetone showed higher antibacterial activity against E. coli as compared to standard 
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Kanamycin (MIC-100 μg/ml). The high performance thin layer chromatography 
(HPTLC) fingerprints were used for the quantitation of two bioactive markers: 
gibberellic acid and quinol R in the plant powder of different organs. Maximum content 
of gibberellic acid was found in acetone extract of the root (59.74%, Rf 0.79) followed 
by methanol root extract (53.01%). 77 
 
48. Karthika K et. al., (2014) performed TLC and HPTLC Fingerprint Profiles of 
Different Bioactive Components from the Tuber of Solena amplexicaulis. The profiles of 
various individual secondary metabolites were made and developed for authentication. 
The methanolic tuber extract showed the presence of 5 alkaloids, 6 flavonoids, 2 
glycosides, 10 saponins and 7 terpenoids. The development of such fingerprint can be 
used in differentiation of the species from the adulterant in terms of phytochemical 
constituents and hence act as biochemical markers in the pharma industry and plant 
systematic studies.60 
 
49. Preethi MP et. al., (2014) performed work on Principal Component Analysis and 
HPTLC Fingerprint of In Vitro and Field Grown Root Extracts of Withania Coagulans. 
The HPTLC system was standardized  and was found out that roots of Withania 
coagulans, AUF Wc 024 and AUF Wc 025 had maximum withanolide A accumulation 
(1.17mg/g). The extractive value was found to be high for AUF Wc 021 (392.4 mg/g). 
Toluene: Ethyl acetate: Formic acid (5:5:1) has been standardized as the best solvent 
system for HPTLC analysis of withanolides.105 
 
50. Rashmi Tambe et. al., (2014) studied Phytochemical screening and HPTLC 
fingerprinting of leaf extracts of Psidium guajava Linn. and Preliminary phytochemical 
screening of the extracts showed the presence of alkaloids, triterpenes, tannins, saponins, 
glycosides, phenolic compounds and flavonoids. The proximate analysis showed 
satisfactory result with respect to foreign matter, moisture content, ash value and 
extractive values. HPTLC finger printing of methanol extract of leaf powder revealed 
presence of three polyvalent phytoconstituents with their Rf value 0.95, 1.11, 1.41 at 
220nm. Component number 3 at Rf 1.41 showed maximum concentration and presence 
of total five components with their Rf value 0.18, 0.91, 1.21, 1.42, 1.52 at 
450nm.Component number 4 at Rf 1.41 showed maximum concentration. Aqueous 
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extract of leaf powder showed total six components with their Rf value 0.29, 0.74, 0.85, 
0.96, 1.31 at 220nm.Component number 4 at Rf 0.96 showed maximum concentration. 
122 
 
51. Manickam Murugan et. al., (2014) performed Phytochemical, FT-IR and 
antibacterial activity of whole plant extract of Aerva lanata (L.) Juss. Ex. Schult. 
Qualitative phytochemical analysis of the methanol and ethanol extracts prepared from 
Aerva lanata whole plant revealed the presence of alkaloids, anthraquinones, catechins, 
coumarins, flavonoids, phenols, quinones, saponins, steroids, sugar, glycosides, tannins 
and xanthoproteins. The FT-IR spectrum confirmed the presence of alkyl group, methyl 
group, alcohol group, ethers, esters, carboxylic acid and anhydrides. 69 
 
52. Nidhi Agarwal et. al., (2014) reported Paneer Doda (Withania coagulans Dunal): A 
Promising Therapeutic Agent. The amino acids present are proline, hydroxyproline, 
valine, tyrosine, aspartic acid, glycine asparagin, cysteine and glutamic acid. A variety of 
withanolides have been found in the plant which are responsible for its therapeutic 
properties. It is widely used in treating diabetes mellitus, nervous exhaustion, disability, 
insomnia, wasting diseases and failure to thrive in children. The fruits of the plant are 
reported to be sedative, emetic, alterative and diuretic. They are also helpful in liver 
complaints, asthma and biliousness.93 
 
53. Geethu MG et. al., (2014) studied Fourier-Transform Infrared Spectroscopy 
Analysis of Different Solvent Extracts of Water Hyacinth (Eichhornia Crassipes Mart 
Solms.) An Allelopathic Approach. Eichhornia crassipes samples extracted with different 
solvents continuously was subjected to FTIR to determine whether the plant can be 
discriminated on the basis of biochemical profiles using solvents. The extraction factor 
was superior in water rich in polar molecules. The FTIR signal at 900, 1500, 1714, 3000, 
3100cm-1 were considered as an indicator of polyphenols. The functional groups of each 
extract were identified.42 
 
54. Rajeshwari Sahu et. al., (2014) performed studies on Ultraviolet-Visible and 
Fourier Transform Infrared Spectroscopic Studies on Non-Conventional Species of 
Curcuma. FTIR method was performed on a Perkin Elmer spectrophotometer system, 
which was used to detect the characteristic peak values and their functional groups. The 
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UV-VIS profile of C. caesia. rhizome methanolic extract showed the peaks at 256.00 nm, 
288.00 nm and 330.00 nm with the absorption 0.617,1.235 and 0.557respectively.56 
55. Neha Sahu et. al., (2013) studied Phytochemical Analysis of Bougainvillea Glabra 
Choisy by FTIR and UV-VIS Spectroscopic Analysis. FTIR method was performed on a 
Perkin Elmer spectrophotometer system, which was used to detect the characteristic peak 
values and their functional groups. As the result UV-VIS profile showed the peaks at 
324.00nm and 290.00nm for flavonoid and FTIR spectra showed the peak at 3364.58cm-
1 for OH group.90 
 
56. Priyanka Pandey et. al., (2013) concluded the Physico-chemical and preliminary 
phytochemical screening of Psoralea corylifolia. The presence of alkaloids, glycosides, 
carbohydrates, steroids, polyphenol, saponins and terpenoids were indicated by the test 
conducted. The three Rf value (0.82; 0.63; 0.45) of ethanol extracts and two Rf value 
(0.72; 0.65) of aqueous extracts were found in TLC plate. HPLC method was developed 
for the fingerprinting of bakuchiol, psoralen, and angelicin present in Psoralea corylifolia 
extract. 108 
 
57. Suman Kumar R et. al., (2013) studied Phytochemical Screening of some 
compounds from plant leaf extracts of Holoptelea integrifolia (Planch.) and Celestrus 
emarginata (Grah.) used by Gondu tribes at Adilabad District, Andhrapradesh, India. . 
The phytochemical analysis of leaf extracts in aqueous, methanol, acetone, petroleum 
ether and chloroform extracts of indigenous medicinally important plants of Holoptelea 
integrifolia and Celestrus emarginata were investigated. The phytochemical analysis 
revealed the presence of alkaloids, saponins, tannins, flavonoids, terpenoids, coumarins, 
quinines, cardiac glycosides, Xanthoproteins, glycosides, steroids, phenols, resins, 
carboxylic acid group in varying concentrations. 162 
 
58. Librado A Santiago et. al., (2013) carried out work on  Acute Oral Toxicity Study 
Of The Crude Ethanolic Leaf Extract Of Ficus Pseudopalma Blanco (Moraceae) In 
Sprague Dawley Rats. Acute oral toxicity of the crude ethanolic leaf extract of F. 
pseudoplama was performed according to the guidelines set by OECD 425 on six 8-12 
week old female Sprague Dawley rats weighing from 160-210g. One rat was treated with 
normal saline solution that served as the control. Toxicological and pharmacological 
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observations were completed for 14 days. On day 14, all test animals were sacrificed via 
cervical dislocation and subjected to gross necropsy; liver samples were subjected to 
histopathological examination. Gross examination of the rodent’s organs was all normal 
and regarded as unremarkable. 67 
 
59. Sabeeha Shafi et. al., (2013) concluded the Acute Oral Toxicity And 
Hypoglycaemic Study Of Ethanolic Extract Of Portulaca Oleracea (Whole Plant) In 
Swiss Albino Mice . In acute oral toxicity study, the animals showed behavioural 
changes also.50% of the animals died at the dose level of 500 mg/kg b.w and 100% 
animals died at the dose levels of 1000,1500 and 2000mg/kg b.w, thereby indicating that 
the dose below than 500mg.kg b.w is safe for further studies. In hypoglycemic activity 
the dose of 400mg/kg b.w showed a highly significant reduction of serum glucose levels. 
127 
 
60. Nurul Husna R et. al., (2013) reported Acute Oral Toxicity Effects of Momordica 
Charantia in Sprague Dawley Rats. The extract was administered orally at two different 
doses of 300 mg/kg and 2000 mg/kg of body weight. The toxicity signs were recorded 
within the first 24 hours after forced feeding. Both of the treated groups showed dizziness 
and depression during the first 30 minutes. No significant difference of feeding patterns 
which included water, food intake and body weight gain were observed. Haematological 
evaluations did not show significant differences in white blood cells count (WBC), mean 
corpuscular volume (MCV) and mean corpuscular haemoglobin concentration (MCHC) 
levels.95 
 
61. Vedhanarayanan P et. al., (2013) concluded the Antimicrobial activity and 
phytochemical screening of Wrightia tinctoria (Roxb.) R.Br. The findings showed 
potential antibacterial properties of the extracts against the organisms tested. Among the 
three solvents tested, ethanol extract of leaf showed higher inhibition zone. Ethanol 
extract of Wrightia tinctoria exhibits maximum zone of inhibition against Escherichia 
coli (29 mm), Bacillus subtilis (24 mm) Staphylococcus aureus (30 mm) and 
Pseudomonas aeruginosa (24 mm). Preliminary phytochemical analysis of Wrightia 
tinctoria showed the presence of alkaloids, flavonoids, phenols, saponins, steroids and 
tannins.176 
 
LITERATURE SURVEY 
 
 Page 65 
 
62. Shashank Matthew et. al., (2013) studied Analgesic and Anti-Inflammatory 
Activity of Kalanchoe Pinnata (Lam.) Pers. and investigated ethanol and aqueous 
extracts of dried stem of plant ‘Kalanchoe pinnata (lam.) Pers.’ against with Anti-
inflammatory and in rats and Analgesic activity in mice.151 
 
63. Prashanta KR Deb et. al., (2013)carried out work on In-Vitro Anthelmintic 
Activity of Acorus Calamus Leaves and investigation of the anthelmintic potential of 
crude MeOH extract, 50% EtOH and aqueous extract of the leaves of Acorus calamus on 
Indian earth-worm (Pheretima posthuma). Albendazole in same concentration as those of 
extract was included as standard reference and normal saline water with 1% CMC as 
control. All the extracts exhibited significant anthelmintic activity at a concentration of 
100 mg/ml. Peak activity was exhibited by the MeOH extract at a concentration of 100 
mg/ml.104 
 
64. Jiju V et. al., (2013) performed Evaluation of anthelmintic activity of methanolic 
extract of Asystasia gangeticum. The parameters like the time of paralysis and the time of 
death were determined by using the extract at the concentrations of (10-100 mg/ml). The 
extract exhibited significant anthelmintic activity at highest concentration of 100 mg/ml 
as compared with piperazine citrate (10 mg/ml) as standard reference and distilled water 
as control.57 
 
 
65. Madhavi E et. al., (2013) studied a Review on Medicinal Plants with Potential 
Hypolipidemic Activity.  More than 70 medicinal plants have been documented to have 
significant hypolipidemic action. This reviews these reports published in literatures in the 
last 5 years. This review indicates that the research has stopped with just reporting the 
effect of plant derivates and the findings are not translated into clinical research. Taking 
these finding forward is mandatory to develop new drugs in this area. Hence further 
research into identifying the active principle, conducting preclinical studies & if possible 
clinical studies is needed.177 
 
 
66. Ankur Datta et. al., (2013) reported the Antidiabetic and antihyperlipidemic activity 
of hydroalcoholic extract of Withania coagulans Dunal dried fruit in experimental rat 
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models and it may be concluded that the WCDF extract can be considered as an adjuvant 
in the treatment of type 2 DM which can possibly lower the dose requirement of standard 
oral hypoglycemic agents like glipizide. The hydroalcoholic WCDF extract was effective 
and comparable to atorvastatin in controlling lipid profile in high‑cholesterol 
diet‑induced hyperlipidemia in albino rats.9  
 
67. Shirin Hasani-Ranjbar et. al., (2013) studied a systematic review of anti-obesity 
medicinal plants - an update and explained that studies with Nigella Sativa, Camellia 
Sinensis, Crocus Sativus L, Seaweed laminaria Digitata, Xantigen, virgin olive oil, 
Catechin enriched green tea, Monoselect Camellia, Oolong tea, Yacon syrup, Irvingia 
Gabonensi, Weighlevel, RCM-104 compound of Camellia Sinensis, Pistachio, Psyllium 
fibre, black Chinese tea, sea buckthorn and bilberries show significant decreases in body 
weight. 154 
68. Suneetha D et. al., (2013) was undertaked study on Evaluation of Anti-Obesity 
Activity of Methanolic Extract of Sapindus emarginatus by Progesterone Induced 
Obesity on Albino Mice and evaluation of anti obesity activity the organisms used were 
albino mice. The standard drug used was orlistat. The two test doses of methanolic 
extract of pericarps of flowers of Sapindus emarginatus were prepared. The total 
evaluation period was 28 days.164 
 
69. Tejendra Bhakta et. al., (2013) carried out work on In-Vitro Anthelmintic Activity 
of Acorus Calamus Leaves. Three concentrations (25, 50, 100 mg/ml) of each extract 
were studied in activity which involved the determination of time of paralysis 
(vermifuge) and time of death (vermicidal) of the worms. Albendazole in same 
concentration as those of extract was included as standard reference and normal saline 
water with 1% CMC as control. Results: All the extracts exhibited significant 
anthelmintic activity at a concentration of 100 mg/ml. Peak activity was exhibited by the 
MeOH extract at a concentration of 100 mg/ml.104 
 
70. Vijusha M et. al., (2013) studied Screening of Behavioural, Muscle Co-Ordination & 
Anxiolytic Activities of Methanolic Extract of Tabebuia rosea (Bertol). The behavioural 
muscle coordination and anxiolytic activities were evaluated by using various models of 
CNS using mice. Diazepam was used as standard drug for muscle coordination and 
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anxiolytic studies. The extracts were administered orally at 500 mg/kg. The results of the 
present study indicates that the methanolic extract of Tabebuia rosea leaves are effective 
in inducing a significant protection against behavioural, muscle coordination and 
anxiolytic activities, as evidenced by various CNS models with respect to control. This 
study confirmed the behavioural, muscle coordination and anxiolytic activities of this 
plant as it is used in traditional medicine.61 
 
71. Vandana Gupta et. al., (2013) suggested a review of Withania Coagulans Dunal. 
(Paneer Doda). Withanolides are steroidal lactones having significant pharmacological 
activities. In various studies it has been seen that the Withania coagulans posses several 
medicinal properties such as hepatoprotective, antiinflammatory, antihyperglycaemic, 
free radical scavenging, hypolipidaemic, antimicrobial, cardiovascular, central nervous 
system depressant, immunomodulating, antitumour and cytotoxic activities. 175 
 
72. Jhansee Mishra et. al., (2013) studied Withania Coagulans in Treatment of 
Diabetics and Some Other Diseases: A Review. The berries of the shrub are used for 
milk coagulation. It is popularly known as Indian cheese maker. In Punjab, the fruits of 
W. Coagulans are used as the source of coagulating enzyme for clotting the milk which is 
called "paneer".55 
 
73. Prakash Chandra Gupta et. al., (2012) studied Withania Coagulans Dunal- An 
Overview. The fruits of the plant are reported to be sedative, emetic, alterative and 
diuretic. Further, they are used for liver complaints, asthma and biliousness. The active 
compounds, in particular, withanolides isolated from the plant are considered to have 
antimicrobial, anti-inflammatory, antitumor, hepatoprotective, anti-hyperglycemic, 
cardiovascular, immuno-suppressive, free radical scavenging and central nervous system 
depressant activities. 101 
 
74. Kirtikar Shukla et. al., (2012) carried out work on the Aqueous Extract of 
Withania coagulans Fruit Partially Reverses Nicotinamide/Streptozotocin-Induced 
Diabetes Mellitus in Rats. Daily treatment with aqueous W. coagulans at 250mg/kg of 
body weight for 30 days restored plasma glucose, HbA1c, tissue glycogen, and glucose 
metabolic enzymes to nearnormal ranges in bothMD and SD animals. The results of this 
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study reveal that the regular administration of aqueous W. coagulans extract for 30 days 
significantly improved glycemic status and nearly normalized plasma glucose 
concentrations. 63 
 
75. Abidemi J Akindele et. al., (2012) studied Anxiolytic activity of aerial part 
hydroethanolic extract of Allium ascalonicum Linn. (Liliaceae) in mice and in the hole-
board test, A. ascalonicum significantly (p<0.05, 0.01) increased the number/duration of 
head dips and number of sectional crossings. In the elevated plus maze test, A. 
ascalonicum significantly (p<0.05) increased the number of entries into the open arm 
withcorresponding reduction in number of entries into the closed arm. In the light/dark 
exploration test, A. ascalonicum significantly (p<0.05, 0.01) increased the latency of 
entry into the dark box, time spent in the light box, and number of rearing and assisted 
rearing. 3 
 
76. Naga Kishore R et. al., (2012) was undertaken Evaluation Of Anxiolytic Activity 
Of Ethanolic Extract Of Foeniculum Vulgare In Mice Model and the study was designed 
to investigate the anxiolytic activity of ethanolic extracts of Foeniculum vulgare fruit. 
The anxiolytic activity was evaluated by elevated plus maze, rota rod, open field test, and 
hole board models. The efficacy of extract (100-200mg/kg) was compared with standard 
anxiolytic drugs diazepam (1mg/kg). Extract administered animals showed exploratory 
behavior with all tests similar to diazepam. The results showed that the extract 
significantly increased the number of entries and time spent in the open arm in the 
elevated plus maze apparatus.85 
 
77. Chetan Salwaan et. al., (2012) studied the Investigation of the Pharmacognostical, 
Phytochemical and Antioxidant Studies of Plant Withania coagulans Dunal. It was 
observed that 50% ethanol extract of Withania coagulans contains carbohydrates, 
proteins, glycosides, steroids and sterols, anthraquinones and triterpenoids. The 
antioxidant activity of Withania coagulans Dunal was studied by DPPH and Nitric oxide 
method and it was observed that it has antioxidant activity. It showed more activity in 
DPPH method than Nitric oxide method. Preliminary Phytochemical study of 50% 
ethanolic extract of the root parts is found to contain carbohydrates, protein, some 
steroids, anthraquinone, flavonoids, tannin, phenolic compounds and triterpenoids are 
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present. The antioxidant activity was determined and the plant extract showed low 
activity nitric oxide free radical inhibition method and moderate activity by DPPH 
method. The activity was compared with rutin and ascorbic acid.21 
 
78. Sangh Partap et. al., (2012) carried out work on In-Vitro Anthelmintic Activity of 
Luffa cylindrica Leaves in Indian Adult Earthworm and Different extracts of L. 
cylindrica were taken for anthelmintic activity against Indian earthworm Pheretima 
posthuma. Two concentrations (50 and 100 mg/ml) of various extracts were tested and 
results were expressed in terms of time for paralysis and time for death of worms. 
Albendazole (20 mg/ml) was used as reference standard and carboxy methyl cellulose 
(0.5%) as a control group. Dose dependent activity was observed in the plant extracts but 
methanolic extract exhibited more activity as compared to others. The anthelmintic 
activity of Luffa cylindrical leaves extract has therefore been demonstrated for the first 
time.131 
 
79. Abhishek B et. al., (2012) studied Anthelmintic activity of Cynodon dactylon and 
the phytochemical tests were done to find the presence of the active chemical 
constituents such as alkaloids, glycosides, terpenoides, Steroids, saponins, flavonoids, 
tannins, carbohydrates, proteins and fixed oils. Standardization of Cynodon dactylon was 
carried out to check the extractive value, loss on drying, ash value etc. Anthelmintic 
activity was evaluated on adult Indian earthworm Pheretima Posthuma by using 
albendazole as a standard drug. The aqueous extract of Cynodon dactylon shows 
anthelmintic activity as compared with the standard drug.2 
 
80. Selvamohan T et. al., (2012) reported Antimicrobial activity of selected medicinal 
plants against some selected human pathogenic bacteria. The methanol, ethanol and 
aqueous extracts of seven medicinal plants were evaluated for activity against medically 
important bacteria such as Staphylococcus sp., Escherichia coli, Klebsiella sp., 
Pseudomonas sp. The ethanolic and aqueous extracts showed minimum antimicrobial 
activity when compared to methanolic extracts. The methanolic extract Phyllanthus 
niruri (stone breaker) showed the maximum activity against Staphylococcus sp. 140 
 
81. Saswata Banerjee et. al., (2012) carried out work on Evaluation of Analgesic 
Activities of Methanolic Extract of Medicinal Plant Juniperus Communis Linn. The 
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extract showed a dose dependent and significant (P<0.01) inhibition of writhing 
response. . This has been observed that the plant showed significant activity as anti 
nociceptive agent and was proved to act both peripherally and centrally.134 
 
82. Sai Mangala Divi et. al., (2012) performed a Comparative Study on Evaluation of 
Antidiabetic and Antihyperlipedemic Potential of Aqueous Extract of Moringa oleifera in 
Fructose Fed Insulin Resistant and STZ Induced Diabetic Wistar Rats. Administration of 
aqueous extract of Moringa oleifera for 60 days restored all the alterations to normal/ 
near normal. The study clearly reveals that aqueous extract of Moringa oleifera leaf 
possesses potent antihyperglycemic and antihyperlipedemic effect in both Insulin 
resistant and Insulin deficient rat models.128 
 
83. Mehrana Jafari et. al., (2012) performed studies on Remedial Use of Withanolides 
from Withania Coagolans (Stocks) Dunal and  the biological activities of withanolieds 
from Withania coagulans described. Anti-inflammatory effect, anti cancer and 
alzheimer’s disease and their mechanisms, antihyperglycaemic, hypercholes-terolemic, 
antifungal, antibacterial, cardiovascular effects and another activity are defined. 32 
 
84. Rohit Gundamaraju et. al., (2012) studied Evaluation of Anti-Obesity Activity of 
Lantana camara Var Linn. by Progesterone Induced Obesity on Albino Mice and the 
presence of phyto constituents such as steroids , flavinoids , alkaloids, etc. are resulted in 
the reduction of the body weight. 124 
 
85. Sudhanshu Kumar Bharti et. al., (2012) reported the Antidiabetic effect of 
aqueous extract of Withania coagulans flower in Poloxamer-407 induced type 2 diabetic 
rats. A significant increase in blood glucose, glycosylated haemoglobin (HbA1c), and 
serum insulin levels were observed in control rats. Treatment with W. coagulans extract 
reduced the elevated levels of blood glucose, HbA1c, and insulin in T2DM rats. In oral 
glucose tolerance test, we found a significant improvement in glucose tolerance in the 
rats treated with W. coagulans extract. The insulin sensitivity, that is, both peripheral and 
hepatic insulin resistance was assessed. W. coagulans extract treatment significantly 
improved insulin sensitivity index (KITT) that was decreased in control rats. 161 
 
LITERATURE SURVEY 
 
 Page 71 
 
86. Rohit Jain et. al., (2012) studied the review of Phytochemistry, pharmacology, and 
biotechnology of Withania somnifera and Withania coagulans and presents a 
consolidated account of the phytochemistry, pharmacology and biotechnology involving 
in vitro propagation, genetic transformation and metabolite profiling in W. somnifera and 
W. coagulans.125 
 
87. Abhijeet R Borate et. al., (2011) studied Antihyperlipidemic Effect of 
Protocatechuic Acid in Fructose Induced Hyperlipidemia in Rats. Herbal treatment for 
hyperlipidemia has fewer side effects. Protocatechuic acid (PCA), which is 
predominantly present in the flowers of Hibiscus sabdariffa, possesses 
antihyperlipidemic and free radical scavenging activity. Taking this into consideration 
PCA at the dose of 25 and 50 mg/kg were evaluated against fructose induced 
hyperlipidemia in rats and it has showed a significant decrease (p<0.05, p<0.01 
respectively) in the levels of serum TC, TG and LDL and HDL was significantly 
increased (p<0.05, p<0.01 respectively) in serum when compared to fructose control 
group. Thus Protocatechuic acid has anti-hyperlipidemic activity which may be due to 
increased uptake of LDL cholesterol by hepatic LDL receptor or may be due to its effect 
on enzymes involved in metabolism and excretion of cholesterol.1 
 
88. Debasis Mishra et. al., (2011) carried out work on an Experimental Study of 
Analgesic Activity of Selective Cox-2 Inhibitor with Conventional NSAIDs and the 
study was carried out to investigate the analgesic activity of Etoricoxib (10 mg) for 
individual drug therapy and etoricoxib (5 mg) for combination therapy with diclofinac 
potassium (10 mg) using Acetic acid induce writhing, Hot plate and Tail immersion 
methods. The test and standard drugs significantly (p<0.001) reduced the number of 
abdominal constriction and stretching of hind limb induce by the injection of acetic acid 
in a dose dependent manner. The Hot plate and Tail immersion test useful in the 
elucidating centrally mediated antinociceptive responses, which focused mainly on 
changes above the spinal cord level. All the test and standard drugs significantly 
(p<0.001) reduced the pain as compare to the control group. 25 
 
89. Tahira Mughal et. al., (2011) performed studies on Antifungal Studies of Withania 
Coagulans and Tamarix aphylla. In vitro studies were carried out to evaluate the 
antifungal activity of methanolic , pet ether and dichloromethane extract of aerial parts of 
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Withania coagulans and Tamarix aphylla against seven fungal strains (Trichoderma 
viridis ,Aspergillus flavus , Fusarium laterifum , Aspergillus fumigatus , Candida 
albicans , Trichophyton mentogrophytes and Microsporum canis) and having better 
antifungal efficacy. 167 
90. Girija K et. al., (2011) carried out work on Anti-hyperlipidemic activity of 
methanol extracts of three plants of Amaranthus in triton-WR 1339 induced 
hyperlipidemic rats and the test extract possessed better anti- hyperlipidemic activity 
against triton-WR 1339 induced Hyperlipidemia and obtained the better results when 
compared with the standard drug (atrovastatin treated).44 
 
91. Lakshmi BVS et. al., (2011) demonstrated Antihyperlipidemic activity of Bauhinia 
purpurea extracts in hypercholesterolemic albino rats and there was a significant increase 
in high density lipoprotein levels after the treatment with Bauhinia purpurea extracts. 
Ethanol extract of leaves showed a marked effect over body weight reduction and also 
had a significant effect on the lipoprotein profile. There is a lowered atherogenic index, 
TC: HDL-c and LDL: HDL-c ratios in the extract treated groups. 65 
 
92. Pezeshki  A et. al., (2011) suggested the Influence of Withania coagulans Protease 
as a Vegetable Rennet on Proteolysis of Iranian UF White Cheese. Extraction of protease 
from Withania coagulans’ fruits and the effect on proteolysis of Iranian UF white cheese 
in comparison with pure chymosin and fungi rennet (fromase) were investigated during 
ripening. The results indicated that, except for pH which was significantly (P< 0.05) 
lower in cheeses made with Withania coagulans, there was no significant difference 
observed among the cheeses produced with different rennet preparations as in moisture, 
fat and salt contents during ripening. 100 
 
93. Das R et. al., (2011) performed In Vitro Anthelmintic Activity of Leaves of Juglans 
Regia L against Pheretima Posthuma and attempt to evaluate anthelmintic activity of 
different extracts of leaves of J. regia L. Different extracts of the plant material were 
tested against adult Indian earthworms Pheretima posthuma (Pheritimidae) as test 
worms. The bioassay involved determination of the time of paralysis and time of death 
control. Piperazine citrate (10 mg/mL) was used as standard reference drug. 23 
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94. Prashant Tiwari1 et. al., (2011) studied Comparative Anthelmintic Activity of 
Aqueous and Ethanolic Stem Extract of Tinospora Cordifolia and aqueous and Ethanolic 
extracts of stem of Tinospora cordifolia using Eisenia foetida at four different 
concentrations  (10, 25, 50 and 100 mg/ml) respectively. The study involved the 
determination of time of paralysis (P) and time of death (D) of the worms. At the 
concentration of 100 mg/ml both the ethanolic and the aqueous extracts exhibited very 
significant activities as compared to the standard drug piperazine citrate (10 mg/ml). 103 
 
95. Deepika Mathur et. al., (2011) studied Evaluation of in vivo antimutagenic 
potential of fruits extracts of Withania coagulans. The results confirmed that a single i.p 
administration of W. coagulans fruit extract at the dose of 500, 1000 and 1500 mg/kg 
body weight prior to 24 hours have significantly prevented the micronucleus formation in 
dose dependent manner in bone marrow cells of mice as compared to cyclophosphamide 
group.27 
 
96. Deo SS et. al., (2011) studied Antimicrobial Activity and HPLC Fingerprinting of 
Crude Ocimum Extracts. The crude aqueous extracts of Ocimum sanctum showed strong 
antimicrobial activity against S.aureus and moderate against others. Whereas the crude 
aqueous extracts of Ocimum kilimandsacharicum showed moderate activity against the 
gram positive and gram negative organisms and strong activity against C. albicans at 
higher concentration, same as that shown by the standard for C. albicans.28 
 
97. Simona Zavoi et. al., (2011) worked on a Comparative Fingerprint and Extraction 
Yield of Medicinal Herb Phenolics with Hepatoprotective Potential, as Determined by 
UV-Vis and FT-MIR Spectroscopy.. The value of the MIR signal at 1743 cm-1 may be 
considered a good indicator of phenolics concentration in such extracts. Combined UV-
Vis and FTIR spectroscopy are recommended as rapid and reliable tools to investigate 
the fingerprint and to predict the composition of medicinal plants or to evaluate the 
quality and authenticity of different standardized formulas.156 
 
98. Onasanwo SA et. al., (2010) studied Antidepressant and Anxiolytic Potentials of 
Dichloromethane Fraction from Hedranthera barteri and was investigated in animal 
models of depression and anxiety in mice. Graded doses (25-200mg/kg p.o. bw) of 
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DMHBR reduced the immobility time with significant effects produced by 50mg/kg 
(43.7%), 100mg/kg (45.6%) and 200mg/kg (31.5%) in the tail suspension test (TST) and 
by 100mg/kg (66.3%) in forced swimming test (FST), indicating a possible 
antidepressant-like activity when compared with standard antidepressant drug, 
imipramine.97 
 
99. Prasad SK et. al., (2010) reported Pharmacognostical Standardization of   Withania 
coagulans Dunal. The study includes macroscopical and microscopical evaluation along 
with estimation of its physicochemical parameters such as ash and extractive values, 
preliminary phytochemical screening and fluorescence analysis. It also includes 
quantification of some of the active constituents such as withanolides (withaferin-A) by 
HPTLC, total phenolic, tannin, flavonoids and flavonols. 102 
 
100. Janak Dabheliya et. al., (2010) carried out work on Diuretic Potential of Aqueous 
Extract of Fruits of Withania Coagulans Dunal in Experimental Rats. The diuretic 
activity of the aqueous extract of fruits of Withania coagulans was studied by invivo 
Lipschitz test model with slight modifications using furosemide as a standard. The 
volumes of urine, urinary concentration of sodium, potassium and chloride ions were the 
parameters of the study. The results indicated significant (P < 0.001) increase in the urine 
volume by 79.12 % and 71.02 % in 500 mg/kg and 750 mg/kg doses respectively, when 
compared to control group. Urinary electrolyte excretions were increased with both the 
doses when compared to control. 54 
 
101. Sumathi P et. al., (2010) suggested Antimicrobial activity of some traditional 
medicinal plants. The results showed that the minimum inhibitory concentration (MIC) 
of P. niruri leaf extract was 50 μg/ml against Salmonella typhi and Staphylococcus 
aureus, whereas, the MICs of T. bellerica fruit extract against Escherichia coli and S. 
aureus were 50 and 200 μg/ml respectively. However, the leaf extracts of the 
Andrographis paniculata, T. Chebula and V. negundo have not shown any antimicrobial 
activity in the tested concentrations.163 
 
102. Zulfiker AHM et. al., (2010) studied In vivo analgesic activity of ethanolic extracts 
of two medicinal plants - Scoparia dulcis L. and Ficus racemosa Linn. The crude 
extracts of both the plants were found to have significant (p<0.001) analgesic activity at 
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the oral dose of 100 & 200 mg/kg b. wt., in the tested models. In hot plate test S. dulcis 
showed increased latency period than F. racemosa whereas in acetic acid induced 
writhing test F. racemosa showed reduced number of writhes than S. dulcis at two dose 
levels which are significant (p<0.001) compared to control. 188 
 
103. Eliana H Akamine et. al., (2010) carried out work on Obesity induced by high-fat 
diet promotes insulin resistance in the ovary and the ovary from high-fat-fed female rats 
showed a reduction in the insulin receptor substrate/phosphatidylinositol 3-kinase/AKT 
intracellular pathway, associated with an increase in FOXO3a, IL1B, and TNFa protein 
expression. These changes in the insulin signaling pathway may have a role in the 
infertile state associated with obesity.34 
 
104. Islam MR et. al., (2010) obeserved Analgesic, anti-inflammatory and antimicrobial 
effects of ethanol extracts of mango leaves and analgesic bioassay, oral administration of 
the ethanol leaves extract significantly (P<0.01) reduced the writhing response. The 
degree of inhibition of leaves extract was 55.8% compared to the effect of standard 
analgesic drug, Diclofenac Sodium (75.28%). On the other hand, though leaves extract 
reduce paw edema but they did not show any significant effect.53 
 
105. Yash Prashar et. al., (2010) carried out work on Anti-Obesity Activity of Bauhinia 
Variegata Linn. in High Fat Diet Induced Obestity in Female Rats and emphasized to 
explore the effect of AEBV 200 &400mg/kg, p.o on energy balance disorders like, 
obesity, hyperphagia, hyperglycaemia and hyperlipidemia. They predicted that Bauhinia 
variegata root extracts exerted significant anti-obese activity due to its hypophagic, 
hypoglycaemic and hypolipidemic effect in rats fed on high fat diet. 186 
 
106. Yonghua Zhanga et. al., (2009) studied Progesterone metabolism in adipose cells 
and reported induction of preadipocyte differentiation increased expression levels of 
AKR1C1 and modified the pattern of progesterone metabolism substantially, leaving 20- 
hydroxyprogesterone as the main metabolite generated. On the other hand, progesterone 
itself showed no consistent effect on adipocyte differentiation. They concluded, 
preadipocytes and lipid-storing, mature adipocytes efficiently generate progesterone 
metabolites in women, which is consistent with rather modest effects progesterone on 
abdominal fat cell differentiation.187 
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107. Oliveira LMB et. al., (2009) studied Anthelmintic activity of Cocos nucifera L. 
against sheep gastrointestinal nematodes. The in vitro assay was based on egg hatching 
(EHT) and larval development tests (LDT) with Haemonchus contortus. The 
concentrations tested in the EHT were 0.31, 0.62, 1.25, 2.5 and 5 mg/ml, while in the 
LDT they were 5, 10, 20, 40 and 80 mg/ml. The extract efficacy in the EHT and LDT, at 
the highest concentrations tested, was 100% on egg hatching and 99.77% on larval 
development. The parameters evaluated in the controlled test were not 
statisticallydifferent, showing that despite the significant results of the in vitro tests, the 
LGCHF ethyl acetate extract showed no activity against sheep gastrointestinal 
nematodes.96 
 
108. Wasswa Peter et. al., (2006) carried out work on the In-Vitro Ascaricidal Activity 
of Selected Indigenous Medicinal Plants Used in Ethno Veterinary Practices in Uganda. 
The research findings showed that Tetradenia riparia, Cassia occidentalis, Carica 
papaya, Momordica foetida and Erythrina abysinnica may be of value in the treatment of 
helminthiasis; whereas Moringa oleifera and Cannabis sativa are probably ineffective or 
of limited value for the same purpose.116 
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3. OBJECTIVE OF THE WORK 
The plants are the key source of medicine in Ayurveda for treatment and prevention of 
diseases and maintenance of healthy life. The plants are used in medicine since antiquity. 
Much of the medicinal plants are documented in the Ancient Ayurvedic classics and these 
plants are still used successfully to treat different ailments. One of these plants which is used 
to treat various disease is Withania coagulans Dunal. The shrub is important for the property 
of coagulating milk, possessed by its berries; they are used for this purpose in North-West 
India and adjoining country. 
Withania coagulans are the most reputed medicinal plants of Ayurveda and has well-
descript pharmacological activities such as physiological and metabolic restoration, anti-
arthritic, anti-aging, cognitive function, improvement in geriatric states and recovery from 
neurodegenerative disorders.75, 132 
Based on the literature review, it was planned to carry out the biological screening as 
outlined below 
 
 To validate acute oral toxicity 
 To study the behavioral coordination in rats 
 To study the antiobesity activity in progesterone induced obese rats 
 To study the antihyperlipidemic activity in fructose induced hyperlipidemic rats 
 To study the analgesic activity  
 To evaluate the antimicrobial activity and anthelmintic activity 
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4. PLAN OF THE WORK 
 Collection of the Withania flowers 
 Authentication of the flowers 
 Extraction with the suitable solvent – Ethanolic extraction 
 Phytochemical screening of the extract 
• Analytical studies 
 FTIR spectral analysis 
 HPTLC method 
• Invivo  studies 
 Acute oral toxicity test - Validation 
 OECD guideline 423 
 Behvioural coordination study  
 Hole board test in rats  
 Antiobesity activity 
 Progesterone induced obesity in rats 
 Antihyperlipidemic activity 
 Fructose  induced hyperlipidemia in rats 
 Analgesic activity 
 Tail immersion test in rats 
• Invitro studies  
 Antimicrobial activity  
 Disc diffusion method  
 Anthelmintic activity 
 Study of paralysis and death time in various worms 
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5. PLANT DESCRIPTION 
PLANT AUTHENTICATION 
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Fig. No. 4: Floral diagram of Withania coagulans Dunal 
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Withania coagulans Dunal (Flower bud) 
The dried flower buds of Withania coagulans Dunal was collected in Chennai from an 
authenticated dealer on March 2017.  
 
Fig. No. 5: Plant showing flowers of Withania coagulans Dunal 
 
 
 
Fig. No. 6: Dried flowers of Withania coagulans Dunal 
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Taxonomical classification of Withania coagulans Dunal21, 101 
Table No. 4: Taxonomical classification of Withania coagulans Dunal 
Rank Scientific Name and Common Name 
Kingdom Plantae – Plants 
Subkingdom Tracheobionta – Vascular plants 
Superdivision Spermatophyta – Seed plants 
Division Magnoliophyta – Flowering plants 
Class Magnoliopsida – Dicotyledons 
Subclass Asteridae 
Order Solanales 
Family Solanaceae  
Genus Withania  
Species coagulans (L.) Dunal 
 
Other common names132 
Table No. 5: Common names of Withania coagulans Dunal 
Tamil  Panir poo 
Hindi  Akri, Punir 
English  Indian cheese maker, Vegetable rennet 
Punjabi  Spin bajja, panir 
Marathi  Kaknaj 
Sindhi  Punirjafota, Punirband 
Persian  Kaknajehindi, Punirbad 
Arabic  Javzulmizaja, Kaknajehindi 
Telugu  Panneru-gadda 
Urdu  Hab kaknaj 
 
 
 
                                                                                       PLANT DESCRIPTION 
 
 Page 83 
 
Botanical description and Characteristic feature101 
Macroscopical  
 A rigid, grey under shrub, 60-120 cm high 
A rigid grey- tomentose undershrub 0.3-0.9 m. high, branches terete, clothed with 
dense grey or yellowish white tomentum 
Leaves  
2.5-5.7 by 1-2.2 cm., lanceolate-oblong, obtuse, entire, clothed with a persistent not 
easily detachable greyish tomentum, of a uniform colour on both sides, thick, more or less 
rugose, base acute, running down into an often obscure petiole; petiole 6 mm. long but often 
indistinct 
Flowers 
Dioecious, in axillary clusters; pedicles 0-6mm. long, deflexed, slender 
Calyx 6 mm. long, campanulate, clothed with fine stellate grey tomentum; teeth 
triangular, 2.5 mm. long.  
Corolla 8 mm. long, stellately mealy outside, divided about 1/3 the way down; lobes 
ovateoblong, subacute 
Male flowers 
Stamens about level with the top of the corolla- tube; filaments 2 mm. long, glabrous; 
anthers 3-4 mm. long. Ovary ovoid, without style or stigma 
 
Female flowers 
Stamens scarcely reaching ½ way up the corolla-tube; filaments about 0.85 mm. long; 
anthers smaller than in the male flowers, sterile 
Ovary 
Ovoid, glabrous; style glabrous; stigma mushroom- shaped, 2- lamellate 
Fruits  
Berry 6-8 mm. diam., globose, smooth, closely girt by the enlarged membranous calyx 
which is scurfy pubescent outside 
Seeds  
2.5-3mm diam., dark brown, ear shaped, glabrous 
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Flowering period 
From January to April and berries ripen during January to May 
The natural regeneration is from seed 
Habitat 
It grows as short shrub (35-75 cm) with central stem. This shrub is common 
Afghanistan and East Indian. It has milk coagulating property. It is also found in North West 
India, in Punjab and in Pakistan. It is also known as Pakistani herb. 
Chemical Constituents 
Berries contain milk coagulating enzyme esterase, free amino acids, fatty oil, essential 
oil and alkaloids. The essential oil was active against Micrococcus pyogenes var. aureus and 
also shows anthelmintic activity.  
The withanolides, withacoagin, coagulan and withasomidienone have been isolated 
from plant along with other withanolides and withaferin. 3- β-hydroxy-2, 3- 
dihydrwithanolide E isolated from plant showed significant hepatoprotective activity and anti-
inflammatory activity equal to hydrocortisone.  
Uses 
 It is used as Emetic, Diuretic and Anti Diabetic agent 
 Ripe fruits used as sedative, CNS depressant and anti-inflammatory 
 Also used in chronic liver trouble 
 Dried fruits used as carminative, dyspepsia and flatulence 
 Leaves used as alterative and febrifuge 
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6. METHODOLOGY 
6. 1. Extraction21 
Extraction is defined as the process of isolation of material from an insoluble 
residue which may be liquid or solid, by treatment with a solvent on the basis of the 
physical nature of crude drug to be extracted, that is liquid or solid.  
Flower buds of Withania coagulans Dunal were collected; dried material was 
ground into coarse powder which was used for further study to extract with ethanol using 
Soxhlet apparatus. 
Petroleum ether extract 
About 500gm of dried coarse powder was extracted with 2.5 litre of petroleum 
ether by (60-80°C) continuous hot percolation using Soxhlet apparatus. The extraction was 
continued for 24 hours and defatting was done using petroleum ether. After completion of 
extraction, the petroleum ether extract was filtered and solvent was removed by distillation 
under reduced pressure. A dark green coloured residue was obtained. Then the extract was 
stored in a dessicator. The marc was stored for further extraction with ethanol. 
Ethanolic Extract 
Marc obtained from the petroleum ether extract was dried and finally extracted 
with 2.5 litre of ethanol. The extraction was continued for 24 hours. After completion of 
extraction, the extract was filtered and solvent was removed by distillation under reduced 
pressure. A brown coloured residue was obtained. Then it was stored in dessicator. 
The extracts were used for identification of constituents by phytochemical 
screening and for pharmacological studies.  
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6. 2. Identification of Plant Constituents by Preliminary Phytochemical Tests21, 101 
The plant extracts were subjected to preliminary phytochemical screening for the 
detection of various plant constituents present. The term qualitative analysis refers to the 
establishing and proving the identity of a substance. The active ingredients, after isolation, 
can be incorporated into the modern medicine system for the development of newer 
formulation for therapeutic ailments. Systematic investigation of the plant material for its 
phytochemical behavior involves four different stages. 
 Procurement of raw material and quality control 
 Extraction, isolation, purification and characterization of the constituents of interest 
 Investigation of biosynthetic pathways of the particular compound 
 Quantitative evaluation 
 
Qualitative Phytochemical Analysis 
The ethanolic extract of Flower buds of Withania coagulans Dunal were subjected 
to the following chemical tests separately for the identification of various active 
constituents. 
Tests for Alkaloids 
1. Dragendorff's Test: To 1 mL of the extract, added 1 mL Dragendorff’s reagent, 
and orange red precipitate indicated the presence of alkaloids. 
 
2. Wagner's Test: To 1 mL of the extract, added 2 mL of Wagner's reagent. The 
formation of a reddish brown precipitate indicated the presence of alkaloids 
 
3. Mayer's Test: To 1 mL of the extract, added 2 mL of Mayer's reagent, a dull white 
precipitate revealed the presence of alkaloids. 
 
4. Hager's Test: To 1 mL of the extract, added 3 mL of Hager's reagent, the 
formation of yellow precipitate confirmed the presence of alkaloids. 
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Tests for Carbohydrates 
 
1. Molisch Test: To 2 mL of the extract, added 1mL of α - naphthol solution, and 
concentrated sulfuric acid through the sides of test tube. Purple or reddish violet 
color at the junction of the two liquids revealed the presence of carbohydrates. 
2. Fehling's Test: To 1 mL of the extract, added equal quantities of Fehling's solution 
A and B, upon heating formation of a brick red precipitate indicated the presence of 
carbohydrates. 
 
3. Benedict's Test: To 5 mL of Benedict's reagent added 1 mL of extract solution and 
boiled for 2 minutes and cooled. Formation of a red precipitate showed the 
presence of carbohydrates. 
 
Tests for Proteins and Amino Acids 
 
1. Biuret Test: To 1 mL of the extract added 1mL of 40% sodium hydroxide solution 
and 2 drops of 1% copper sulfate solution. Formation of violet color indicated the 
presence of proteins. 
2. Xanthoprotein Test: To 1 mL of the extract added 1 mL of concentrated nitric 
acid. A white precipitate was formed, it was boiled and cooled. Then, 20% of 
sodium hydroxide or ammonia was added. Orange color indicated the presence of 
aromatic amino acids. 
 
3. 3. Lead Acetate Test: To the extract, 1 mL of lead acetate solution was added. 
Formation, of proteins. 
 
Tests for Steroids 
 
1. Liebermann Burchard Test: Dissolved the extract in 2 mL of chloroform in a dry 
test tube. Added 10 drops of acetic anhydride and 2 drops of concentrated sulfuric 
acid. The solution became red, then blue and finally bluish green, indicated the 
presence of steroids. 
 
METHODOLOGY 
 
 Page 88 
 
2. Salkowski Test: Dissolved the extract in chloroform and added equal volumes of 
concentrated sulfuric acid. Formation of  bluish red to cherry red color in 
chloroform layer and green fluorescence in the acid layer represented the steroid 
components in the tested extract. 
 
3. Ninhydrin Test: Added two drops of freshly prepared 0.2% ninhydrin reagent to 
then extract solution and heated. Development of blue color revealed the presence 
of proteins, peptides or amino acids. 
 
Tests of Glycosides 
 
1. Legal's Test: Dissolved the extract in pyridine and added sodium nitroprusside 
solution to make it alkaline. The formation of pink red to red color showed the 
presence of glycosides. 
 
2. Baljet Test: To 1 mL of the test extract added 1 mL sodium picrate solution and 
the yellow to orange color revealed the presence of glycosides. 
 
3. Borntrager's Test: Added a few mL of dilute sulfuric acid to 1 mL of the extract 
solution.Boiled, filtered and extracted the filtrate with chloroform. The chloroform 
layer was treated with 1 mL of ammonia. The formation of red color showed the 
presence of anthraquinone glycosides. 
4. Keller Kiliani Test: Dissolved the extract in acetic acid containing traces of ferric 
chloride and transferred to a test tube containing sulfuric acid. At the junction, 
formation of a reddish brown color, which gradually became blue, confirmed the 
presence of glycosides. 
 
Test for Flavonoids 
 
1. Shinoda Test: To 1 mL of the extract, added magnesium turnings and 1-2 drops of 
concentrated hydrochloric acid. Formation of red color showed the presence of 
flavonoids. 
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5. 3. Infrared Spectroscopy143 
Fourier Transform –Infra Red Spectrophotometer 
Fourier transform infrared (FTIR) spectroscopy is a measurement technique 
that allows one to record infrared spectra. Infrared light is guided through an 
interferometer and then through the sample (or vice versa). A moving mirror inside the 
apparatus alters the distribution of infrared light that passes through the interferometer. 
The signal directly recorded, called an "interferogram", represents light output as a 
function of mirror position.  
A data-processing technique called Fourier transform turns this raw data into the 
desired result (the sample's spectrum): Light output as a function of infrared wavelength 
(or equivalently, wavenumber). As described, the sample's spectrum is always compared to 
a reference.. 
 
Fig. No. 7: Fourier Transform Infra Red Spectrometer 
Table No. 6: Specifications of FTIR Spectrophotometer 
Model Spectrum RX I 
Make Perkin Elmer 
Range 4000cm-1 to 400cm-1 
Specimen Solids, Liquids 
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5. 4. HPTLC Fingerprinting47 
CAMAG HPTLC system equipped with Linomat 5 applicator, TLC scanner 3, 
repro star 3 with 12 bit CCD camera for photo documentation, controlled by WinCATS-4 
software were used. All the solvents used for HPTLC analysis were obtained from 
MERCK. A total of 100 mg extract was dissolved in 5 mL of ethanol and used for HPTLC 
analysis as test solution.  
The samples (10 µl) were spotted in the bands of width 8 mm with a Camag 
microlitre syringe on pre-coated silica gel glass plate 60 F- 254. The sample loaded plate 
was kept in TLC twin trough developing chamber (after saturated with Solvent vapor) with 
respective mobile phase and the plate was developed up to 83 mm in the respective mobile 
phase.  
Linear ascending development was carried out in 20 cm X 10 cm twin trough glass 
chamber saturated with the mobile phase and the chromatoplate development with the 
same mobile phase to get good resolution of phytochemical contents. The optimized 
chamber saturation time for mobile phase was 30 min at room temperature. The developed 
plate was dried by hot air to evaporate solvents from the plate.  
The plate was photo-documented at UV 366 nm and white light using photo 
documentation chamber. Finally, the plate was fixed in scanner stage and scanning was 
done at 366 nm. The plate was kept in photo-documentation chamber and captured the 
images under white light, UV light at 254 and 366 nm. Densitometric scanning was 
performed on Camag TLC scanner III and operated by CATS software (V 3.15, Camag). 
5. 4. 1. HPTLC Fingerprinting – Alkaloids  
TLC Details T1, T2-10, 20 μL of Test Solution  
Identity Test  
Test Solution: Weigh about 0.5g of sample and shaken for 15min with 15mL of 0.1N 
sulphuric acid and then filtered. The filtrate is washed with 0.1N sulphuric acid to a 
volume of 20mL; 1mL of concentrated ammonia is added. The mixture is shaken with 
chloroform; separated chloroform layer is passed over anhydrous sodium sulphate, and 
evaporated to dryness. The dried residue is dissolved in methanol used for TLC analysis.  
Stationary phase: Silica Gel 60 F254  
Mobile phase: Toluene: Ethyl Acetate: Diethylamine (7: 2: 1)  
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Procedure: Applied 10, 20μL of test solutions spotted on a precoated silica gel 60 F254 
HPTLC plate (E. Merck) of uniform thickness 0.2mm using Linomat5 sample applicator. 
Developed the plate in the solvent system to a distance of 8cm. Observed the plate under 
UV light at 254nm & 366nm using CAMAG REPROSTAR3. 
5. 4. 2. HPTLC Fingerprinting – Flavanoids  
TLC Details - T1, T2-5, 10μL of Test solution. 
Identity Test 
Test Solution: About 100mg of extract was dissolved in ethanol used for TLC analysis. 
Stationary phase: Silica Gel 60 F254 
Mobile phase: Toluene: Ethyl acetate: Formic acid (5: 4: 1) 
Procedure: Applied 5, 10μL of test solutions spotted on a precoated silica gel 60 F254 
HPTLC plate (E. Merck) of uniform thickness 0.2mm using Linomat5 sample applicator. 
Developed the plate in the solvent system to a distance of 8cm. Observed the plate under 
UV light at 254nm & 366nm using CAMAG REPROSTAR3. 
5. 4. 3. HPTLC Fingerprinting – Glycosides  
TLC Details - T1, T2-5, 10 μL of T.S.  
Identity Test  
Test Solution: About 0.5g of sample refluxed with 25mL of 7.5% hydrochloric acid for 
15min.After cooling, the mixture is extracted with ether. The ether phase was concentrated 
to dryness and the collected residue was dissolved in methanol was used for TLC analysis.  
Stationary phase: Silica Gel 60 F254  
Mobile phase: Ethyl Acetate: Methanol: Water (100: 13.5: 10)  
Procedure: Applied 5, 10μL of test solutions spotted on a precoated silica gel 60 F254 
HPTLC plate (E. Merck) of uniform thickness 0.2mm using Linomat5 sample applicator. 
Developed the plate in the solvent system to a distance of 8cm. Observed the plate under 
UV light at 254nm & 366nm using CAMAG REPROSTAR3. 
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5.5. ANIMAL EXPERIMENTATION 
 
 Pharmacological evaluation of the ethanolic extract of Withania coagulans Dunal 
(Flower Buds) was carried out in the Department of Pharmacology, Periyar college of 
Pharmaceutical Sciences, Tiruchirappalli, Tamilnadu, India. Animal facility of this 
institute is approved by CPCSEA. The experimental protocols for the antiobesity and 
antihyperlipidemic activities have been approved by the Insititutional Animal Ethics 
Committee and conducted according to the guidelines of Indian National Sciences 
Academy for the use and care of experimental animals. IAEC approved this proposal with 
approval number PCP/IAEC/002/2017. The animals were maintained at a well ventilated, 
temperature controlled 30oC ± 1oC animal room for 7days prior to the experimental period 
and provided with food and water ad libitum. The animals were acclimatized to laboratory 
conditions before the test. Each animal was used only once. 
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5. 5. 1. Toxicity Studies – Validation4 
Validation of Acute Toxicity  
Acute Toxic Class method: Guideline number- 423 
 The test substance will be administered orally to a group of experimental animals at 
one of the defined doses. The substance will be tested using a stepwise procedure, each 
step using three animals of a single sex (normally female). Absence or presence of 
compound related mortality of the animals dosed at one step will determine the next step 
i.e. 
 no further testing is needed 
 dosing of three additional animals, with the same dose 
 dosing of three additional animals at the next higher or the next  lower dose level 
 
 Healthy young rats were used. The test substance was administered in a single dose 
(2000 mg/kg, b.w., p.o.) by gavage using a stomach tube.  
 
 Animals were observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the first 
4 hours and daily thereafter, for a total of 14 days. 
 
Observed changes in skin and fur, eyes and mucous membranes, and also 
respiratory, circulatory, autonomic and central nervous systems, and somatomotor activity 
and behavior pattern. Attention was directed to observations of tremors, convulsions, 
salivation, diarrhoea, lethargy, sleep and mortality. In addition, behavioral changes, body 
weight, histopathological studies and biochemical parameters were also observed. 
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5. 5. 2. Behavioural Activity61 
Hole Board Test 
Behavioural activity was evaluated by using Hole-board model.   
Wistar albino rats of either sex weighing 150-200g were divided into four groups 
of six animals each. The animals were fasted overnight for 18h. The dosage of the drugs 
administered to the different groups was as follows 
Group-1: Control (Normal Saline 5mL/kg, b.w., p.o.).  
Group-2: Standard drug (Diazepam 1mg/kg, b.w., i.p.).   
Group-3: Test (Ethanolic extract of Withania coagulans 200mg/kg, b.w., p.o.).   
Hole board test is a generally used method for screening the potential anxiolytic 
character of the drugs.  
Dimensions of the hole board  
The Hole board consists of wooden chamber (60×60×45cm) with 16 holes 
(diameter of 5 cm) on the floor, elevated from the ground so that the rat could peep 
through the holes. Each rat will be placed individually in the apparatus for recording the 
anxiolytic parameters. 
Experimental Design 
The Ethanolic extract of Withania coagulans was freshly dissolved in a suitable 
amount of distilled water. Diazepam (1mg/kg, b.w., i. p.) was dissolved in distilled water. 
Control groups received only normal saline. 
One hour after oral administration of the test extract and standard drug, the animals 
were submitted to the Hole board test. The cut off time is 5 minutes. 
Evaluation  
The various evaluation tests for Hole board test like latency to the first head dips, 
no. of head dips in the holes, total time spent with the head dips, no. of rearings and no. of 
defecation units.  
Statistical analysis 
The results are expressed are Mean ± SEM (n=6) two way ANOVA using Graph 
pad PRISM software version. *** P<0.001, ** P<0.01 and * P<0.05 were considered as 
statistically significant. 
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5. 5. 3. Antiobesity Activity29, 164 
Progesterone Induced Obesity  
Principle 
Progesterone is a steroidal female sex hormone playing an important role in 
menstrual cycle and pregnancy. Progesterone impairs fat metabolism and induces obesity 
due to fat accumulation induced by the absorption of lipase from the GIT. Progesterone 
induced obesity is a well-known model for screening the anti-obesity effect of drugs. 
Wistar albino rats of either sex weighing 150-200g were divided into four groups 
of six animals each. The animals were fasted overnight for 18h. The dosage of the drugs 
administered to the different groups was as follows 
Group 1   : Normal Saline (5mL/kg, b.w., p.o.). 
Group 2   :  Obesity control (10mg/kg Progesterone b.w., s.c.).   
Group 3 (Standard) :  Progesterone (10mg/kg b.w., s.c.) + Orlistat 
     (10mg/ kg b.w. p.o.)            
Group 4 (Test)  : Progesterone (10mg/kg b.w., s.c.)+ Ethanolic extract 
     of Withania coagulans (200mg/kg b.w., p.o.) 
  
Experimental Design 
Progesterone is the obesity control used to induce obesity. The dose of obesity 
control is 10mg/kg of body weight. It was prepared by dissolving in distilled water and a 
dose of 10 mg/kg was administered subcutaneously in the dorsal neck region for 28 days. 
The test drugs were injected 30 min before progesterone administration. 
The extract and standard Orlistat were soluble in distilled water and administered 
by gavage using a stomach tube. 
The total time period for the evaluation of anti-obesity activity was 28days. Body 
weight, food consumption behavior and behavioral changes for every week were examined 
and recorded. After completion of 28 studies the animals were sacrificed and before that 
the blood is collected from each group for biochemical estimation. 
Evaluation 
Body weight 
The body weights every rat (g) were recorded for every week for 28 days in each 
group just before dosing by using electronic weighing balance. 
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Rearing, grooming and ambulatory moments were studied. 
Assessment of food consumption behavior in rats 
It is very important to assess the food consumption behavior of all groups so the 
consumption behavior was studied on days 1, 7, 14, 21, and 28. On experimental days, 30 
min after last drug administration, 10 g of sweetened chow was presented to groups of 
mice in glass Petri dishes and food intake was recorded at 0.5, 1, and 2 h time intervals. 
Nearest to 0.1 g with correction for spillage and the amount of food consumed/ 20 g body 
weight was calculated. 
Biochemical parameters 
On 29th day the blood is collected from all the mice by retro orbital puncture 
method, and subjected for centrifugation at 3000 rpm immediately. The serum samples of 
all the blood samples were carefully collected and preserved for bio chemical estimation. 
Serum glucose levels, total cholesterol, LDL- C, HDL- C, VLDL- C, Triglycerides, SGOT, 
and SGPT were estimated. 
Histopathology of Liver 
After the biochemical examination was over the animals were sacrificed for 
histopathology studies .The liver of each animal from all four groups were isolated for 
histopathology studies. The isolated livers were carefully kept in 10% formalin solution in 
order to prevent the damage. 
Statistical analysis 
The results are expressed are Mean ± SEM (n=6) two way ANOVA using Graph 
pad PRISM software version. *** P<0.001, ** P<0.01 and * P<0.05 were considered as 
statistically significant. 
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5. 5. 4. Antihyperlipidemic Activity01 
Fructose Induced Hyperlipidemia 
Male Wistar albino rats weighing 200-250g, used for the study were fed on pellet 
diet and water ad libitum. Hyperlipidemia was induced by supplementing their drinking 
water with 10% fructose.  
Priniciple  
Fructose has been reported to induce hypertriglyceridemia associated with insulin 
resistance, hyperinsulinemia and hypertension. After absorption in GIT, Fructose is transported via 
portal circulation to the liver, where it enters hepatocytes via the glucose transporter GLUT- 5 
independently of insulin and is rapidly metabolised. Fructose is metabolised into “glycerol-3-
phosphate” and “acetyl CoA”. These two intermediate metabolites are then used as substrates for 
glycerides synthesis, contributing to VLDL-TG production in liver. The exposure of liver to such 
large quantities of fructose leads to rapid stimulation of lipogenesis and TG accumulation which in 
turn contributes to reduced insulin sensitivity and hepatic insulin resistance/glucose intolerance 
Treatment 
Rats were divided into the following 4 groups of 6 each:  
Group I : Normal diet water ad libitum  
Group II : Normal diet and 25% Fructose in water (Positive Control) 
Group III : Normal diet and 25% Fructose in water + Ethanolic extract of Withania 
   coagulans (200 mg /kg, p.o.) 
 Group IV : Normal diet and 25% Fructose in water + Atrovastatin (10mg/kg, p.o.) 
Experimental Design 
Each group of animals were administered vehicle or drugs daily for 3 weeks by 
gavage using oral feeding needle. Feeding of animals by fructose and extracts were done 
simultaneous from the beginning. At the end of the 3 weeks period, animals were kept for 
overnight fasting and the blood samples were collected from the tail vein in the 
centrifuging tubes.  
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Biochemical analysis 
On the 21st day, blood was collected by retro orbital sinus puncture, under mild 
ether anaesthesia. The collected samples were centrifuged for 10 minutes at 3000rpm. 
Then serum samples were collected and used for various biochemical experiments. The 
serum and liver extract were assayed for total cholesterol, triglycerides, high density 
lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) 
and serum blood glucose. 
 
Histopathological studies 
At the end of the treatment period, the animals were sacrificed for histopathology 
studies .The livers of each animal from all four groups were isolated for histopathology 
studies. The isolated livers were carefully kept in 10% formalin solution in order to 
prevent the damage. 
Statistical analysis 
The results are expressed are Mean ± SEM (n=6) two way ANOVA using Graph 
pad PRISM software version. *** P<0.001, ** P<0.01 and * P<0.05 were considered as 
statistically significant. 
 
5. 5. 5. Analgesic Activity25 
Tail Immersion Test in Mice  
Wistar albino rats of either sex weighing 150-200g were divided into four groups 
of six animals each. The animals were fasted overnight for 18h. The dosage of the drugs 
administered to the different groups was as follows 
Group-1: Control - Normal Saline (5mL/kg, b.w., p.o.). 
Group-2: Standard (Diclofenac sodium 10mg/kg in 10mL of normal saline, p.o.) 
Group-3: Test (Ethanolic extract of Withania coagulans 200mg/kg, p.o.) 
Experimental Design 
The procedure is based on the observation that morphine-like drugs are selectively 
capable of prolonging the reaction time of the typical tail-withdrawal reflex in rats induced 
by immersing the end of the tail in warm water of 55 °C. 
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The lower 5 cm portion of the tail is marked. This part of the tail is immersed in to 
the water bath of exactly 55 °C. Within a few seconds the rat reacts by withdrawing the 
tail. After each determination the tail is carefully dried. The reaction time is determined 
before and periodically after oral administration of the test and standard substance. The cut 
off time is 15sec.  
Evaluation 
Tail withdrawal reflex  
Statistical analysis 
The results are expressed are Mean ± SEM (n=6) two way ANOVA using Graph 
pad PRISM software version. *** P<0.001, ** P<0.01 and * P<0.05 were considered as 
statistically significant. 
5. 5. 6. Anthelmintic Acitivity2, 104 
The dosage of the drugs administered to the different groups was as follows 
Group-1: Control (Normal saline 10mL)  
Group-2: Standard drug (Albendazole 20mg/ mL) 
Group-3: Test (Ethanolic extract of Withania coagulans 25mg/ mL) 
Group-4: Test (Ethanolic extract of Withania coagulans 50mg/ mL) 
Group-5: Test (Ethanolic extract of Withania coagulans 75mg/ mL) 
Group-6: Test (Ethanolic extract of Withania coagulans 100mg/ mL) 
Experimental worms 
All the experiments were carried out in Indian adult earthworms (Pheretima 
posthuma) due to its anatomical resemblance with the intestinal roundworm parasites of 
human beings. They were collected from moist soil and washed with water to remove all 
fecal matters. 
 
Administration of Albendazole 
Albendazole (20 mg/mL) was prepared by using 10 mL of Normal Saline as a 
vehicle. 
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Administration of extract 
The suspension of Ethanolic extract of Withania coagulans at different 
concentration (25, 50, 75 & 100mg/ 10mL) were prepared by using 10 mL of Normal 
Saline as a vehicle and final volume was made up to 10 mL for respective concentration. 
Albendazole was used as standard. Groups of approximately equal size worms consisting 
of six earthworms individually in each group were released into in each 10 mL of desired 
concentration of drug and extracts in the petridish. 
 
Experimental Design 
On adult Indian earth worm Pheretima posthuma as it has anatomical and 
physiological resemblance with the intestinal round worm parasites of human beings. 
Pheretima posthuma was placed in petridish containing different concentrations (25, 50, 75 
& 100 mg/ 10 mL) of Ethanolic extract of Withania coagulans. Each petridish was placed 
with 6 worms and observed for paralysis or death. Mean time for paralysis was noted when 
no movement of any sort could be observed, except when the worm was shaken 
vigorously; the time death of worm (min) was recorded after ascertaining that worms 
neither moved when shaken nor when given external stimuli. The test results were 
compared with Reference compound Albendazole (20 mg/ mL) treated samples. The time 
period of the study is 3 hours.  
 
Statistical analysis 
The results are expressed are Mean ± SEM (n=6) two way ANOVA using Graph 
pad PRISM software version. *** P<0.001, ** P<0.01 and * P<0.05 were considered as 
statistically significant. 
 
5. 5. 7. Anti- Microbial Screening15 
Principle 
 Known concentration of Ciprofloxacin and Nystatin antibiotic disc was placed on 
agar plate that has been inoculated or seeded uniformLy over the entire plate with a culture 
of the bacterium to be tested. The test compound was  inoculated for 18 - 24 hour at 370C. 
During this period the antibacterial agents diffuses through the agar and may prevent the 
growth of organism. Effectiveness of susceptibility is proportional to the diameter of zone 
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of inhibition around the disc, organism which grows up to the edge of the disc are 
resistant.  
Material and methods 
Medias  
Media for bacteria  - Nutrient agar  
 Media for fungi - Sabouraud Dextrose Agar (SDA) 
Organisms Used 
Bacteria 
     Gram- positive 
 Staphylococcus aureus (NCIM 2079) 
 Bacillus substilis (NCIM 2063) 
Gram- negative 
 Proteus vulgaris (NCIM 2027) 
 Klebsiella species (NCIM 2098) 
      Fungi 
 Aspergillus niger (NCIM 105) 
 Candida albicans (NCIM 3102) 
Antibiotic disc used  
 Ciprofloxacin (5µg/ disc)- Bacteria 
 Nystatin (100 units/ disc)- Fungi                                                                                                                                                           
were used repectively as standards for bacterial and fungal strains. 
Test Sample 
 Ethanolic ectract of Withania coagulans Dunal (25, 50, 75, 100 & 250mg/ disc) 
Table No. 7: Composition of Nutrient Agar Medium 
S.No Ingredients g/l 
1 Yeast extract  5g 
2 Meat Extract  10g 
3 .pectin 5g 
4 Sodium chloride 5g 
5 Agar 20g 
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Suspended 2g agar in 100 mL distilled water and added all ingredients. Mix well 
and heat to dissolve the medium completely. Sterilized by autoclaving at 15 lbs pressure 
(1210c) for 15 min.  
Table No. 8: Composition of Sabouraud Dextrose Agar Medium 
S.No Ingredients      g/l 
1 Glucose      4% 
2 Peptone      1% 
3 Water      100 mL 
 
 For sabouraud dextrose agar medium 2% agar powder was mixed with above 
constituents pH was maintained at 5.4 for fungal media. This media was sterilized by 
autoclaving at 1210C at 15 lbs pressure for 20 min.  
Determination of Zone of Inhibition15 
The disc diffusion method was used to determine the antimicrobial activities of the 
newly synthesized compounds. Muller Hington Agar media was prepared, sterilized and 
used as the growth medium for bacteria culture. 20 mL of the sterilized medium was 
poured into each sterilized petri dish, covered and allowed to solidify. The plates were then 
seeded with the test organism (bacterial culture) by sterile cotton swabs 
For fungal culture Saboraud Dextrose Agar was prepared and transferred into 
sterile petri dishes and solidified. The sterilised paper discs were soaked in prepared 
solution of synthesized compounds and were dried at 50ºC. The dried paper disc was then 
placed on both plates (Muller Hington and Saboraud Dextrose Agar) seeded with test 
micro organisms. 
The plates were then incubated for bacterial culture for 37 ºC for 24 hours and for 
fungus the plates were incubated at room temperature for 48 hours and the zone of 
inhibition were measured. 
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6.1.RESULTS 
Table No. 9: Preliminary Phytochemical Studies 
S.No 
Plant 
Constituents 
Test / reagent 
Ethanolic extract of 
Withania coagulans 
1.  Steroids 
Salkovaski  
+ Liberman Burchard Test 
2.  Alkaloids 
Dragendroff’s 
Hager’s test 
Mayer’s test 
Wagner’s test 
 
 
+ 
3.  Saponin 
Forms test 
Haemolysis test 
 
- 
4.  Fat and oils Filter paper test - 
5.  
Tanins and 
phenolic 
compounds 
Ferric chloride test 
Lead  acetate test 
Pot. Dichromate 
Bromine water 
 
- 
6.  Flavonoids 
Shinoda test 
Lead  acetate test 
 
+ 
7.  Carbohydrates 
Molisch  test 
Fehling’s test 
Barfoed’s test 
 
+ 
8.  Proteins 
Millons test 
Biuret test 
Xanthoprotein test 
 
+ 
9.  Amnio acid test Ninhydrine test + 
10.  Glycosides 
Legal’s test 
Baljet test 
Bontrager’s test 
Keller Kiliani test 
+ 
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Table No. 10: IR Spectral Data of the Ethanolic extract of Withania coagulans 
 
 
 
S. No Wavenumber (cm-1) Interpretation 
1. 3418.82 & 3382.21 
Polymeric association of alcohols and phenols indicates 
presence of miscellaneous chromophoric groups 
2. 2974.21 Chromophoric hydrocarbon - Alkene 
3. 2934.88 Chromophoric hydrocarbon - Alkene 
4. 2112.11 Alkene monosubstituted 
5. 1722.28 Saturated 6-membered and higher ring 
6. 1662.94 α, β - unsaturated bending- acyclic 
7. 1575.63 C-NO2 aromatic nitro compounds 
8. 1414.44 Phenolic OH bending 
9. 1215.63 Aliphatic CN vibrations 
10. 1049.29 Aromatic C-C multiple bond stretching 
11. 925.15 CH bending; Alkene monosubstituted 
12. 879.63 One Hydrogen atom bending 
13. 814.00 Two adjacent hydrocarbon atoms 
14. 777.55 C-X stretching 
15. 648.58 C-X stretching 
16. 621.68 C-H stretching 
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HPTLC Fingerprinting - Alkaloids 
Table No. 11: Chromatogram Data of 10µl of test solution 
Peak 
Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Height 
% 
End 
Rf 
End 
Height 
Area 
Area 
% 
1. 0.04 1.7 0.06 17.0 3.27 0.08 0.1 243.1 1.49 
2. 0.09 0.1 0.10 14.5 2.78 0.13 0.3 197.7 1.21 
3. 0.13 0.3 0.15 13.9 2.67 0.17 8.2 246.7 1.51 
4. 0.17 8.7 0.20 36.5 7.03 0.22 3.1 685.2 4.19 
5. 0.22 3.4 0.23 11.6 2.24 0.24 0.1 63 0.39 
6. 0.34 6.0 0.42 178.3 34.31 0.46 36.9 6266.6 38.34 
7. 0.46 37.2 0.49 62.7 12.06 0.54 6.0 1804.0 11.04 
8. 0.57 9.7 0.58 17.9 3.44 0.62 3.2 506.6 3.10 
9. 0.64 3.7 0.67 39.1 7.52 0.71 17.2 1115.9 6.83 
10. 0.71 17.01 0.74 42.7 8.21 0.84 0.1 1894.0 11.59 
11. 0.87 0.3 0.92 85.6 16.47 0.99 0.1 3320.0 20.31 
 
 
 
Table No. 12: Chromatogram Data of 20µl of test solution 
Peak 
Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Height 
% 
End 
Rf 
End 
Height 
Area 
Area 
% 
1. 0.0 16.6 0.01 20.0 1.68 0.02 4.2 161.0 0.41 
2. 0.03 4.2 0.04 18.7 1.57 0.05 2.5 198.7 0.51 
3. 0.06 2.6 0.07 22.6 1.90 0.09 1.0 268.1 0.68 
4. 0.09 0.2 0.11 17.0 1.43 0.13 0.2 257.5 0.66 
5. 0.14 0.3 0.16 17.6 1.48 0.17 12.7 288.7 0.74 
6. 0.18 12.9 0.20 48.8 4.10 0.24 3.4 1086.0 2.77 
7. 0.32 2.3 0.43 268.1 22.53 0.47 64.0 9999.9 25.49 
8. 0.47 64.2 0.50 103.2 8.67 0.56 7.5 3295.0 8.40 
9. 0.56 8.8 0.59 19.7 1.66 0.63 1.3 596.1 1.52 
10. 0.64 0.1 0.68 72.2 6.07 0.72 30.4 2061.3 5.25 
11. 0.72 30.9 0.75 64.5 5.42 0.83 0.2 2871.8 7.32 
12. 0.84 0.1 0.92 517.8 43.51 0.99 0.8 18144.7 46.25 
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HPTLC Fingerprinting - Glycosides 
Table No. 13: Chromatogram Data of 5µl of test solution 
Peak 
Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Height 
% 
End 
Rf 
End 
Height 
Area 
Area 
% 
1. 0.00 0.1 0.03 22.1 2.57 0.08 5.9 713.0 1.06 
2. 0.08 6.0 0.12 30.3 3.53 0.18 15.0 1391.0 2.06 
3. 0.19 16.0 0.24 46.7 5.43 0.30 13.5 1948.9 2.89 
4. 0.33 10.2 0.34 10.5 1.22 0.38 0.8 244.2 0.36 
5. 0.57 3.8 0.70 168.5 19.59 0.71 162.7 6200.5 9.19 
6. 0.71 163.3 0.82 582.1 67.67 0.97 3.6 56939.5 84.43 
 
 
 
Table No. 14: Chromatogram Data of 10µl of test solution 
Peak 
Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Height 
% 
End 
Rf 
End 
Height 
Area 
Area 
% 
1. 0.05 0.4 0.08 23.5 3.08 0.09 17.7 423.0 0.57 
2. 0.10 18.4 0.16 44.4 5.84 0.18 37.0 1565.5 2.10 
3. 0.22 38.2 0.27 79.3 10.43 0.39 1.6 4321.2 5.79 
4. 0.57 0.3 0.82 613.2 613.2 0.97 2.6 68369.5 91.55 
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HPTLC Fingerprinting - Flavanoids 
Table No. 15: Chromatogram Data of 5µl of test solution 
Peak 
Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Height 
% 
End 
Rf 
End 
Height 
Area 
Area 
% 
1. 0.01 16.4 0.01 21.2 2.94 0.03 0.2 219.9 1.05 
2. 0.20 1.9 0.25 35.3 4.91 0.28 8.4 1011.6 4.84 
3. 0.31 11.3 0.35 30.4 4.23 0.39 14.1 1080.5 5.17 
4. 0.40 12.7 0.48 402.1 55.86 0.53 51.4 13030.4 62.37 
5. 0.53 51.6 0.54 53.3 7.40 0.57 17.3 944.5 4.52 
6. 0.57 17.4 0.60 40.1 5.57 0.62 25.6 1003.6 4.80 
7. 0.62 25.8 0.65 56.4 7.84 0.70 15.1 2029.9 9.72 
8. 0.70 15.2 0.73 22.4 3.12 0.78 3.0 715.4 3.42 
9. 0.92 0.3 0.95 18.9 2.63 0.96 15.7 395.8 1.89 
10. 0.97 15.9 0.98 39.7 5.51 0.99 25.3 459.5 2.20 
 
 
Table No. 16: Chromatogram Data of 10µl of test solution 
Peak 
Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Height 
% 
End 
Rf 
End 
Height 
Area 
Area 
% 
1. 0.01 17.8 0.01 23.3 2.00 0.03 0.2 223.7 0.62 
2. 0.07 0.2 0.11 10.6 0.91 0.16 0.0 295.8 0.82 
3. 0.20 0.2 0.24 46.8 4.03 0.28 10.3 1267.0 3.52 
4. 0.30 13.9 0.35 45.7 3.93 0.40 18.1 1892.7 5.25 
5. 0.40 18.2 0.48 479.2 41.19 0.52 86.0 16772.4 46.54 
6. 0.52 86.9 0.53 98.4 8.46 0.56 39.1 1973.3 5.47 
7. 0.57 39.4 0.59 83.4 7.17 0.61 60.3 2059.3 5.71 
8. 0.61 60.5 0.64 113.3 9.74 0.69 50.5 4328.8 12.01 
9. 0.70 50.9 0.73 112.6 9.66 0.78 61.6 4693.1 13.02 
10. 0.78 61.5 0.80 65.5 5.63 0.87 0.0 1700.7 4.72 
11. 0.96 0.8 0.98 84.4 7.25 0.99 49.9 835.7 2.32 
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Pharmacological Evaluation 
Toxicity Studies - Acute Oral Toxicity 
Table No. 17: Behavioral Changes in Acute Oral Toxicity in Albino rats 
S.No. Symptoms 
Control 
(Normal Saline 
5ml/kg, p.o.) 
 
Ethanolic extract of 
Withania coagulans 
(2000mg/kg, p.o.) 
 
1 Death -- -- 
Autonomous Nervous System   
2 Head movements -- -- 
3 Scratching -- -- 
4 Altered reactivity to touch -- ++ 
5 Loss of righting reflex -- -- 
6 Loss of corneal reflex -- -- 
7 Defecation/Diarrhea -- -- 
8 Salivation -- ++ 
9 Lacrimation -- -- 
10 Myosis/ Mydriasis -- -- 
11 Loss of traction -- -- 
Central Nervous System   
12 Convulsions -- -- 
13 Tremor -- -- 
14 Straub tail -- -- 
15 Sedation -- -- 
16 Excitation -- -- 
17 Jumping -- ++ 
18 Abnormal gait -- -- 
19 Motor in-coordination -- -- 
23 Akinesia -- -- 
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S.No. Symptoms 
Control 
(Normal Saline 
5ml/kg, p.o. ) 
 
Ethanolic extract of 
Withania coagulans 
(2000mg/kg, p.o.) 
 
24 Catalepsy -- -- 
25 Loss of balance -- -- 
26 Fore-paw treading -- -- 
27 Writhing -- -- 
28 Stereotypy -- -- 
29 Altered fear -- -- 
30 Altered respiration -- -- 
31 Aggression -- -- 
32 Analgesia -- -- 
33 Body Temperature -- -- 
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Table No. 18: Effect of Test compound on Body Weight in Acute oral toxicity in          
Albino rats 
S. No Group 
Body weight (gm) 
Initial 
At the end of the 
study 
1. 
Control 
(Normal Saline 5ml/kg ) 
245.66  ± 6.09 249.50 ± 4.43 
2. 
Test drug 
(Ethanolic extract of Withania 
coagulans 2000mg/mL) 
241.66  ± 5.57 245.83 ± 7.70 
n = 6 Values are expressed as ± S.E.M.  
 
Table No. 19: Effect of Test compound on Biochemical parameters in Acute oral 
toxicity in Albino rats 
S. No Biochemical Parameters 
Control 
(Normal Saline 
5ml/kg ) 
Test Drug 
(Ethanolic extract of 
Withania coagulans 
2000mg/ml) 
1 Glucose (mg/dl) 156.33 ± 1.08 137.66 ± 0.49 
2 Blood Urea(mg/dl) 15.34 ± 0.06 15.16 ± 0.30 
4 Total cholesterol(mg/dl) 81.00 ± 0.25 80.66 ± 0.33 
5 SGOT (U/l) 112.00 ± 0.85 115.00 ± 0.25 
6 SGPT(U/l) 74.83 ± 0.30 76.00 ± 1.12 
7 Albumin (gm/dl) 3.32 ± 0.06 3.50 ± 0.09 
n = 6 Values are expressed as ± S.E.M.  
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Behavioural Coordination Study – Hole Board Test 
Table No. 20: Effect of Ethanolic extract of Withania coagulans on Head dips in 
Albino rats 
S. 
N
o 
Groups 
Total time spent with 
the head dips 
No. of head dips in the holes 
30 
min 
60 
min 
90 min 
120 
min Before 
Treatment 
After 
Treatment 
1 
Control 
(Normal 
Saline 
5mL/kg, 
b.w., p.o.) 
67 
± 
6.87 
67 
± 
7.58 
15 
± 
2.85 
19 
± 
0.49 
13 
± 
0.24 
16 
± 
0.92 
2 
Standard 
(Diazepam 
1mg/kg, 
b.w., i.p.) 
62 
± 
6.17 
179 
± 
27.57 
34 
± 
1.8
4 
34 
± 
0.28 
35 
± 
0.92 
39 
± 
0.37 
3 
Test 
Ethanolic 
Extract of 
Withania 
coagulans 
(200mg/kg, 
p.o.) 
66 
± 
6.52 
155 
± 
11.71*** 
32 
± 
0.9 
** 
29 
± 
0.98
** 
30 
± 
0.47** 
34 
± 
0.74** 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. 
Where, *** P<0.001, ** P<0.01 and * P<0.05 
 
Table No. 21: Effect of Ethanolic extract of Withania coagulans on Anxiety 
Parameters in Albino rats 
S. 
No 
Groups 
 
No. of 
rearings 
No. of 
defecation 
units 
No. of first head 
dips to each of 
the hole 
1
1. 
Control 
(Normal Saline 5mL/kg, 
b.w., p.o.) 
30 ± 0.96 7±0.28 9±0.92 
2
2. 
Standard (Diazepam 
1mg/kg, b.w., i.p.) 
25±0.85** 5±0.49*** 14±0.24*** 
2
3. 
Test 
Ethanolic Extract of 
Withania coagulans 
(200mg/kg, p.o.) 
22±0.39** 4±0.98** 16±0.47** 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. 
Where, *** P<0.001, ** P<0.01 and * P<0.05 
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Antiobesity Activity - Progesterone Induced Obesity 
Table No. 22: Effect of Ethanolic extract of Withania coagulans on Body Weight in 
Progesterone induced obesity in Albino rats 
S. 
No. 
Group 1stday 7thday 14thday 21stday 28thday 
1.  
Normal (Normal 
saline 
5ml/kg p.o.) 
225.66 
± 
0.33 
224.50 
 ± 
0.34 
230.83 
±  
0.40 
244.83  
± 
 0.30 
225.33 
 ±  
 0.21 
2.  
Positive control 
(Progesterone 
10mg/kg, i.p.) 
227.83  
±  
0.30 
350.50 
 ±  
0.34 
375.16 
±  
0.30 
435.33  
± 
 0.21 
495.00 
 ± 
 0.25 
3.  
Test (Ethanolic 
Extract of 
Withania 
coagulans 
200mg/kg, p.o.) 
228.33 
 ± 
 0.33 
270.66 
 ± 
 0.33*** 
285.16 
±  
0.30*** 
298.66 
±  
0.49*** 
310.50  
± 
 0.34*** 
4.  
Standard 
(Orlistat 
10mg/kg, p.o.) 
235.66 
 ± 
 0.33*** 
286.00  
± 
 0.63*** 
297.50 
± 
0.34*** 
324.83 
 ± 
 1.01*** 
357.00 
 ± 
 0.51*** 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. 
Where, *** P<0.001, ** P<0.01 and * P<0.05 
 
 
Table No. 23: Histopathological Studies of Progesterone Induced Obesity in Albino 
Rats (T.S of Liver) 
S. No Group Description 
1. Normal Normal architecture 
2. Positive Control 
Presence of the necrotic lesions in the liver cells and the 
presence fatty liver was found 
3. Standard Normal architecture regained with the drug treatment 
4. Test 
Focal necrosis and slight hepatic toxicity. Fatty deposition 
got reduced 
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Table No. 24 
 
Effect of Ethanolic extract of Withania coagulans on Food consumption in Progesterone induced obesity in Albino rats 
 
S. 
No.  
Group  
Food Consumption (g) 
0.5 hr  1 hr  2 hr  
1st  
day  
7th  
day  
14th  
day  
21st  
day  
28th  
day  
1st  
day  
7th  
day  
14th  
day  
21st  
day  
28th  
day  
1st  
day  
7th  
day  
14th  
day  
21st  
day  
28th  
day  
1.  
Normal 
(Normal saline  
5ml/kg p.o.)  
3.27 
± 
0.12 
3.25 
± 
0.35 
3.66 
± 
0.33 
3.54 
± 
0.35 
3.65 
± 
0.16 
3.10 
± 
0.12 
3.90 
± 
0.16 
3.87 
± 
0.10 
3.58 
± 
0.33 
3.55 
± 
0.27 
3.55 
± 
0.21 
3.45 
± 
0.28 
3.55 
± 
0.23 
3.65 
± 
0.45 
3.57 
± 
0.75 
2.  
Positive 
control  
(Progesterone  
10mg/kg, i.p.)  
3.26 
± 
0.16 
7.81 
± 
0.22 
8.55 
± 
0.35 
8.68 
± 
0.37 
8.97 
± 
0.33 
3.27 
± 
0.17 
7.65 
± 
0.33 
6.65 
± 
0.10 
8.35 
± 
0.22 
8.55 
± 
0.27 
3.63 
± 
0.23 
6.66 
± 
0.33 
7.65 
± 
0.22 
8.88 
± 
0.17 
8.45 
± 
0.16 
3.  
Test 
(Ethanolic 
Extract of 
Withania 
coagulans 
200mg/kg, 
p.o.)  
3.80 
± 
0.12** 
6.55 
± 
0.27** 
6.54 
± 
0.24** 
 
7.54 
± 
0.27** 
5.55 
± 
0.29
** 
3.97 
± 
0.13 
** 
7.54 
± 
0.15 
** 
6.51 
± 
0.32 
** 
5.55 
± 
0.35 
** 
5.31 
± 
0.27 
** 
3.78 
± 
0.18 
** 
5.55 
± 
0.21 
** 
5.54 
± 
0.31 
** 
5.64 
± 
0.58** 
5.32 
± 
0.27** 
4.  
Standard  
(Orlistat  
10mg/kg, p.o.)  
3.98 
± 
0.21** 
5.55 
± 
0.32** 
4.54 
± 
0.25** 
4.56 
± 
0.39** 
4.57 
± 
0.15
** 
3.82 
± 
0.23 
** 
5.55 
± 
0.27 
** 
5.65 
± 
0.26 
** 
5.63 
± 
0.55 
** 
6.45 
± 
0.65 
** 
3.77 
± 
0.12 
** 
5.53 
± 
0.36 
** 
5.35 
± 
0.33 
** 
4.54 
± 
0.87 
** 
4.65 
± 
0.95 
** 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. Where, *** P<0.001, ** P<0.01 and * P<0.05 
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Table No. 25 
 
Effect of Ethanolic extract of Withania coagulans on Ambulatory movements, Rearing and Grooming in Progesterone Induced Obesity 
in Albino rats 
 
 
S. 
No. 
Group 
Ambulatory movements Rearing Grooming 
1st 
day 
7th 
day 
14th 
day 
21st 
day 
28th 
day 
1st 
day 
7th 
day 
14th 
day 
21st 
day 
28th 
day 
1st 
day 
7th 
day 
14th 
day 
21st 
day 
28th 
day 
1.  
Normal (Normal 
saline 
5ml/kg p.o.) 
- - - - - - - - - - - - - - - 
2.  
Positive control 
(Progesterone 
10mg/kg, i.p.) 
+ + + + + + + + + + + + + + + 
3.  
Test (Ethanolic 
Extract of 
Withania 
coagulans 
200mg/kg, p.o.) 
- - - - - - - - - - - - - - - 
4.  
Standard 
(Orlistat 
10mg/kg, p.o.) 
- - - - - - - - - - - - - - - 
 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. Where, *** P<0.001, ** P<0.01 and * P<0.05 
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Table No. 26 
 
Effect of Ethanolic extract of Withania coagulans on biochemical parameters in Progesterone induced obesity in Albino rats 
 
 
S.No Treatment 
Glucose 
(mg/dl) 
Total 
Cholesterol 
(mg/dl) 
TG 
(mg/dl) 
HDLC 
(mg/dl) 
LDLC 
(mg/dl) 
VLDL - C(mg/dl) 
SGOT 
(U/l) 
SGPT 
(U/l) 
 
1 
Normal (Normal saline 
5ml/kg p.o.) 
118.31 
±  
3.6  
105.6  
±  
4.3  
29.61  
±  
2.00  
58.24  
±  
0.8  
14.2  
±  
0.9  
79.30  
±  
1.30  
128.54  
±  
1.60  
65.15  
±  
1.5  
 
2 
Positive control 
(Progesterone 
10mg/kg, i.p.) 
186.02 
±  
4.3  
142.6 
±  
2.5  
76.75 
±  
1.2  
74.04 
±  
1.5  
22.23 
±  
0.18  
152.9 
±  
1.6  
190.02 
±  
0.7  
90.2 
±  
1.45  
 
3 
Test (Ethanolic Extract 
of Withania coagulans 
200mg/kg, p.o.) 
150.0 
±  
4.0***  
128.9 
±  
2.43***  
27.14 
±  
0.4***  
60.4 
±  
1.08***  
18.02 
±  
1.5***  
120.2 
±  
2.4***  
150.5 
±  
4.15***  
65.9 
±  
1.11***  
 
4 
Standard 
(Orlistat 
10mg/kg, p.o.) 
125.8 
±  
4.4*** 
120.6 
±  
1.5**  
24.05 
±  
2.62**  
40.2 
±  
2.8**  
11.11 
±  
0.12***  
90.6 
±  
2.0**  
134.7 
±  
1.65**  
52.04 
±  
2.1**  
 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. Where, *** P<0.001, ** P<0.01 and * P<0.05 
 
 
 
RESULTS AND DISCUSSION 
 
 Page 116 
Antihyperlipidemic Activity – Fructose Induced Hyperlipidemia  
Table No. 27 
Effect of Ethanolic extract of Withania coagulans on biochemical parameters in Fructose induce hyperlipidemia in Albino rats 
S. 
No 
Treatment 
Glucose 
(mg/dl) 
Total 
Cholesterol 
(mg/dl) 
TG 
(mg/dl) 
HDLC 
(mg/dl) 
LDLC 
(mg/dl) 
VLDL - C(mg/dl) 
SGOT 
(U/l) 
SGPT 
(U/l) 
 
1 
Normal                 
(Normal saline 0.5ml/kg 
p.o.)  
111.21         
±                
3.7 
102.6 
± 
4.3 
30.61 
± 
2.00 
54.24 
± 
0.8 
16.2 
± 
0.9 
89.30 
± 
1.30 
126.54  
± 
1.60 
64.15 
± 
1.5 
 
2 
Positive control              
(25% Fructose in water)  
182.02       
±              
4.3 
152.6            
±                
2.5 
76.75 
± 
1.2 
24.04 
± 
1.5 
42.23 
± 
0.18 
152.9 
± 
1.6 
180.02 
± 
0.7 
91.2 
± 
1.45 
 
3 
Test                        
(Ethanolic Extract of 
Withania coagulans 
200mg/kg, p.o.) +  25% 
Fructose in water  
122.0         
±              
4.0*** 
125.9 
± 
2.43*** 
25.14 
± 
0.4*** 
60.4 
± 
1.08*** 
21.02 
± 
1.5*** 
115.2 
± 
2.4*** 
145.5 
± 
4.15*** 
69.9 
± 
1.11*** 
 
4 
Standard  
(Atrovastatin  10mg/kg, 
p.o. + 25% Fructose in 
water ) 
126.8              
±            
4.4*** 
120.6            
±            
1.5** 
28.05            
±               
2.62** 
63.2             
±              
2.8** 
19.11            
±           
0.12*** 
95.6                       
±                         
2.0** 
126.7             
±             
1.65** 
62.04            
±             
2.1** 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. Where, *** P<0.001, ** P<0.01 and * P<0.05
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Table No. 28 
Histopathological Studies of in Fructose induce hyperlipidemia in Albino rats 
T.S of Liver 
 
S. No Group Description 
1. Normal Normal architecture 
2. Positive Control 
Presence of the fatty changes in the liver cells and the 
presence of necrosis and fatty liver was found 
3. Standard Mild necrosis was found and fatty deposition got reduced 
4. Test Focal necrosis and slight hepatic toxicity 
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Analgesic Activity - Tail Immersion Test in Mice 
Table No. 29: Analgesic activity of Ethanolic Extract of Withania coagulans against 
Tail Flick Test in Wistar Albino Rats 
S. 
No 
Groups 
Basal 
reaction 
time 
(Secs.) 
Reaction Time  (Secs.) 
60mins. 90mins. 120mins. 180mins. 
1. 
Group 1 
Control 
(Administered With   
1mL Of Distilled 
Water Orally) 
3.18 
  ±  
0.03 
3.40  
± 
 0.05 
3.83  
 ± 
  0.04 
3.76  
 ± 
 0.05 
3.83 
  ±  
0.04 
2. 
Group2              
Standard Drug 
(Pentazocin10mg/Kg 
In 10ml Of Normal 
Saline) 
3.25  
 ±  
0.03 
6.60  
 ±  
0.03*** 
7.81   
±  
0.03*** 
8.53  
 ±  
0.11*** 
7.87 
  ±  
0.02*** 
3. 
Group 3 
Test 
(Ethanolic Extract Of 
Withania Coagulans 
200mg/Kg, p.o.) 
3.29 
  ±  
0.06 
7.76  
 ±  
0.04*** 
7.82   
±  
0.07*** 
8.36   
± 
 0.06*** 
7.79 
  ± 
 0.07*** 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. 
Where, *** P<0.001, ** P<0.01 and * P<0.05 
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Anthelmintic Acitivity 
Table No. 30: Anthelmintic activity of Ethanolic Extract of Withania coagulans 
against Pheretima posthuma 
S. No Group 
Concentration 
(Mg/Ml) 
Pheretima posthuma 
Paralysis (min) Death (min) 
1. 
Control 
(1% CMC in 10ml of Normal 
Saline) 
10 ml of 5% 
CMC 
180.40  ± 0.24 244.50  ± 0.22 
2. 
Standard 
(Albendazole + 1% CMC in 
10ml of Normal Saline ) 
20mg/10ml 8.00 ± 0.25*** 22.66 ± 0.16*** 
3. 
Test 
(Ethanolic Extract Of 
Withania Coagulans + 1% 
CMC in 10ml of Normal 
Saline ) 
25 mg/10ml 15.00 ± 0.25** 19.66 ± 0.21** 
50 mg/10ml 13.00 ± 0.25** 14.83 ± 0.21** 
75 mg/10ml 11.00 ± 0.25** 12.16 ± 0.16** 
100 mg/10ml 7.33 ± 0.21*** 21.16 ± 0.16*** 
n = 6 Values are expressed as ± S.E.M. Values are Mean ± SEM (n=6) two way ANOVA. 
Where, *** P<0.001, ** P<0.01 and * P<0.05 
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Anti- Microbial Screening 
Table No. 31: Antimicrobial screening of Ethanolic Extract of Withania coagulans  
S. No 
Test 
Organism 
Zone of Inhibition (mm) 
Solvent Standard 
Test 
25 mg 50mg 75mg 100mg 250mg 
1.  
Bacillus 
subtilis 
0.08 
 
34.66 
 
8.66 
 
2.66 
 
10.00 
 
22.00 
 
32.66 
 
2.  
Staphyloccus 
aureus 
0.06 
 
40.50 
 
8.66 
 
10.50 
 
15.66 
 
20.00 
 
38.33 
 
3.  
Proteus 
vulgaris 
0.08 
 
30.50 
 
2.00 
 
7.83 
 
10.50 
 
10.00 
 
 
32.66 
 
4.  
Klebsiella 
pneumoniae 
0.08 
 
31.00 
 
2.83 
 
7.16 
 
7.58 
 
10.00 
 
33.16 
 
5.  
Candida 
albicans 
2.16 
 
32.33 
 
2.83 
 
12.66 
 
14.33 
 
16.00 
 
33.50 
 
6.  
Aspergillus 
niger 
1.33 
 
35.00 
 
2.50 
 
10.33 
 
12.16 
 
20.00 
 
37.83 
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6.2. DISCUSSION 
6.2.1. Extraction of plant material 
The Flower buds of Withania coagulans Dunal was collected, dried and extracted using 
ethanol and prior to the ethanolic extraction the plant is milled and defatted using 
petroleum ether. The yield of the Ethanolic extract is 60%. 
 
6.2.2. Preliminary Phytochemical studies 
 As a part of the preclinical study, the ethanolic extract of Flower buds of Withania 
coagulans Dunal was subjected to qualitative chemical test and confirmed the presence of 
carbohydrates, alkaloids, steroids, flavanoids, glycosides, proteins and amino acids shown 
in Table No.9 
 
6.2.3. IR Spectral Data of the Ethanolic extract of Withania coagulans 
 The ethanolic extract of Flower buds of Withania coagulans Dunal was subjected 
to the Infra Red Spectroscopy for their possible functional group (Table No. 10). The 
ethanolic extract of Flower buds of Withania coagulans Dunal showed the possible 
stretching and bending shows the presence of the functional group. 
6.2.4. HPTLC Fingerprinting 
The HPTLC fingerprinting of Ethanolic extract of Flower buds of Withania 
coagulans Dunal was studied. The HPTLC fingerprinting was done for confirming the 
presence of alkaloids, Flavanoids and glycosides. These are done after the identification 
tests and indicate the presence of alkaloids, Flavanoids and glycosides. The stationary and 
the mobile phases are selected based on the identification test. Three different 
chromatograms are obtained and photo documentation was done (Fig. Nos. 9, 13& 17). 
The 3D display of the chromatogram was obtained from 10 μl and 20μl of the test solution 
(Fig. Nos. 10, 14 &18) and the Peak display at 10 μl and 20 μl of the test solution was 
shown (Fig. Nos. 11, 12, 15, 16, 19 & 20. The interpreted data of the Peak display at 10 μl 
and 20 μl of the test solution was shown in Table Nos. 11-16. 
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6.2.5. Pharmacological Screening 
6.2.5.1. Toxicity Studies – Validation  
Validation of Acute Toxicity  
In acute oral toxicity studies, ethanolic extract of Flower buds of Withania 
coagulans Dunal did not produce mortality at a dose of 2000mg/kg body weight in rats 
and hence 1/10th of LD50 (i.e.) 200mg/kg was considered as the dose level for further 
pharmacological screening. The parameters observed were behavioral changes, 
biochemical parameters, body weight, histopathological studies and mortality. 
Behavioural Changes 
Behavioral changes observed were death, abnormal gait, aggression, akinesia, 
altered fear, altered muscle tone, altered respiration, analgesia, body temperature, 
catalepsy, convulsions, excitation, fore paw treading, jumping, loss of balance, motor in-
coordination, sedation, stereotypy, straub tail, tremor, writhing, altered reactivity to touch, 
defecation/diarrhoea, head movements, lacrimation, loss of corneal reflux, loss of righting 
reflux, loss of traction, miosis/mydriasis, salivation and scratching. Among the behavioral 
parameters observed the animal showed positive response for altered fear, catalepsy, 
excitation and stereotypy (Table No. 17). 
Biochemical Parameters and Body Weight 
The biochemical parameters observed in animals treated with 2000 mg/kg of 
ethanolic extract of Flower buds of Withania coagulans Dunal were albumin, blood urea, 
glucose, SGOT, SGPT, total cholesterol. All the biochemical parameters were in normal 
range. The increase in level of SGOT, SGPT, blood urea and decrease in level of Uric acid 
were observed (Table No. 19) (Fig. No. 22). The body weights of the groups are studied 
on the first day of the administration of the drugs and at the end of the 14 days of study. 
There is no change in the body weight of the rats as shown in Table No. 18 & Fig. No. 21. 
Histopathological Studies  
Fig. Nos. 23-30 represents the transverse sections of Heart, Kidney, Liver and 
Pancreas showing normal histology upon administration of 2000mg/kg of Test Compound 
and the histopathology of the test group was compared with the control group. It shows the 
normal architecture and there is no change in the cells indicates the absence of toxicity 
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6.2.5.2. Behavioural Activity 
Hole Board Test 
The various evaluation tests for Hole board test like latency to the first head dips, 
no. of head dips in the holes, total time spent with the head dips, no. of rearings and no. of 
defecation units as shown in Table Nos. 20 & 21 & Fig. Nos. 31-33. The increase in the 
number of head dips and the total time spent with the head dips and the decrease in the no. 
of rearings, defecation units indicates the anxiolytic property of the test drug when 
compared with the standard drug.  
6.2.5.3. Antiobesity Activity 
Progesterone Induced Obesity  
The body weight of every rat (g) were recorded for every week for 28 days         
(Table No. 22 & Fig. No. 34) and the food consumption behavior was studied on days 1, 
7, 14, 21, and 28. The food intake was recorded at 0.5, 1, and 2 h time intervals           
(Table No. 24 & Fig. No. 40). 
Rearing, grooming and ambulatory moments were studied (Table No. 25). 
Serum glucose levels, total cholesterol, LDL- C, HDL- C, VLDL- C, Triglycerides, 
SGOT, and SGPT were estimated (Table No. 26 & Fig. No. 39). 
Table Nos. 23 & Fig. Nos. 35-38 represents the transverse sections Liver obtained 
from various groups such as Normal, Control, Standard and Test groups. 
6.2.5.4. Antihyperlipidemic Activity 
Fructose Induced Hyperlipidemia 
Daily administration of 25 % of fructose in drinking water for 21 days significantly 
increased (P < 0.01) hyperlipidemia in rats by increasing the serum TC, TG, LDL- C, 
glucose levels and serum HDL-C levels was significantly decreased (P < 0.01) in fructose 
control group when compared to the normal control group. The effect of Ethanolic extract 
of Withania coagulans on serum lipid profile levels was showed in Table 1. Treatment 
with Ethanolic extract of Withania coagulans significantly reduced (P < 0.05, P < 0.01 
respectively) the serum TC, TG, LDL-C levels, glucose and serum HDL-C levels was 
significantly increased (P < 0.01) when compared to the fructose control group. The 
change in lipid levels in test groups combinations were comparable with group of 
individual test drug treated rats. At 21st day, two hours after the final treatment, animals 
were anaesthetized and blood from each animal was withdrawn from retro-orbital 
plexus.The serum were assayed for total cholesterol, triglycerides, high density lipoprotein 
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(HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and serum 
blood glucose (Table No. 27 & Fig. No. 41). 
Table No. 28 & Fig. Nos. 42-45 represents the transverse sections of liver obtained 
from various groups such as Normal, Control, Standard and Test groups and the histology 
of liver was studied  
 
6.2.5.5. Analgesic Activity  
The analgesic activities of the ethanolic extract of Withania coagulans was 
evaluated by employing the tail flick method. The result of analgesic activity of Ethanolic 
extract of Withania coagulans in Table No. 29 respectively. The results are also 
graphically illustrated in Fig. No. 46 
 
6.4.5.6. Anthelmintic Activity 
The data reveals that of Ethanolic extract of Withania coagulans showed paralysis and death 
at different concentrations (25, 50, 75 & 100mg/ml) (Table No. 30 & Fig. Nos. 47-53). The 
effects are comparable with that of the effects produced by the standard drug            
albendazole (10mg/ml). The activity reveals concentration dependent nature of different 
extracts. The activity of the extracts was found to be inversely proportional to the time taken 
for paralysis/death of the worms and due to the presence of alkaloids, flavanoids and 
glycosides present in the extracts.  
 
6.5.5.7. Antimicrobial Activity 
The antimicrobial activity of the Ethanolic extract of of Withania coagulans Dunal  
have been tested against Staphylococcus aureus, Bacillus subtilis, Proteus vulgaris, 
Klebseilla species, Candida albicans and Asperigellus niger and compared with the 
standard drugs such as Ciprofloxacin (5µg/disc) for Bacteria and Nystatin                     
(100 units/disc) for Fungi (Table No. 31).  
Selective Toxicity is the property of an ideal antimicrobial agent. It means that the 
drug is harmful to a parasite but not to the host. Usually the effects is relative rather 
absolute, i.e. a drug in a concentration tolerated by the host may damage an infecting 
microorganism. The different mechanisms are Inhibition of cell wall synthesis, Inhibition/ 
Alteration of cell wall membrane, Inhibition of Protein synthesis, Inhibition of nucleic acid 
RESULTS AND DISCUSSION 
 
 Page 125 
synthesis. Alteration of cell membrane function, Polymyxin, Amphotericin B, Imidazole 
are examples.  
These drugs act by disruption of the functional integrity of the cytoplasmic 
membrane of bacteria and fungi has a structure different from that of animal cells, and can 
be more readily disrupted by certain chemotherapeutic agents. Ethanolic extract of 
Withania coagulans Dunal exhibited appreciable activity against the Staphylococcus 
aureus, Bacillus subtilis, Proteus vulgaris, Klebseilla species, Candida albicans and 
Asperigellus niger The Ethanolic extract of of Withania coagulans Dunal was exhibiting 
competent biological activity both gram negative & gram positive bacterial species and 
also fungus (Fig. Nos. 54-65). The results are also graphically illustrated in Fig. No. 66 
Analytical Determination 
IR - Spectroscopy 
 
Fig. No. 8: IR – Spectrum of the Ethanolic extract of Withania coagulans
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HPTLC fingerprinting profile EEWC - Alkaloids 
 
Fig. No. 9: Photo Documentation   Fig. No. 10: 3D Display @ 254nm             
        Under UV 
     AT 254nm               AT 366nm 
 
                                
        T1     T2      T1     T2 
 
 
 
 
 
Fig. No. 11:  PEAK DISPLAY                                    Fig. No. 12:  PEAK DISPLAY 
                (10µl of test solution)  (20µl of test solution) 
                    
 
 
 
 
 
 
 
HPTLC fingerprinting profile of EEWC - Glycosides 
Fig. No. 13: Photo Documentation   Fig. No. 14: 3D Display @ 254nm             
        Under UV 
     AT 254nm               AT 366nm 
                               
      T1     T2   T1     T2 
 
 
 
 
 Fig. No. 15:  PEAK DISPLAY                          Fig. No. 16:  PEAK DISPLAY 
                (05µl of test solution)                                          (10µl of test solution) 
     
                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
HPTLC Fingerprinting Profile of EEWC – Flavanoids 
Fig. No. 17: Photo Documentation   Fig. No. 18: 3D Display @ 254nm             
        Under UV 
     AT 254nm               AT 366nm 
                             
      T1     T2   T1     T2 
 
        
Fig. No. 19:  PEAK DISPLAY                                Fig. No. 20:  PEAK DISPLAY 
                (05µl of test solution)                                               (10µl of test solution) 
   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. No. 21: Effect of Test compound on Body Weight in Acute oral toxicity in Albino 
rats 
 
 
 
 
 
Fig. No. 22: Effect of Test compound on Biochemical parameters in Acute oral 
toxicity in Albino rats 
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Histopathological Studies of Acute Oral Toxicity 
Control 
Fig. No. 23: T.S of Kidney     Fig. No. 24: T.S of Heart 
     
Fig. No. 25: T.S of Liver     Fig. No. 26: T.S of Pancreas 
    
Control - Normal saline 5 ml/kg, p.o 
  
Test 
Fig. No. 27: T.S of Kidney     Fig. No. 28: T.S of Heart 
    
Fig. No. 29: T.S of Liver    Fig. No. 30: T.S of Pancreas 
    
Test drug - Ethanolic extract of Withania coagulans (2000 mg/kg, p.o.) 
 
  Fig. No. 30:  Effect of Ethanolic extract of Withania coagulans on Time spent with 
the head dips 
 
 
 
  Fig. No. 32:  Effect of Ethanolic extract of Withania coagulans on Head dips into the 
holes 
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  Fig. No. 33:  Effect of Ethanolic extract of Withania coagulans on Anxiety 
Parameters in Albino rats 
 
 
 
 
 
Fig. No. 34: Effect of Ethanolic extract of Withania coagulans on Body Weight in 
Progesterone induced obesity in Albino rats 
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 Histopathological Studies of Progesterone Induced Obesity in Albino Rats  
 T.S of Liver 
Fig. No. 35: Normal     Fig. No. 36: Obesity control 
 
  
             Fig. No. 37: Standard     Fig. No. 38: Test 
 
  
 
 
Normal - Normal Saline (5ml/kg  p.o.) 
Obesity Control  - Progesterone (10mg/kg, s.c.)  
Standard – Orlistat (10mg/kg, p.o.) + Progesterone (10mg/kg b.w., s.c.)  
Test  - Ethanolic Extract of Withania coagulans (200mg/kg, p.o.) + Progesterone 
 (10mg/kg, b.w., s.c.)  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. No. 39: Effect of Ethanolic extract of Withania coagulans on biochemical 
parameters in Progesterone induced obesity in Albino rats 
 
 
 
 
Fig. No. 40: Effect of Ethanolic extract of Withania coagulans on Food consumption 
in Progesterone induced obesity in Albino rats 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
160
180
200
Control Positive
control
Test Standard
B
io
ch
em
ic
a
l 
V
a
lu
es
 (
in
 U
n
it
s)
Groups
Biochemical parameters
Glucose (mg/dl)
Total Cholesterol (mg/dl)
TG  (mg/dl)
HDLC (mg/dl)
LDLC  (mg/dl)
VLDL - C(mg/dl)
SGOT  (U/l)
SGPT  (U/l)
0
1
2
3
4
5
6
7
8
9
10
Normal Positive control Test Standard
F
o
o
d
 C
o
n
su
m
ed
 (
g
)
Group
Food Consumption Behaviour
0.5 hr  1st  day
0.5 hr  7th  day
0.5 hr  14th  day
0.5 hr  21st  day
0.5 hr  28th  day
1 hr  1st  day
1 hr  7th  day
1 hr  14th  day
1 hr  21st  day
1 hr  28th  day
2 hr  1st  day
2 hr  7th  day
2 hr  14th  day
2 hr  21st  day
2 hr  28th  day
Fig. No. 41: Effect of Ethanolic extract of Withania coagulans on biochemical 
parameters in Fructose Induced Hyperlipidemia in Albino rats 
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Fig.No. 42 : Normal       Fig.No. 43: Lipidemic Control 
 
    
                 
             Fig.No. 44: Standard                    Fig.No. 45: Test 
 
 
  
 
Normal - Normal Saline (5ml/kg p.o.) 
Lipidemic Control  - 25% Fructose in water  
Standard – Orlistat (10mg/kg, p.o.) + 25% Fructose in water  
Test  - Ethanolic Extract of Withania coagulans (200mg/kg, p.o.) + 25% Fructose in water 
 
 
 
 
 
 
 
 
 
 
Fig. No. 46: Analgesic activity of Ethanolic Extract of Withania coagulans 
against Tail Flick Test in Wistar Albino Rats 
 
 
 
 
 
 
Fig. No. 47: Anthelmintic activity of Ethanolic Extract of Withania coagulans against 
Pheretima posthuma 
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Fig. No. 48:  Control    Fig. No. 49:  Standard 
 
      
            
Fig. No. 50:  Test I     Fig. No. 51:  Test II 
 
            
 
Fig. No. 52:  Test III   Fig. No. 53:  Test IV      
                       
 
             
Control - 1% CMC in 10ml of Normal Saline 
Standard - Albendazole  
Test I - 25 mg/ml of Ethanolic Extract of Withania Coagulans  
Test II - 50 mg/ml of Ethanolic Extract of Withania Coagulans  
Test III - 75 mg/ml of Ethanolic Extract of Withania Coagulans  
Test IV - 100 mg/ml of Ethanolic Extract of Withania Coagulans 
Fig. No. 54:  Zone of inhibition of Test drug  25, 50, 75 & 100mg against 
Staphylococcus aureus 
 
 
Fig. No. 55:  Zone of inhibition of Test drug 250mg against Staphylococcus 
aureus 
 
 
Fig. No. 56:  Zone of inhibition of Test drug 25, 50, 75 & 100mg against    
Bacillus substilis 
 
 
Test drug: Ethanolic Extract of Withania coagulans (25, 50, 75, 100 & 250mg/ disc) 
Standard: Ciprofloxacin (5µg/ disc) – Bacteria & Nystatin (100 units/ disc) – Fungi 
Solvent:     DMSO 
 
 
Fig. No. 57:  Zone of inhibition of Test drug 250mg against Bacillus substilis 
 
 
Fig. No. 58:  Zone of inhibition of Test drug 25, 50, 75 & 100mg against  
Proteus vulgaris 
 
 
Fig. No. 59:  Zone of inhibition of Test drug 250mg against Proteus vulgaris 
 
 
Test drug: Ethanolic Extract of Withania coagulans (25, 50, 75, 100 & 250mg/ disc) 
Standard: Ciprofloxacin (5µg/ disc) – Bacteria & Nystatin (100 units/ disc) – Fungi 
Solvent:     DMSO 
 
 
 
 
Fig. No. 60:  Zone of inhibition of Test drug 25, 50, 75 & 100mg against  
Klebsiella aerogenes 
 
 
Fig. No. 61:  Zone of inhibition of Test drug 250mg against 
Klebsiella aerogenes 
 
 
Fig. No. 62:  Zone of inhibition of Test drug 25, 50, 75 & 100mg against  
Candida albicans 
 
 
Test drug: Ethanolic Extract of Withania coagulans (25, 50, 75, 100 & 250mg/ disc) 
Standard: Ciprofloxacin (5µg/ disc) – Bacteria & Nystatin (100 units/ disc) – Fungi 
Solvent:     DMSO 
      
 
      Fig. No. 63:  Zone of inhibition of Test drug 250mg against Candida albicans 
 
 
 
Fig. No. 64:  Zone of inhibition of Test drug 25, 50, 75 & 100mg against  
Aspergillus niger 
 
 
 
Fig. No. 65:  Zone of inhibition of Test drug 250mg against Aspergillus niger 
 
 
            
 
Test drug: Ethanolic Extract of Withania coagulans (25, 50, 75, 100 & 250mg/ disc) 
Standard: Ciprofloxacin (5µg/ disc) – Bacteria & Nystatin (100 units/ disc) – Fungi 
Solvent:     DMSO 
 Fig. No. 66: Antimicrobial screening of Ethanolic Extract of Withania coagulans 
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8. CONCLUSION 
 
From  the study entitled "Pharmacological Evaluation of Withania coagulans Dunal (Flower 
buds), the following conclusion could be drawn 
 The present study has thus duly supported the traditional use of Ethanolic Extract of 
Withania coagulans Dunal have scientifically proved the behavioral coordination, 
antiobesity, antihyperlipidemic, analgesic, anthelmintic, and  antimicrobial activity 
 
 Apart from the suggested actions listed in discussion part absence of acute toxicity 
may also offer a new hope for safe treatment in future 
 
 Preliminary phytochemical study ethanolic extract of Withania coagulans Dunal was 
found to contain Carbohydrates, Protein, Steroids, Flavanoids, Alkaloids, Glycosides 
and Amino Acids are present 
 
 Presence of Alkaloids, Flavanoids and Glycosides in the ethanolic extract of Withania 
coagulans Dunal was concluded by IR & HPTLC analysis. Though present in small 
quantities, it was found to produce considerable effects 
 
 The results of the present study indicate that the ethanolic extract of Withania 
coagulans was non-toxic up to dose level of 2000mg/kg body weight in albino rats as 
per acute oral toxicity studies. 1/10th of the LD50 Dose is 200mg/kg is used for 
Pharmacological screening 
 
 Evaluation of anti-obesity activity of ethanolic extract of Withania coagulans showed 
significant anti obesity property by the obtained significant results against 
Progesterone induced obesity. From the results observed in the Progesterone induced 
obesity, it may be concluded that the test compound at the dose of 200mg/kg body 
weight displays a significant anti- obesity activity compared to standard drug Orlistat 
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 The ethanolic extract of Withania coagulans at a dose of 200mg/kg exhibited 
significant hypolipidemic activity in Fructose induced hyperlipidemic rats. This is 
showed by the reduction of serum lipid parameters such as triglycerides, total 
cholesterol, LDL, VLDL, SGOT and SGPT with an increase in HDL concentration in 
the group treated with 200mg/kg of Ethanolic Extract of Withania coagulans. It is 
found that there is a significant reduction in the Serum glucose 
 
 The ethanolic extract of Withania coagulans was subjected to the Tail Flick Analgesic 
test, showed a significant inhibitory effect  
 
 The ethanolic extract of Withania coagulans was subjected to the Anthelmintic 
activity against Pheritima posthuma, showed a significant inhibitory effect at higher 
doses 75mg/10ml of Normal Saline & 100mg/10ml of Normal Saline 
 
 The ethanolic extract of Withania coagulans was subjected to the antimicrobial test, 
showed a significant inhibitory effect on both gram positive, gram negative bacteria 
and also fungi 
 
 In future, further investigation might provide an insight to identify the functional 
groups in the ethanolic extract of Withania coagulans active responsible for the  
behavioral coordination, antiobesity, antihyperlipidemic, analgesic, anthelmintic, and  
antimicrobial effect and to elucidate the exact mechanism of action, which is 
responsible for the observed significant activity with low toxicity and better 
therapeutic index 
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